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  Chromaffin cells are a modified post-ganglionic sympathetic neuron, which 
synthesise and secrete catecholamines.  The neoplastic transformation of chromaffin cells is 
demonstrated by the tumour phaeochromocytoma, a functional tumour that recapitulates the 
normal role of chromaffin cells by synthesising, storing and releasing excess 
catecholamines.  Within this thesis we have explored several aspects of chromaffin cell and 
phaeochromocytoma tumour biology, including the specific expression of key 
sympathoadrenal markers such as the noradrenaline transporter (NAT), neuropeptide Y 
(NPY) and chromogranin A (CGA) in normal human and mouse chromaffin cells versus 
phaeochromocytomas of human and mouse origin.   
 
  Catecholamine-mediated signalling in chromaffin cells is terminated by the 
sequestration of extracellular catecholamines back into the cell via the noradrenaline 
transporter (NAT).  Following observations that within the rat adrenal medulla, NAT is 
expressed in PNMT-positive chromaffin cells we explored whether this pattern of 
expression is also present in the human adrenal medulla.  While we successfully established 
that NAT and PNMT are co-localised, we also found that all human adrenal chromaffin 
cells are PNMT-positive.  In the rat, NAT is also observed within the cytoplasm and has 
been suggested to be associated with secretory vesicles, thus using the secretory vesicle 
marker, CGA, we demonstrate that NAT is associated with secretory vesicles.  However, in 
contrast to our findings within the normal chromaffin cells, in situ NAT expression in 
human phaeochromocytoma tumour samples was distorted, with observed changes 
including the level and type of staining observed, and disruptions to the strict NAT-CGA 
association observed in the normal adrenal.   
 
  Continuing our theme of NAT, we investigated if pre-treating the 
phaeochromocytoma PC12 cell line with the chemotherapy drug cisplatin had an effect on 
the expression of NAT, to give an indication of the efficacy of this compound in the   iv 
treatment of metastatic phaeochromocytoma with radiolabelled 
131Iodo-
metabenzylguanidine (
131I-MIBG), a noradrenaline analogue which can be incorporated 
into phaeochromocytoma tumour cells though uptake through NAT.  The premise of this 
study is derived from previous work in which neuroblastoma cells pre-treated with cisplatin 
were more responsive to (
131I-MIBG) accumulation due to increased activity and 
expression of the transporter.  Thus we treated PC12 cells for 24-hours in a range of 
cisplatin concentrations and measured the effect on NAT expression.  However, unlike the 
findings in neuroblastoma cells, in our study, we did not observe an effect of cisplatin pre-
treatment on NAT activity or expression in PC12 cells.   
 
  Upto 30% of phaeochromocytoma arise as apart of a hereditary syndrome.  The von 
Hippel-Lindau (VHL) syndrome, due to germline mutations to the VHL gene, and Multiple 
Endocrine Neoplasia type 2 (MEN 2), due to germline mutations to the RET gene represent 
two examples of hereditable endocrine disorders where phaeochromocytoma is a presenting 
feature.  Notable differences in clinical presentation and tumour biology have been 
identified in phaeochromocytomas from patients with VHL and MEN 2.  These differences 
prompted us to explore whether these observations extend to the chromaffin granule 
constituents, NPY and CGA.   
  Patients with MEN 2 disease have a greater incidence of hypertension than patients 
with VHL disease, MEN 2 are characterised by an adrenergic phenotype (produce 
predominantly-adrenaline), whereas VHL phaeochromocytomas are noradrenergic 
(produce predominantly-noradrenaline).  Neuropeptide Y, which has powerful vasoactive 
properties capable of significantly elevating blood pressure, is stored and released with 
catecholamines and is thought to be associated with PNMT-positive chromaffin cells.  
Thus, we questioned whether the differences in the symptomatology between VHL and 
MEN 2 patients may be related to differences in NPY expression between the two groups, 
and whether any differences in NPY relate to adrenaline and/or PNMT content, or are 
linked to hereditary factors.   Thus we compared tumour samples from four cohorts of 
patients: (i) adrenergic versus noradrenergic phenotype, (ii) hereditary versus no hereditary 
syndrome.  Results demonstrated that although tumour NPY levels (mRNA and peptide) 
correlate with PNMT expression and/or adrenaline content, when NPY expression was   v 
compared between groups of patients (adrenergic vs noradrenergic; hereditary versus non-
hereditary) difference in NPY levels were only significant between VHL and MEN 2 
tumour and not between sporadic adrenergic and noradrenergic Immunohistochemistry also 
supported the above observations.  Hence, we concluded that NPY expression in all groups 
of phaeochromocytoma examined in this study, this effect is not related to tumour 
biochemical phenotype but rather appears to be a specific unique trait of VHL 
phaeochromocytomas. 
  Continuing our theme of the possible differential expression of chromaffin granule 
constituents between VHL and MEN 2 patients, we also investigated CGA levels in plasma 
and tumour samples.  Given, VHL tumours possess less chromaffin granules than MEN 2 
tumours, and CGA has been implicated as a key director of secretory vesicle biogenesis we 
investigated whether CGA was differentially expressed between VHL and MEN 2 tumours.  
We found CGA expression was significantly greater in MEN 2 tumours (mRNA; 3-fold, 
and protein; 20-fold), with western blot confirming this trend.  We also found that plasma 
CGA was greater in MEN 2 patients but not significantly, consequently, we explored the 
co-variables tumour size and tumour secretory activity (measured by plasma catecholamine 
concentrations), which influence plasma CGA and found that tumour size and plasma CGA 
are related but there was no influence of genotype on this relationship.  In contrast, plasma 
CGA was significantly related to tumour secretory activity and the effect of genotype on 
this relationship narrowly missed significance, but when we expressed plasma CGA as a 
ratio of plasma catecholamines, plasma CGA was 2-fold greater in MEN 2 patients than 
VHL patients.  Thus despite the tendency of phaeochromocytomas from VHL disease to 
readily and continuously release their catecholamine stores, plasma CGA levels still 
appeared to be higher in MEN 2 patients. 
 
  Finally, we examined whether the expression of NPY, Leu-enkephalin (Leu-Enk), 
NAT and the vesicular monoamine transporters type 1 and 2 (VMAT1 and VMAT2,), in 
normal mouse adrenal glands, and in histologically-confirmed adrenal 
phaeochromocytomas generated by injected nude mice with a phaeochromocytoma (MPC) 
cells line. The results of this study established that similar to the rat and human NAT 
expression is preferentially localised with PNMT within mouse chromaffin cells, while   vi 
VMAT1 and NPY are found in both PNMT-negative and PNMT-positive cell populations, 
although expression of NPY was reduced in PNMT-negative cells.  In contrast, both 
VMAT2 and Leu-Enk were found in PNMT-negative noradrenergic cells, and VMAT2 was 
present in all noradrenergic chromaffin cells while Leu-Enk was observed in a sub-
population of noradrenergic chromaffin cells.  In contrast to the normal adrenal but similar 
to our findings in human phaeochromocytoma, the pattern of marker expression within 
adrenal phaeochromocytoma lesions of MPC-injected mice are severely disrupted related to 
both the level of expression of the respective markers, and association with PNMT within 
the tissue.  Thus, the experimentally generated phaeochromocytoma mouse model provides 
a valuable tool in studying human phaeochromocytoma.   
 
  The data presented in this thesis further validate the heterogeneity observed in many 
aspects of phaeochromocytoma tumour biology, including the expression several 
chromaffin cell markers such as NAT, NPY and CGA.  The altered expression of these 
markers may contribute to the clinical picture of these tumours, particularly relating to 
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NAT  Noradrenaline transporter 
NF1  Neurofibromatosis 
NGF  Nerve growth factor 
NPY  Neuropeptide Y 
PNMT  Phenylethanolamine N-methyltransferase 
Q-PCR  Quantitative Polymerase Chain Reaction 
SDHB   Succinate dehydrogenase subunit B 
SDHD   Succinate dehydrogenase subunit D 
TH  Tyrosine hydroxylase 
VHL  von Hippel-Lindau 
VMAT   Vesicular Monoamine Transporter 
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Part A – The adrenal gland, catecholamines and 
chromaffin cells 
 
I.  A brief introduction to the autonomic nervous system 
 
  The autonomic nervous system is an assortment of efferent nerves linking the 
central nervous system to the tissues of the body.  There are two efferent branches of the 
autonomic nervous system, which co-ordinate divergent, yet parallel systems necessary to 
balance the requirements of the inner world in response to stimuli evoked from the outer 
world.  Together, the complementary roles of the sympathetic and parasympathetic nervous 
system act respectively as the “accelerator” and “breaks” of the autonomic nervous system, 
and provide the checks and balances necessary to regulate internal homeostasis. 
The sympathetic nervous system is composed of a network of cholinergic preganglionic 
neurons with regulatory inputs from various brain centres including the rostral ventrolateral 
medulla, nucleus of the solitary tract and paraventricular nucleus of the hypothalamus.  
These centres project through the spinal cord to innervate the pre- and para-vertebral 
sympathetic ganglia, the adrenal glands and enteric or cardiac neuronal networks (Guyenet, 
2006).  Cholinergic sympathetic efferents synapse with post-ganglionic sympathetic 
neurons that project to target organs distributed throughout the body, including the heart, 
kidneys and smooth muscle cells of the vasculature.  Following central stimulation, a 
cascade of events, including the release of acetylcholine from preganglionic nerves, leads to   2 
sympathetic nerve firing causing the release of noradrenaline from sympathetic nerve 
varicosities, and adrenaline from the adrenal medulla, which subsequently bind to 
adrenoceptors on target organs.   
A central function mediated by the autonomic nervous system is the control of blood 
pressure.  Blood pressure can be considered a function of vascular resistance and cardiac 
output, which in turn, is regulated by end-diastolic volume, myocardial contractility and 
heart rate.  While blood pressure can oscillate significantly over a short-term period (i.e, 
seconds to minutes) according to behavioural (e.g., feeding) or environmental (e.g., fear) 
signals, long-term (i.e., over a 24-hour period) control of blood pressure is under strict 
regulation (Guyenet, 2006).  Hypertension, representing a chronic elevation of average 24-
hour blood pressure, can manifest in a number of conditions including essential 
hypertension or as secondary hypertension due to a primary defect.  The aetiology of 
essential hypertension is a source of great debate, but has been suggested to be due to 
activation of the sympathetic nervous system, including to nerves innervating the heart, 
kidneys and skeletal muscle, in which increased sympathetic nervous system activity both 
initiates and sustains elevated blood pressure (Esler et al., 2003).  Secondary hypertension, 
can be caused by an array of conditions including Cushings disease, renal parenchymal 
disease, aldosteroma, renal artery stenosis, hyperparathyroidism (Calhoun, 2006) or due to 
catecholamine-producing tumours such as phaeochromocytoma and paraganglioma 
(Zelinka et al., 2007).  While mounting evidence suggests that essential hypertension is 
intrinsically related to the activation of one or many components of the sympathetic 
nervous system, the development of hypertension secondary to the presence of the 
chromaffin cell tumour phaeochromocytoma represents a rare and under appreciated form   3 
of sympathetic nervous system dysfunction in which excessive catecholamines are released 
from the adrenal gland.  Several of the checks and balances put in place by the sympathetic 
nervous system are impaired in the setting of phaeochromocytoma, and these shall be 
explored in greater detail herein.   
II. The adrenal gland: Historical vignette  
 
  The adrenal glands were first described by the anatomist Eustachius in 1563 (Figure 
1.1), and in 1892 were correctly identified by Joh Carl Jacobj as an endocrine organ. In the 
many years following this discovery, the adrenals have been identified as central 
components of the endocrine system. These unassuming paired pyramid shaped structures 
are vital for life and play a crucial role in the regulation of the body’s adaptive responses to 
stress, water and salt maintenance and blood pressure control.  In 1805, George Cuvier 
established that the adrenals are composed of two morphologically distinct regions, and in 
1836 Nagel assigned the separate names to the outer cortex and inner medulla.  These 
terminologies still apply today.  It is now understood that the adrenal gland is a composite 
of two embryologically and functionally distinct endocrine organs incorporating the adrenal 
cortex and adrenal medulla.  
The adrenal cortex 
  The outer cortical region of the adrenal represents about 90% of the weight of the 
gland and is derived from mesodermal origin. The adrenal cortex is divided into three 
histologic zones represented by the outer zona glomerulosa, the middle zona fasciculata and 
the zona reticularis, which lies proximal to the adrenal medulla.   4 
Figure 1.1  “Glandulae Renibus Incumbentes”:  The kidney and adrenal gland   5 
  The cortex is primarily responsible for the synthesis and release of adrenal steroidal 
hormones incorporating the three main classes of adrenocortical hormones: glucocorticoids, 
mineralcorticoids and androgens.  
Mineralcorticoids, including aldosterone, are synthesised from the zona glomerulosa and 
are important regulators of electrolyte and fluid balance via direct effects on the secretory 
epithelia of the kidneys and colon (Connell & Davies, 2005), with other effects occurring 
centrally via the stimulatory actions of aldosterone on brain regions such as the amygdala 
and hypothalamus which are involved in salt appetite and osmotic regulation (Rashid & 
Lewis, 2005, Geerling et al., 2006).  Similarly, the glucocorticoids cortisol and 
corticosterone, synthesised within the zona fasciculata and reticularis, are also important for 
sodium and water balance, but play a central a catabolic role in stress responses, mediating 
changes in carbohydrate and lipid metabolism (Rashid & Lewis, 2005).  The third class of 
cortical hormones, the adrenal androgens, including dehydroepiandrosterone, are 
synthesised within the zona reticularis and are implicated in the immunity and maintenance 
of musculoskeletal integrity (Rainey et al., 2002, Dharia & Parker, 2004).   
The adrenal medulla 
  The role of the adrenal gland as an endocrine organ was put forth in 1892, followed 
soon after by the seminal discovery of Oliver and Schäfer, that purified adrenal extracts had 
potent effects on blood pressure (Oliver & Schäfer, 1895). The pressor actions of the 
adrenal extracts have since been attributed to catecholamines.  
The inner portion of the adrenal gland, the adrenal medulla, is another critical component of 
the adaptive response to stress, which secretes catecholamines, a class of chemical 
messengers with divergent but complementary roles to the adrenal cortical steroids. In   6 
humans, up to 90% of circulating adrenaline is derived from the adrenal medulla, whereas 
only 7% of circulating noradrenaline is adrenal derived, with the remaining 93% via 
sympathetic nerves (Eisenhofer et al., 1995a).  Catecholamines released as a 
neurotransmitter from sympathetic nerves, or as ahormone from the adrenal medulla, elicit 
an effect on target organs and tissues by binding to adrenoceptors.  
III.  Catecholamines 
Introduction 
  The three major endogenous catecholamines consist of dopamine, noradrenaline and 
adrenaline, which are synthesised within the central nervous system, sympathetic nerves, 
adrenal medulla, gastrointestinal tract and kidneys (Mezey et al., 1996).  Within the central 
nervous system, populations of dopaminergic and noradrenergic neurons are widely 
distributed, while within the brain adrenergic neurons are less abundant and are found 
predominantly within the brainstem (Hökfelt et al., 1984).  Peripherally, noradrenaline acts 
as a sympathetic postganglionic neurotransmitter and dopamine regulates renal and 
gastrointestinal function.  Adrenaline, from the adrenal medulla, plays a major role in 
regulating sympathetic tone, metabolism and the adaptive response to stress.   
From tyrosine to catecholamines:  the catecholamine biosynthetic 
pathway 
  Catecholamines are organic compounds containing a catechol nucleus (consisting of 
a benzene ring with two adjacent hydroxyl substituents) and an amine group (Flatmark, 
2000).  The synthesis of the various catecholamines occurs via a series of enzymes within   7 
the catecholamine biosynthetic pathway (Figure 1.2), and the tissue specific availability of 
these enzymes determines which of the respective catecholamine molecules will be 
generated.    
Catecholamine biosynthesis begins with the amino acid L-tyrosine, which is typically 
acquired through dietary sources, or through the liver via the metabolism of phenylalanine 
(Schulz et al., 2004).  Circulating L-tyrosine is taken into the brain and other catecholamine 
synthesising tissues via a neutral amino acid transporter (Schulz et al., 2004) and oxidised 
into 3, 4-dihydroxyphenylanaline (L-DOPA) by the rate-limiting enzyme tyrosine 
hydroxylase (TH; tyrosine 3-monoxygenase), a substrate-specific stereospecific enzyme 
that requires molecular oxygen, Fe
2+ and tetrahydrobiopterin (BH4) cofactors for activity.   
In humans, four variants of TH have been identified (hTH1 – 4), with hTH1 and hTH2 the 
major isoforms present within the brain and adrenal medulla.  The activity of the 
catecholamine biosynthetic pathway at the point of TH can be augmented by increased 
substrate availability (Lehnert et al., 1984, Asbach et al., 2001), however, catecholamines 
themselves are competitive inhibitors of TH, and excess tyrosine and BH4 concentrations 
have also been demonstrated to inhibit TH activity (Okuno & Fujisawa, 1991, Alterio et al., 
1998).  
The generation of dopamine occurs through the metabolism of L-DOPA within the cytosol 
by the enzyme aromatic L-amino acid decarboxylase (AAD, or DOPA decarboxylase), and 
the cofactor pyridoxal phosphate (vitamin B6).  In dopamine producing cells, this step is 
the end point in the catecholamine biosynthetic pathway. Up to 45% of dopamine synthesis 
occurs within the mesenteric organs (Eisenhofer et al., 1996a).     8 
Figure 1.2  Catecholamine Biosynthetic Pathway 
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  Within noradrenergic and adrenergic cells, dopamine is converted to noradrenaline 
via the actions of the enzyme dopamine β-hydroxylase (DβH; dopamine β-
monooxygenase), which requires molecular oxygen and ascorbate for full activity.  The 
conversion of dopamine to noradrenaline by DβH occurs within secretory vesicles 
(Eisenhofer et al., 1996b).  Finally, the conversion of adrenaline occurs through the 
methylation of noradrenaline by the soluble enzyme phenylethanolamine N-
methyltransferase (PNMT), which requires S-adenosyl methionine as a methyl donor.  This 
reaction occurs within the cytosol of adrenergic cells and thus relies on noradrenaline 
leakage from vesicular stores (see section on catecholamine metabolism).   
 
In the context of the adrenal gland, the expression of the catecholamine biosynthetic 
enzymes TH and PNMT are also frequently utilised to confirm the presence of 
catecholamine biosynthetic machinery, and differentiate between noradrenaline and 
adrenaline synthesising cells.   
Catecholamines elicit their effects on physiology by binding to 
adrenoceptors 
  Catecholamines released by peripheral sympathetic nerves and the adrenals act on 
an array of peripheral structures, but have very little effect centrally due to their inability to 
cross the blood brain barrier (Molina, 2004) and adrenoceptors form the bridge linking the 
sympathetic nervous system with the target organs and tissues of the body.  The binding of 
the endogenous agonists, noradrenaline and adrenaline, to adrenoceptors causes direct or 
indirect effects on stress and arousal, including cognitive function, cardiovascular responses 
and metabolic effects, classically associated with allowing energy mobilisation during the   10 
archetypal sympathetic nervous system “flight, fright or fight” response.   However, 
adrenoceptors also participate in maintaining sympathetic tone.  There are two broad 
subtypes of adrenoceptor: alpha and beta; that are located on an array of structures 
throughout the body.  Of these two groups, currently nine subtypes of adrenoceptors have 
thus far been cloned and characterised (Alexander et al., 1999).  Both alpha and beta 
adrenoceptors are G-protein coupled receptors.  The effect elicited by ligand binding to 
adrenoceptors depends on the subtype of G-protein to which they are associated, and the 
specific signal transduction pathway linked to the receptors.   
Alpha adrenoceptors 
  Alpha adrenoceptors consist of two subtypes, alpha1 and alpha2, which can be 
further subdivided into alpha1A, 1B and 1D, and alpha2A – 2C.  The mechanism of receptor 
action differs between the respective alpha adrenoceptors (Alexander et al., 1999).   
Alpha1-adrenoceptors generally consist of G-protein Gαq/11 coupled receptors that activate 
phospholipase C causing the activation of protein kinase C via diacylglycerol, and an 
increase in intracellular Ca
2+ and phospholipase A2 (Alexander et al., 1999). The alpha 
adrenoceptors post-synaptically mediate many aspects related to vascular smooth muscle 
contraction and modulate vasoconstriction in peripheral vascular beds.  However, alpha 
adrenoceptors also have metabolic effects, including inhibition of insulin release and 
indirectly limiting skeletal muscle glucose deposition by reducing blood flow to skeletal 
muscle, thereby limiting the effects of insulin on skeletal muscle and increasing plasma 
glucose by increasing hepatic glycogenolysis (Shannon et al., 2000).  The alpha 
adrenoceptors also affect lipid metabolism, possibly by influencing lipoprotein lipase 
activity and triglyceride levels (Nash, 1990, Shannon et al., 2000).  The activation of   11 
alpha1-adrenoceptors on the smooth muscle vasculature of skeletal muscles is a central 
component of sympathetically mediated vasoconstriction, where activation of alpha1 
receptors causes vasoconstriction, increased peripheral resistance and increased blood 
pressure (Dinenno & Joyner, 2006).  However, the dilatory effects of alpha1 activation can 
be observed in the eyes, where stimulation of alpha1-adrenoceptors causes the contraction 
of iris smooth muscle cells and mydriasis (Michel et al., 2006).  Alpha2-adrenoceptors 
operate via varied second messenger systems, including Gαi and G0 proteins, and function 
in a number of ways including decreasing adenylate cyclase activity, activating K
+ 
channels, inhibiting Ca
2+ channels, activating phospholipase Cβ or activating 
phospholipase A2 (Alexander et al., 1999).  The alpha2-adrenoceptors also influence 
vascular resistance and other hemodynamic effects, but also act presynaptically as a 
negative feedback mechanism to control noradrenaline and adrenaline release from 
sympathetic nerves and the adrenal medulla (Starke, 2001, Brede et al., 2003, Fagerholm et 
al., 2004, Moura et al., 2006, Michel et al., 2006).   
Beta Adrenoceptors 
  There are three subtypes of beta-adrenoceptors: beta1, beta2 and beta3, which are 
activated by Gαs proteins, and upon activation, cause an increase in cyclic adenosine 
monophosphate (Alexander et al., 1999).  If the alpha-adrenoceptors commandeer the 
peripheral cardiovascular effects of catecholamines such as increased peripheral resistance, 
the beta adrenoceptors supervise the direct effects of catecholamines on the heart.  The 
beta1 and to a lesser degree the beta2 adrenoceptors are expressed in atrial and ventricular 
cardiomocytes (Molenaar et al., 1997) and stimulation of beta1 and beta2-adrenoceptors   12 
augments the contractile force of cardiomyocytes, increasing cardiac output of the heart 
(Santos & Spadari-Bratfisch, 2006).  The beta3-adrenoceptors have also been identified in 
the myocardium (Gauthier et al., 2000), where stimulation is thought to inhibit 
cardiomyocyte contraction in an adenylate cyclase-independent manner (Sartiani et al., 
2006).  The beta-adrenoceptors also mediate other responses including relaxation of 
bronchial smooth muscle, thermogenesis and lipolysis (Liu et al., 2004, Tavernier et al., 
2005).   
Catecholamine metabolism 
  Catecholamine metabolism (Figure 1.3) involves multiple enzymes and pathways, 
which differ between tissues and cell types.  Correctly identifying the different metabolites, 
and their site of generation, has important implications for understanding catecholaminergic 
systems and how alterations of these systems can manifest in disease.  
Dopamine metabolism 
  The major pathway for dopamine metabolism occurs through the deamination of 
dopamine via monoamine oxidase (MAO) to produce the short-lived aldehyde intermediate 
to 3,4-dihydroxyphenylaldehyde (DOPAL), from which DOPAL is then rapidly 
metabolised by aldehyde dehydrogenase (AD) into 3,4-dihydroxyphenylacetic acid 
(DOPAC), or by aldehyde reductase (AR) into 3,4-dihydroxyphenylethanol (DOPET) 
(Erwin & Deitrich, 1966, Tank et al., 1981).  Homovanillic acid (HVA) represents the 
major end product of dopamine metabolism, generated via the O-methylation of DOPAC.  
The brain contributes approximately 12% of circulating HVA (Lambert et al., 1993).   13 
 
Figure 1.3  Pathways of catecholamine metabolism 
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Noradrenaline and adrenaline metabolism 
  By and large catecholamines are either deaminated (i.e., through MAO), or O-
methylated (i.e., through COMT), and the journey along each of these respective pathways 
is related to whether the catecholamines themselves are of intra- or extra-neuronal origin.  
Within nerves, noradrenaline and adrenaline are metabolised by MAO into an aldehyde 
metabolite 3,4-dihydroxyphenylglycoaldehyde (DOPEGAL).  Due to the presence of a β-
hydroxyl group DOPEGAL is largely metabolised by AR to form 3,4-
dihydroxyphenylglycol (DHPG), with only a small fraction of DOPEGAL metabolised by 
AD into 3,4-dihyroxymandelic acid (Eisenhofer et al., 2004a).  Following its conversion 
into DHPG, the noradrenaline metabolite is then O-methylated into 3-methoxy-4-
hydroxyphenylglycol (MHPG) via catechol-O-methyltransferase (COMT) and sequentially 
metabolised to 3-3-methoxy-4-hydroxyphenylglycolaldehyde (MOPEGAL) by alcohol 
dehydrogenase (ADH), and subsequently into vanillylmandelic acid (VMA) via AD.  The 
major end product of noradrenaline and adrenaline metabolism is VMA (Armstrong & Mc, 
1959).  Up to 94% of VMA is produced in the liver, which is able to convert almost all 
inflowing catecholamines and their metabolites into VMA.  Of the hepatic derived VMA, 
approximately 87% is through the metabolism of MHPG and DHPG, 11% via 
noradrenaline and adrenaline and less than 2% via the major catecholamine metabolites 
from the adrenal medulla, normetanephrine and metanephrine (Eisenhofer et al., 1996a).  
Thus, the production of VMA provides a more accurate indication of catecholamine 
metabolism within nerves than in the adrenal medulla.   15 
Neuronal vs adrenal catecholamine metabolism 
  The ability to distinguish between adrenal or extra-adrenal sources is a clinical 
necessity.  That the metabolites of neuronal and extraneuronal (intra-adrenal) pathways 
possess significant differences has important implications for understanding 
catecholaminergic systems in disease, including the ability to differentiate between elevated 
plasma catecholamines due to increased sympathetic activity, such as observed in essential 
hypertension, from conditions with elevated adrenal catecholamines such as 
phaeochromocytoma.    
Sympathetic nerves contain MAO, but not COMT.  Thus within sympathetic nerves 
noradrenaline is deaminated by MAO to yield DHPG.  Consequently DHPG represents the 
major intra-neuronal metabolite of noradrenaline (Graefe & Henseling, 1983).  Chromaffin 
cells contain both MAO and COMT, and the form of COMT found within chromaffin cells 
is a membrane bound form of the enzyme with a greater affinity for substrate than the 
soluble form found in other tissues such as the kidney and liver (Roth, 1992, Eisenhofer et 
al., 1998).  Consequently, within chromaffin cells the O-methylation of noradrenaline and 
adrenaline by COMT to form normetanephrine and metanephrine respectively represents 
the major pathway of intra-adrenal catecholamine metabolism. The adrenals are the largest 
contributor to O-methylated metabolites present within the circulation.  In humans 
approximately 93% of circulating metanephrine, and 25 – 40% of circulating 
normetanephrine is derived from the adrenals (Eisenhofer et al., 1995b).  Thus plasma 
DHPG indicates intra-neuronal metabolism and activity, whereas plasma metanephrine and 
normetanephrine provide an indication of metabolism of catecholamines in the adrenal 
medulla or extraneuronal tissues.    16 
IV.  The Adrenal Medulla 
 
  When Oliver and Schäfer (1894) made their discovery that purified adrenal extracts 
have a potent pressor effect, they set the stage for two important discoveries.  Firstly, that 
catecholamines have a potent effect on blood pressure and secondly that catecholamines are 
found within the adrenal gland.  The adrenal medulla represents approximately 10% of the 
total mass of the adrenal gland, and is embryologically derived from the neural crest. The 
major cell type of the adrenal medulla is the chromaffin cell, a modified postganglionic 
neuron of sympathetic origin void of neuron specific traits such as dendrites and axons 
(Hodel, 2001).  It has since been discovered that the adrenal catecholamines are synthesised 
and stored within chromaffin cells, with the name chromaffin cell, assigned by Alfred 
Kohn, due to the profound colourific “chromaffin reaction” observed when these cells are 
exposed to (di)chromate salts (Kohn, 1902). The adrenal medulla also contains minor 
populations of small intensely fluorescing (SIF) cells and cholinergic or noradrenergic 
ganglionic neurons (Aunis & Langley, 1999, Tischler, 2002). Although the largest 
population of chromaffin cells is found within the adrenal, extra-adrenal chromaffin cells, 
termed paraganglia, are also found in the retroperitoneum, pre-aortic region (the organ of 
Zuckerkandl) and the carotid body (Langley & Grant, 1999). 
  A hallmark feature of chromaffin cells is the presence of a cytoplasmic organelle 
known as chromaffin granules, in which catecholamines and other protein constituents are 
packaged (Coupland, 1965b) and concentrated to levels suggested to be up to 10,000-fold 
higher than within the cytosol (Parsons, 2000).  Chromaffin granules (also known as dense 
core granules, DCGs) are the chromaffin cell equivalent of the large dense core vesicle   17 
(LDCV) of sympathetic neurons.  However both chromaffin granules and LDCVs are a 
membrane bound organelle, which contain catecholamines in a storage complex with other 
peptides and proteins (Winkler, 1993).  Although catecholamines make up a large 
proportion of the chromaffin granule cargo, other substances are also stored alongside 
catecholamines including secretogranins, chromogranins, enkephalins, dynorphin, galanin, 
vasoactive peptide (VIP), substance P, neurotensin, somatostatin, calcitonin gene related 
peptide (CGRP) and neuropeptide Y (Langley & Grant, 1999, Laslop & Mahata, 2002). 
  Morphologic differences between adrenaline- and noradrenaline-containing 
chromaffin granules have been detected.  Adrenaline-containing granules possess a round 
shape with moderate electron density, and are between 50 – 300 nm in diameter. In 
contrast, noradrenaline-containing granules are oval, elliptical or irregular in shape, have 
larger dimensions than adrenaline granules, and possess a strongly electron dense content 
often eccentrically located core (Coupland, 1965a, Crivellato et al., 2006b). 
The Developmental Lineage of Chromaffin Cells 
  Cells of the sympathetic nervous system, including sympathetic nerves and 
chromaffin cells, in addition to a diverse array of cells autonomous of the sympathetic 
nervous system ranging from connective tissue to melanocytes are derived from the neural 
crest, a transiently expressed and early embryonic para-axial structure. The neural crest 
originates at the edge of the neural grove and subsequently emerges from the dorsal surface 
of the neural tube (Le Douarin & Kalcheim, 1999, Vaglia & Hall, 1999, Mora & Gerald, 
2004, Huber, 2006) allowing the formation of three distinct branches: the cranial, cardiac 
and trunk branches, which are derived according to the position from which the respective 
branches originate along the embryonic axis and also the cell types formed from each   18 
branch (Le Douarin & Kalcheim, 1999, Vaglia & Hall, 1999, Huber, 2006).  The first 
branch of the neural crest is the cranial branch which gives rise to cells which develop into 
many of the structures of the craniofacial skeleton including connective tissue, cartilage, 
bone, odontoblasts of teeth and neurons and glia of the cranial ganglia (Bronner-Fraser, 
1995). The second branch of the neural crest, the cardiac (vagal) branch, which is essential 
for the development of neuronal and ectomesenchymal components of the heart, aorta and 
pulmonary arteries, and connective tissue to the thyroid, thymus and parathyroid glands 
(Kirby, 1988, Vaglia & Hall, 1999).  The final branch of the neural crest, the trunk region, 
is responsible for the generation of pigment cells (melanocytes), sensory neurons, glia, 
Schwann cells and the sympathoadrenal cell lineage (Bronner-Fraser, 1995, Huber, 2006). 
Cells of the sympathoadrenal lineage aggregate at the dorsal aorta and subsequently migrate 
to distinct locations (Figure 1.4), and develop into catecholamine containing sensory and 
sympathetic neurons, adrenal- and extra-chromaffin cells and SIF cells (Le Douarin & 
Kalcheim, 1999, Huber, 2006).     19 
 
Figure 1.4  Migratory pathway of neural crest progenitors giving rise to the two major 
pathways of the sympathoadrenal lineage.   20 
 
The transition from trunk neural crest progenitor cell to fully differentiated 
sympathoadrenal cells (i.e., the development of sympathetic nerves versus chromaffin cells) 
is classically thought to occur as a result of exposure of these immature cells to various 
environmental cues.  
Are glucocorticoids the key to chromaffin cell development?   
  That environmental signals are required for sympathoadrenal differentiation and 
migration is undebated. In spite of this, the specific cue(s) required has been a longstanding 
source of uncertainty. For the last two decades, glucocorticoids were the leading candidate 
underscoring the transition of an immature cell to differentiated adult chromaffin cell.  
According to this hypothesis progenitor cells migrating to the adrenal are exposed to a 
glucocorticoid rich microenvironment (via the adrenal cortex) and are consequently 
prompted “in house” to differentiate into chromaffin cells.  In contrast, the same progenitor 
cells migrating to the primary ganglia, are not exposed to glucocorticoids, and thus develop 
into sympathetic nerves.  Largely this assumption was based on in vitro data demonstrating 
that cultured chromaffin cells treated with nerve growth factor (NGF) develop a neuronal 
phenotype, while cultures treated with glucocorticoids retained an endocrine phenotype 
(Unsicker et al., 1978, Bohn et al., 1981, Doupe et al., 1985, Anderson & Axel, 1986).  The 
ability of glucocorticoids to suppress the development of a neuronal pathway was further 
thought to occur by inhibiting the ability of neurotrophic factors such as NGF to promote a 
neuronal phenotype (Anderson, 1993), and possibly this effect was due to sites on the 
glucocorticoid receptor for regulatory factors which in PC12 cells (an in vitro chromaffin 
cell model), can block NGF-induced neuronal differentiation (Barrett & Vedeckis, 1996,   21 
Medina-Ortiz & Garcia-Arraras, 2000).  However, with the advent of the post-genomic 
era, the development of knockout animals has cast new light on the mechanisms regulating 
the development of the sympathoadrenal system and fundamentally challenged the absolute 
requirement of glucocorticoids in this process.   In particular, glucocorticoid receptor (GR) 
knockout mice, which despite being insensitive to the effects of glucocorticoids, 
demonstrate normal chromaffin cell development including proper migration to the adrenal 
analgen and the development of typical chromaffin cell machinery, such as chromaffin 
granules (Finotto et al., 1999). Steroidogenic factor-1, is an orphan nuclear receptor 
implicated in the regulation of steroid hydroxylases that has been shown to be an absolute 
requirement of the development of the adrenal cortex and gonads (Luo et al., 1994). 
Knockout mice where the steroidogenic factor-1 has been eliminated lack an adrenal cortex 
and gonads, but develop differentiated chromaffin cells which again show proper migration 
(Luo et al., 1994, Gut et al., 2005).  Together these data fundamentally challenge the 
longstanding theory that glucocorticoid cues govern the proper migration and 
differentiation of sympathoadrenal progenitors.  
If glucocorticoids don’t govern chromaffin cell development, what 
factors do? 
  Beyond the glucocorticoid hypothesis of sympathoadrenal development a central 
questions remains: what factors govern sympathoadrenal migration and differentiation? 
Several genes have been implicated as key putative cues necessary for the transition of 
trunk neural crest progenitors to fully differentiated cell types.  Although a single gene 
which co-ordinates the process is yet to be identified other candidates with a crucial role to 
play have been identified.  For instance, Sox10 is expressed in all neural crest cells as they   22 
emerge from the neural tube and allows neural crest cells to maintain the glial and neuronal 
differentiation pathways.  The extinction of Sox10 prevents cells from continuing along the 
pluripotentiality of the neural crest lineage, causing them to develop into smooth muscle 
(Kim et al., 2003).  Exposure to bone morphogenetic proteins (BMPs), including BMP2/4 
and BMP7, produced at the area dorsal aorta, also appear to play a vital role in the direction 
of cells down a sympathoadrenal pathway (Reissmann et al., 1996, Shah et al., 1996, 
Schneider et al., 1999). In the chick embryo BMP4 and BMP7, in particular, are thought to 
be crucial (Reissmann et al., 1996).  The ablation of BMP function by noggin, a BMP 
antagonist, also rescinds expression of enzymes characteristically expressed by 
sympathoadrenal cells including TH and DBH (Schneider et al., 1999).  Although solid 
empirical data confirming the role of BMPs on the mammalian embryo is currently lacking, 
these genes are also presumed to play a similar in vivo role in mammals. While the critical 
role of BMPs is explicit, other signals are almost certainly needed, as BMPs are also 
necessary for the development of cells not related to the sympathoadrenal lineage such as 
parasympathetic neurons (Muller & Rohrer, 2002).  Intense interest has been directed 
towards the transcription factors mammalian achaete-scute homolog 1 (MASH-1; also 
called ASCL1) and the paired homeobox domain gene (PHOX2B).  It has been 
demonstrated that both Phox2b and MASH-1 are essential for the acquisition of 
catecholaminergic and sympathoadrenal traits in neural crest cells and are thought to 
regulate the activity of transcription factors such as dHAND and PHOX2A (Brunet & 
Pattyn, 2002).  MASH-1 is a helix-loop-helix transcription factor transiently expressed in 
all neural crest derived autonomic progeny (Guillemot & Joyner, 1993).  In the chick 
embryo, MASH-1 expression appears prior to BMP4 in the dorsal aorta (Ernsberger et al.,   23 
1995), and the ablation of BMP4 by noggin reduces MASH-1 levels but does not impair its 
expression entirely, suggesting that MASH-1 may appear before BMP4 (Schneider et al., 
1999).  Mice lacking MASH-1 develop primary sympathetic ganglia but lack an autonomic 
nervous system.  These animals also fail to express typical neuronal markers such as 
SCG10 and peripherin, while the expression of other markers necessary for neural crest 
differentiation including Phox2b, c-RET and Hand2 are unaffected, (Howard et al., 2000).  
Most chromaffin cells in MASH-1 null mice develop abnormally and display the 
ultrastructural features of an immature neuroblast (Huber et al., 2002), but interestingly, a 
fraction (~20%) of chromaffin cells in MASH-1 null animals develop normally and express 
typical chromaffin cell features such as chromaffin granules, TH and PNMT.  The 
homeodomain transcription factor PHOX2B, is found in all central and peripheral 
noradrenergic nerves, in addition to many nerves involved with autonomic pathways 
(Dauger et al., 2003).  Similarly, PHOX2B deficient mice show severely impaired 
autonomic development, reduced MASH-1 expression and abolished expression of 
downstream sympathoadrenal genes including c-RET, neurofilament, TH, PHOX2a and 
Hand2 (Huber et al., 2005). The phenotype of chromaffin cells in Phox2b null mice also 
appear more structurally immature than MASH-1 null mice, and unlike MASH-1 
knockouts where a small fraction of chromaffin cells appeared to develop and differentiate 
normally, in the Phox2b knockout normal chromaffin cell development was not 
demonstrated (Huber et al., 2005).  Thus, Phox2b is important for the maintenance of 
MASH-1 and has a fundamental role in the proper differentiation of chromaffin cells 
(Guillemot & Joyner, 1993, Sommer et al., 1995, Huber et al., 2002, Huber et al., 2005).  
However, while the appearance and expression of the transcription factors Phox2b and   24 
MASH-1 appear crucial to the acquisition of a catecholaminergic phenotype and the correct 
differentiation of developing sympathoadrenal cells, studies on mice lacking Phox2b and 
MASH-1 clearly demonstrate that neither are an absolute requirement for the migration of 
immature progenitors cells into the adrenal analgen.  The search continues for the specific 
cues necessary to prompt correct cell differentiation from progenitor to mature cell type. 
Don’t give up on glucocorticoids just yet… 
  In several species there are two populations of adrenal chromaffin cells routinely 
delineated according to whether the cells express PNMT and thus possess an adrenergic 
(PNMT positive) or noradrenergic (PNMT negative) phenotype.  In species such as the rat 
and mouse approximately 85% of cells express PNMT, while in other species such as the 
rabbit all chromaffin cells contain PNMT (Suzuki & Kachi, 1996).  Why these two separate 
populations of chromaffin cells exist, and how they are generated remains a mystery, but 
several lines of evidence suggest a dependence on glucocorticoids for PNMT expression.  
Several extra-adrenal tissues show PNMT expression and activity, including the kidney and 
spleen (Kennedy et al., 1995), the retina (Ziegler et al., 2002), brainstem (Bohn & Engele, 
1992) the embryonic and adult rat heart (Huang et al., 2005).  Altogether, this may suggest 
that while the close spatial proximity of PNMT expressing cells to steroidal sources, such 
as seen with the adrenal gland, may not be necessary, it strongly implies a relationship 
between the two factors, where steroidal cues are required for the induction and 
maintenance of PNMT expression.   
  Although the role of glucocorticoids in the migration and differentiation of 
sympathoadrenal cells has been largely disproved, there is still strong evidence for a crucial 
role of glucocorticoids in the induction and maintenance of PNMT expression and an   25 
adrenergic phenotype.  As discussed, glucocorticoid receptor and steroidogenic factor-1 
knockout mice have impaired development of the adrenal cortex but exhibit largely normal 
chromaffin cell development, with the exception of PNMT expression, which is notably 
absent in both animal strains (Luo et al., 1994, Finotto et al., 1999, Gut et al., 2005).  
Interestingly, work by Ceccatelli et al, suggest that the glucocorticoid receptor is 
preferentially expressed in adrenergic chromaffin cells of the rat and absent from 
noradrenergic cells (Ceccatelli et al., 1989) hinting at a mechanistic link between the 
disappearance of PNMT in glucocorticoid knockout mice, which still demonstrate normal 
numbers of noradrenergic chromaffin cells.  Equally, in hypophysectomized animals, there 
is a decrease in PNMT mRNA and protein levels (Evinger, 1998), which can be rescued by 
the administration of the synthetic glucocorticoid dexamethasone. Other work linking the 
temporal appearance of chromaffin cells within the adrenal to the induction of PNMT 
expression, have advocated a critical relationship between glucocorticoids and PNMT 
(Unsicker et al., 1978, Bohn et al., 1981, Doupe et al., 1985, Anderson & Axel, 1986).  
Together these data support the hypothesis that glucocorticoids are necessary for proper 
PNMT expression.   
Cortical – chromaffin cell interactions:  a reciprocal agreement 
  Although the influence of adrenal glucocorticoids is an important factor in the 
induction of PNMT expression in medullary chromaffin cells, it may also be necessary for 
the maintenance of PNMT expression as observed by the reduced levels of adrenaline in 
patients with Addison’s disease (Bornstein et al., 1995).  However, the effect of 
glucocorticoids on chromaffin cells also hints at a much larger relationship in place 
between the cortex and medulla.  The neuroactive steroid dehydroepiandrosterone (DHEA)   26 
and the sulfate conjugate dehydroepiandrosterone-sulfate (DHEAS), secreted from the zona 
reticularis layer of the cortex directly adjacent to medulla, are thought to play a peregrine 
role with chromaffin cells where they interact with growth factors to influence chromaffin 
cell proliferation (Sicard et al., 2006, Sicard et al., 2007).  The modulatory effect of DHEA 
and DHEAS are further thought to be age-dependent, with different effects of the respective 
cortical hormones observed in young and adult animals (Sicard et al., 2007).  Given the 
abundance of DHEA/DHEAS secretion from the foetal adrenal cortex (Sicard et al., 2006) 
the modulatory action of the cortical hormones, beyond glucocorticoids, may represent an 
additional factor in adrenal development.  However, the “cross-talk” between the cortex 
and medulla is not restricted to an effect of the cortex on the medulla.  For example, 
TH/tyrosinase knockout mice demonstrate marked structural and functional changes in 
cortical cells in addition to reduced plasma levels of corticosterone (Bornstein et al., 2000) 
indicating that proper adrenomedullary function is also required for proper cortical function 
and vice versa.  
In-vitro chromaffin cell models 
  The rat PC12 cell line derived from a rat adrenal phaeochromocytoma was 
generated in the mid 1970’s (Tischler et al., 1976) and has since been a valuable in vitro 
model for research on chromaffin cells and phaeochromocytoma, in addition to neuronal 
and endocrine systems.  Because PC12 cells possess all the necessary machinery for 
catecholamine synthesis, storage, release and reuptake they are equally useful for studying 
catecholaminergic systems.  Exposing PC12 cells to NGF also promotes differentiation 
whereby cells adopt neuronal traits including neurite outgrowths (Tischler et al., 1976).  In 
contrast, when treated with the synthetic glucocorticoid dexamethasone PC12 cells adopt a   27 
neuroendocrine phenotype (Tischler et al., 1983).  However, unlike most adrenal 
chromaffin cells, PC12 cells do not express the enzyme PNMT.  In contrast, the murine 
MPC cell line, derived from a heterozygous neurofibromatosis knockout mouse strain 
(Powers et al., 2000) express endogenous PNMT (Powers et al., 2000).  Similar to 
mammalian adrenals in which distinct sub-populations of adrenergic and noradrenergic 
cells are observed, similarly, MPC cells show clusters of PNMT-positive and PNMT-
negative MPC cells (Dixon et al., 2005).  The observation that MPC cells develop in 
culture in a tight three dimentional clusters (Dixon et al., 2005) with cell-to-cell contact, 
which has been suggested to be a necessary factor required the maintence of endogenous 
PNMT expression in MPC cells (Powers et al., 2000).   
V. The Three R’s regulating catecholamines:  Release, 
Reuptake & Recycling 
Introduction 
  The activation of preganglionic sympathetic nerves from central pathways and 
release of the neurotransmitter, acetylcholine serves as the overture leading to 
catecholamine release from the adrenal medulla.  Upon binding of acetylcholine to 
nicotinic receptors, present on the cell surface, depolarisation occurs allowing an influx of 
Ca
2+ into the cell triggering a cascade of events leading to the release of chromaffin cell 
contents into the interstitial space where they act locally as paracrine substance, or enter the 
circulation to act on distant targets as endocrine hormone. 
Plasma catecholamine levels in excess of 10
-6 mol/L
-1 can have disastrous effects on the 
individual, and at this concentration have the potential to cause serious adverse events   28 
including heart failure, pulmonary oedema, stroke or hypertension-induced coma (Aunis & 
Langley, 1999).  Surprisingly, reports suggest that these levels can be obtained by the 
release of approximately 5% of the total adrenomedullary pool (Aunis & Langley, 1999).  
Thus, with up to 95% of adrenal catecholamine stores still available for release, the adrenal 
gland appears to contain a massive arsenal of “weapons of mass destruction”.  Therefore, 
catecholamine concentrations must be policed with extreme precision to avert the 
catastrophic events that can be caused when circulating catecholamines are in excess.   
Catecholamine concentrations are regulated on three separate but complementary fronts:  
(i) regulated release via exocytosis, (ii) reuptake into the cell following release via specific 
catecholamine transporters such as the noradrenaline transporter (NAT) and (iii) recycling 
from the cytoplasm into storage vesicles via the actions of vesicular monoamine 
transporters (VMATs).  Disruptions to one or all of these systems can have dangerous 
implications for the individual, as observed from conditions such as orthostatic intolerance 
or heart failure (e.g., altered catecholamine transporter function and/or expression) and 
phaeochromocytoma (e.g., inappropriate catecholamine release and storage).  
Gettin’ stuff out: Release 
Constitutive versus regulated secretion 
  Proteins are released from cells via exocytosis, however the mechanics leading to 
this event differ according whether exocytosis occurs as a part of a constitutive or regulated 
exocytotic pathway.  The constitutive mode of exocytosis is a continuous process limited 
by the availability of product and driven by synthesis.  In this setting, release is dictated by 
synthesis of proteins within the trans-Golgi network, and proteins are destined for rapid   29 
fusion with the plasma membrane and rapid release into the extracellular space 
(Ponnambalam & Baldwin, 2003).  The adrenocortical hormones cortisol and aldosterone 
are secreted along this pathway.  In comparison, in the regulated secretory pathway, 
synthesised substances destined for secretion are packaged and stored into secretory 
vesicles, and modulated by secretagogues, allowing for massive and rapid discharge of 
stored proteins at a physiologically suitable moment (Halban & Irminger, 1994, Taupenot 
et al., 2003).  Other fundamental differences between the two pathways relate to the 
kinetics of release.  In the constitutive pathway, secretion occurs at a constant rate, whereas 
in the regulated pathway, proteins can be stored in granules for substantial periods before 
they are released (Halban & Irminger, 1994, Taupenot et al., 2003).  Exocytotic release 
from chromaffin cells occurs via regulated secretion, and chromaffin cells are regularly 
used as a model in the study of the regulated secretory pathway  
“Full Fusion” exocytosis 
  The mechanism by which exocytosis in chromaffin cells operates remains a 
controversial topic, and a number of alternative methods have been hypothesised.  The 
oldest and simplest is the “full fusion”, or “all-or-nothing” model, which describes a 
process whereby the vesicle membrane comes into close proximity to, and then fuses with, 
the plasma membrane, discharging the entire vesicle load into the extracellular space 
(Viveros et al., 1969, Heuser & Reese, 1981, Aunis, 1998). As described previously, 
catecholamines and other neuropeptides are packaged within the same storage vesicles, thus 
the “full fusion” model assumes that both transmitters are released simultaneously.  It has 
been suggested that the “full fusion” model is physiologically relevant during acute stress   30 
and/or sympathetic activation, and in this context, release of both catecholamines and other 
biogenic amines is observed (Takiyyuddin et al., 1994, Fulop et al., 2005). 
“Kiss-and-run” exocytosis  
  The “full fusion” model of exocytosis is at odds with numerous data showing that 
catecholamines and peptides are differentially released depending on the type and intensity 
of stimuli (Takiyyuddin et al., 1990, Takiyyuddin et al., 1994, Giampaolo et al., 2002). 
Consequently, theories taking into account differential transmitter release have been 
developed.  A leading contender is the “kiss-and-run” hypothesis, in which the vesicular 
membrane does not completely fuse with the plasma membrane but forms a transient fusion 
pore, which rapidly closes following the release of stored material, pinching the vesicle 
membrane back from the plasma membrane (Palfrey & Artalejo, 2003).  Significantly, 
“kiss-and-run” exocytosis also implies that unlike “full fusion”, only a fraction of the 
vesicular contents are released. The “kiss-and-run” theory of exocytosis appears to support 
the requirements of the cell at steady state levels when basal catecholamine release 
maintains sympathetic tone.  According to the “kiss-and-run” model, a size exclusion 
process enables smaller catecholamine molecules to be released through a restricted fusion 
pore while larger neuropeptides are retained within the vesicle, whereas increased 
sympathetic activity, such as during acute stress, causes fusion pore dilation allowing the 
release of both transmitter types (Fulop et al., 2005, Fulop & Smith, 2006).  Based upon the 
variety of molecules stored in chromaffin granules, and the different size, solubility and 
electrical charge of each, it seems plausible that pore size could act as a molecular sieve 
allowing regulation of chromaffin granule release (An & Zenisek, 2004).  This model of   31 
release is also more compatible with differential release of transmitters from within the 
same vesicular pool (Fulop & Smith, 2006).   
Piecemeal degranulation? 
  Another alternative to “full fusion” or “kiss-and-run” exocytosis is a process known 
as piecemeal degranulation, whereby discrete packets of transmitter detach from the vesicle 
membrane, transferring small quanta of granule cargo to the plasma membrane for 
subsequent release (Crivellato et al., 2003, Crivellato et al., 2004, Crivellato et al., 2005, 
Crivellato et al., 2006b).  In this process, unlike “full fusion” and “kiss-and-run”, granule-
to-granule or granule-to-membrane fusion does not occur.  Although this form of release is 
typically associated with mast cells (Dvorak, 1998), homologous to chromaffin cells, mast 
cells store immune mediators (e.g., cytokines, chemokines), which have devastating 
consequences if released in excess.  Thus piecemeal degranulation provides the foundation 
for a tightly governed mechanism of catecholamine release, particularly during resting 
conditions (Crivellato et al., 2006a).  
 
  The three alternative models of exocytosis each contain concepts that help explain 
aspects of exocytosis observed within chromaffin cells, but when viewed in isolation, are 
not without flaws, and do not adequately provide a model which explains the many 
elements of exocytosis observed.  Alternatively, it is also possible that exocytosis exists 
along a continuum where elements of each models has a role to play, depending on factors 
such as the transmitter to be released (e.g., catecholamines vs. other peptides) and/or the 
level of stimuli present.  Having three distinct but complementary mechanisms in place to   32 
control release also appears to be a feasible option for a system that must be intricately 
regulated.   
Gettin’ stuff back in. Reuptake:  Catecholamine Transporters 
Catecholamine Transporters  
  Following release, catecholamine clearance from the extracellular space occurs 
along two major pathways, (i) dilution as catecholamines enter the circulation (Roth, 1995, 
Gainetdinov et al., 2002, Gainetdinov & Caron, 2003) and (iii) through the active 
sequestration of released catecholamine back into the cell (Phillips et al., 2001, 
Gainetdinov et al., 2002) by specialised transporters.  Largely this process is mediated by 
the actions of specific monoamine transporters, also known as the uptake -1 system.  
However a less specific uptake-2 system is also capable of catecholamine transport.  
Catecholamines are highly polar chemicals, which do not readily cross plasma membranes 
unassisted (Eisenhofer, 2001).  Thus, they require a system of active transport to facilitate 
their reuptake into the cell.  These transporters are incredibly important modulators of 
neuronal or extra-neuronal catecholamine mediated transmission and are a highly specific 
and effective mechanisms necessary for the removal of catecholamines from the 
extracellular environment.  
Molecular characteristics of catecholamine transporter 
  In 1961 Axelrod and colleagues made the important discovery that noradrenaline 
uptake is ablated by the application of tricyclic antidepressants and cocaine (Axelrod et al., 
1961).  It is now appreciated that this process is mediated through the actions of a substrate   33 
specific monoamine transporter (or uptake-1) system.  Catecholamine transport occurs via 
either the noradrenaline (NAT) or dopamine (DAT) transporters in a Na
+- and temperature 
dependent process, with a high affinity but low capacity for catecholamines (Eisenhofer, 
2001).  
  The noradrenaline and dopamine transporters belong to the solute carrier (SLC) 
supergene family, which includes members of the Na
+/Cl
 - dependent substrate-specific 
neuronal membrane transporter (Zahniser & Doolen, 2001).  The noradrenaline transporter 
was first cloned by Pacholczyk and colleagues, and led to the discovery that NAT and γ-
aminobuturic acid (GABA) transporters share significant sequence homology.  Following 
this discovery, the gene family for neurotransmitter proteins was identified including 
transporters for serotonin (SERT), glycine, taurine, proline, betaine and creatine (Zahniser 
& Doolen, 2001, Gainetdinov & Caron, 2003). The Na
+/ Cl
 - dependent transporters are 
composed of a single subunit with 12 transmembrane domains, including intracellular 
amino- and carboxyl- termini, and a large extracellular loop extending from trasmembrane 
regions 3 and 4, which contains multiple glycosylation sites (Pacholczyk et al., 1991).   
  Catecholamine transporters are critical regulators of transmission, and alterations to 
catecholamine transporter systems can have dramatic down-stream effects on the entire 
catecholaminergic system, including alterations to intensity and duration of transmission. 
For instance DAT knockout mice, have substantially depleted dopamine stores (<5% of 
wildtype), and consequently also exhibit decreased neuronal dopamine release and 
increased extra-neuronal dopamine metabolism and synthesis (Jones et al., 1998).  Equally, 
noradrenaline clearance is also affected in NAT null mice, which have diminished 
noradrenaline storage and release, and prolonged extracellular clearance, which leads to   34 
increased extracellular noradrenaline concentrations, increased extra-neuronal 
noradrenaline metabolism and increased noradrenaline synthesis (Xu et al., 2000).  These 
data also highlight the adaptive response brought about by other aspects of catecholamine 
pathways such as increased extra-neuronal metabolism, synthesis to help counter the loss of 
uptake mechanisms.    
  The catecholamine transporters have an important role to play in vivo, but they also 
represent a useful target for clinical manipulation.  Dysfunction in noradrenaline 
transmission has been implicated in depression (Klimek et al., 1997) and monoamine 
transporters therefore provide a pharmacologic target for the treatment of depression.  
Altered NAT activity and/or expression have also been suggested to be a contributing 
factor in the clinical presentation of orthostatic intolerance (Shannon et al., 2000, 
Robertson et al., 2001) and congestive heart failure (Eisenhofer et al., 1996b, Gerson et al., 
2003).  The noradrenaline transporter can also be utilised as an uptake mechanism for 
radiolabelled catecholamine analogues during functional imaging studies of neuroendocrine 
tumours including carcinoids (Macfarlane et al., 1996), neuroblastoma (Claudiani et al., 
1995, Howman-Giles et al., 2007) and phaeochromocytoma (Castellani et al., 2000, Pacak 
et al., 2001, Ilias et al., 2003), and sympathetic nerves in conditions such as pure 
autonomic failure (Tipre & Goldstein, 2005). 
Regulation of transporter systems 
  Monoamine transporters are regulated on at least two different levels, including 
transcriptional (e.g. by altering transporter synthesis) and post-translational (e.g., altering 
activity through glycosylation and intracellular trafficking).     35 
Transcriptional regulation of transporter expression can be driven by a variety of factors 
including substrate concentration. Lee and colleagues (1983) found that following the 
administration of reserpine (an irreversible VMAT antagonist), radioactive desipramine 
(DMI; a non-selective monoamine transporter antagonist) binding to central and peripheral 
noradrenaline was reduced (Lee et al., 1983).  The depletion catecholamine stores (by 
reserpine) causes decreased substrate availability, and subsequently the down regulation of 
catecholamine transporter molecules.  In contrast, radioactive DMI binding was increased 
when catecholamine deamination was blocked by inhibiting the cytoplasmic enzyme MAO. 
Thus decreasing intra-neuronal metabolism (by the MAO inhibitor) leads to increased 
release and increased synthesis if NAT (Lee et al., 1983) as the cell attempts to recoup the 
lost catecholamines.  On the other hand, reserpine treatment, which depletes catecholamine 
stores by not allowing leaked catecholamines to be recaptured back into storage vesicles, 
causes NAT down-regulation, but TH up-regulation in an apparent attempt to regulate 
extracellular noradrenaline concentrations through increases substrate synthesis but 
decreased clearance (Cubells et al., 1995).  However, in contrast, immobilisation stress 
initiates TH and NAT up-regulation in an effort to maintain transmitter levels through 
increased synthesis while simultaneously allowing for increased catecholamine clearance 
(Hoffman et al., 1998).  Together, these data show that the effect of substrate driven 
regulation are related to stimulatory demands placed on the cell, and that catecholamine 
transporters are modulated “divergently or in parallel” (Eisenhofer, 2001) with changes in 
transporter synthesis and/or substrate availability in order to maintain intra- and extra-
cellular catecholamine levels.  Other substrates can also modify catecholamine uptake 
including angiotensin II (Gelband et al., 1998) and nitric oxide (Kaye et al., 2000).   36 
  Post-translational means of transporter regulation generally occur either by way of 
signal transduction mechanisms (e.g., phosphorylation), or altering the glycosylation state 
of the transporter.  The net effects of these changes are to act on trafficking and/or 
functional activity and in this way modulate transporter activity. 
The effect of protein kinase A (PKA) and protein kinase C (PKC) on the phosphorylation 
of catecholamine transporters are the most well documented signal transduction 
mechanisms known to modify transport function.  Although the activation of PKC by 
phorbol esters causes increased phosphorylation and decreased Vmax (Zhang et al., 1997), 
whereas PKA activation leads to decreased phosphorylation and increased Vmax 
(Batchelor & Schenk, 1998, Page et al., 2004), the effects of PKA/PKC activation on 
transporter function are due to changes in the cell surface expression, and thus the ability 
for transporter to interact with substrate, rather than altering the catalytic capacity of the 
molecule (Apparsundaram et al., 1998, Pristupa et al., 1998, Melikian & Buckley, 1999).   
Other agents including neuramidase and tunicamycin have also been found to decrease 
transporter Vmax and catecholamine uptake (Zaleska & Erecinska, 1987, Zhu & Hexum, 
1992) by inhibiting glycosylation.  Others have shown NAT splice variants with reduced 
transporter activity and cell surface expression have been linked to reduced glycosylation 
capacity (Melikian et al., 1994).  Furthermore, mutant NATs, which lack glycosylation 
sites, have reduced cell surface expression and protein stability (Melikian et al., 1996).  
Therefore, glycosylation represents an important post-translational regulator of transport 
function.     37 
Monoamine clearance is monoamine specific – or is it? 
  The reuptake of the respective catecholamines is not limited to a specific 
transporter.  For instance, although dopamine demonstrates the greatest affinity for DAT, 
noradrenaline and to a lesser extent adrenaline can also be sequestered via DAT 
(Eisenhofer, 2001).  Suprisingly, dopamine is also a much better substrate for NAT than 
noradrenaline or adrenline (Eisenhofer, 2001). Knockout mouse models recapitulate these 
observations of substrate plasticity (Cases et al., 1998, Pan et al., 2001, Moron et al., 
2002).   
  Despite the broad substrate specificity of the respective catecholamine transporters, 
the concept of separate mechanisms for dopamine and noradrenaline uptake within the 
brain was established through work by Coyle and Snyder, which demonstrated regional 
differences in central noradrenaline and dopamine uptake (Coyle & Snyder, 1969), 
implying that the organisation of catecholamine transporters within the CNS follows a 
specific pattern of expression.  Later work by Lorang et al supported this finding, when 
they demonstrated that catecholamine transporter mRNA corresponds to the specific 
catecholamine-containing cell populations and therefore, DAT and NAT mRNA are only 
found in dopaminergic and noradrenergic cell populations respectively (Lorang et al., 
1994).  These data suggest that the expression of catecholamine transporters is cell-type 
specific, implying that although the catecholamine transporters can accumulate a broad 
range of substrates, the respective transporters are preferentially expressed on specific 
populations of catecholamine producing cells, ergo, NAT is strictly associated with 
noradrenergic neurons, and DAT is strictly associated with dopaminergic neurons.  This 
concept, at least in the peripheral nervous system, is not always the case. Pioneering uptake   38 
studies of tritiated catecholamines by Kent and Coupland (1981) demonstrated that 
adrenergic cells actively transport [
3H]-noradrenline four-times and [
3H]-dopamine twice as 
actively as noradrenergic cells, while the accumulation of [
3H]-adrenaline by adrenergic 
cells was similar to noradrenergic cells suggesting that the adrenergic cells of the adrenal 
medulla are major cell type facilitating catecholamine, especially noradrenaline and 
dopamine reuptake within this tissue (Kent & Coupland, 1981).  Further, in the adrenal 
medulla of rats, NAT expression is found in chromaffin cells with an adrenergic phenotype, 
while NAT expression is conspicuously absent from the noradrenergic populations of 
chromaffin cells (Phillips et al., 2001) again suggesting that the adrenergic cells drive 
catecholamine accumulation in the adrenal medulla.   
Catecholamine transporters also mediate catecholamine inactivation   
  Aside from expression in neuronal and extra-neuronal cells, the catecholamine 
transporters are also found in non-catecholaminergic cell populations such as the placenta, 
lung, kidney and gastrointestinal tract, where the role of the transporters is as a 
catecholamine inactivating mechanism rather than as a step in the process of catecholamine 
recycling.  Expression of NAT has been detected in the placenta and lungs, alongside the 
catecholamine inactivating enzymes MAO and COMT (Bryan-Lluka et al., 1998, 
Eisenhofer, 2001).  The appearance of the machinery required for catecholamine 
inactivation within the placenta is important for the clearance of up to 50% of circulating 
catecholamines in the foetus (Bzoskie et al., 1997).  Within the lungs, NAT is also 
important for the inactivation of catecholamines entering the pulmonary vasculature after 
they pass through the left ventricle (Eisenhofer, 2001).  A large proportion of dopamine 
produced outside the brain is synthesised within extra-neuronal tissues such as the kidneys   39 
and gastrointestinal tract, including the stomach and pancreas (Mezey et al., 1998).  In this 
setting, dopamine is thought to be involved in an autocrine/paracrine (Goldstein et al., 
1995) pathway with implications on gut motility (Walker et al., 2000).  Within the kidneys, 
dopamine is thought to assist in sodium excretion (Lee, 1993).   
And adrenaline clearance in chromaffin cells? 
  The question of how adrenaline clearance occurs within chromaffin cells occurs is 
yet to be answered.  To date, an adrenaline-specific transporter has been identified in the 
bull-frog, Rana catesbiana (Apparsundaram et al., 1997) but no other animal, thus leading 
to speculation that within chromaffin cells an alternative mechanisms of adrenaline 
reuptake occurs, including the possibility that adrenaline utilises a transmission mechanism 
distinct from other monoamines, or that adrenaline reuptake occurs via NAT or other 
monoamine transporters (Phillips et al., 2001) expressed by chromaffin cells.  The 
possibility that adrenaline does not need to undergo rapid reuptake (Lorang et al., 1994) by 
chromaffin cells is also plausible.  The predominant role of adrenaline released from the 
adrenal is to act as a hormone thus since adrenaline is acting on sites distant from where it 
was released, potentially, most adrenaline reuptake occurs via extra-neuronal transporters 
within the periphery. 
Alternatives methods of catecholamine reuptake 
  The solute carrier (SLC) supergene family is an extensive family with over 220 
members of transporters (Jonker & Schinkel, 2004).  Most members of the SCL supergene 
family are highly specialised and possess significant substrate specificity, e.g., the 
catecholamine transporters (i.e., the uptake-1 system), however, other SLC members are   40 
not so specific, such as the SLC22 family which encompass the organic cation transporters 
(OCTs) that comprise the uptake-2 system.  Three OCTs have been identified, OCT1, 
OCT2 and OCT3 (also known as the extraneuronal monoamine transporter; EMT), which 
show broad substrate specificity for endogenous and exogenous substrates (Grundemann et 
al., 1999) including catecholamines and other organic cations.  Similar to SLC6 
transporters, SLC22 transporters are structurally composed of 12-transmembrane domains 
with a large extracellular domain, containing three predicted glycosylation sites, between 
transmembrane domains 1 and 2 (Meyer-Wentrup et al., 1998).   
  The OCTs are largely expressed in non-neuronal, including non-chromaffin tissues, 
where functionally they supplement the role of the specific monoamine transporters in 
catecholamine clearance, especially the inactivation of catecholamines within the 
bloodstream, or those which escape the uptake-1 system.   The OCT1 is expressed in the 
liver, kidney and intestines, while OCT2 has been identified in the kidneys and brain, 
including some catecholaminergic subpopulations.  The OCT3 has been identified in a 
diverse range of non-neuronal tissues including the liver, brain, heart, kidney, retina, 
placenta and in endothelial blood vessels.  The role of uptake-2 as an alternative uptake 
mechanism was initially studied in perfused heart preparations (Iversen, 1965), and isolated 
cardiac myocytes (Graefe & Trendelenburg, 1974).  Uptake-2 is characterised by 
noticeable differences from uptake-1, including a lower affinity, but greater capacity for 
catecholamine transporter.  Unlike uptake-1, uptake-2 is not a Na
+/Cl
 - dependent process, 
and is not inhibited by cocaine or tricyclic antidepressants.  The transport kinetics for the 
respective catecholamines with OCTs differs from that observed with catecholamine 
transporters.  Dopamine is significantly more effectively transported by OCT2, than either   41 
noradrenaline or adrenaline (Grundemann et al., 1998b), while dopamine and adrenaline 
are transported at similar efficiencies by OCT1.  Both are transported at much greater 
efficiency by OCT1 than noradrenaline (Breidert et al., 1998).  In contrast, to the 
catecholamine transporters, adrenaline uptake by OCT3 is much greater than noradrenaline 
or dopamine (Grundemann et al., 1998a, Martel et al., 1999). 
Keepin’ stuff in. Recycling: Vesicular Monoamine Transporters 
  The vesicular monoamine transporters function to sequester cytosolic amines into 
vesicles by exploiting a pH gradient across the vesicle membrane, generated by vaculolar 
H
+-ATP-ases, to propel uptake (Kanner & Schuldiner, 1987, Peter et al., 1995).  Two 
distinct VMATs have been cloned, characterised and mapped to separate gene loci.  
VMAT1 is located at 8p21.3 (Peter et al., 1993) and is encoded by the solute carrier family 
18 member 1 gene (SLC18A1) (Erickson et al., 1992) while VMAT2 is located on 
chromosome 10q25 (Surratt et al., 1993) and encoded by the SLC18A2 gene (Liu et al., 
1992b). The two VMAT proteins are also pharmacologically distinct, with differing 
substrate affinities.  VMAT2 has a three-fold greater affinity than VMAT1 for serotonin, 
dopamine and noradrenaline, and approximately one hundred-fold greater affinity for 
histamine (Erickson et al., 1992, Peter et al., 1994), whereas VMAT1 has a greater affinity 
for adrenaline than VMAT2 (Brunk et al., 2006a).  In adult rats and humans, cell and tissue 
specific expression of the two VMATs differs, with VMAT1 typically occurring in 
(neuro)endocrine cells such as chromaffin cells and enterochromaffin cells in of the 
intestinal tract, whereas VMAT2 is predominantly localised to momoaminergic neurons of 
the CNS and sympathetic nervous system (Weihe et al., 1994, Peter et al., 1995).  
However, VMAT2 is also expressed in a sub-population of chromaffin cells (Peter et al.,   42 
1995), and other locations such as the endocrine pancreas, basophils, mast cells, dendritic 
cells and platelets (Eiden et al., 2004). The important function of VMATs in recycling 
catecholamines is demonstrated by the application of reserpine or tetrabenzine, which 
prevents catecholamine sequestration (Liu et al., 1992b, Liu et al., 1992a, Howell et al., 
1994).  Vesicular filling is regulated from four fronts:  the availability and quantity of 
transmitter molecule, the electrochemical gradient over the vesicular membrane, and via 
heterotrimeric G proteins, Gao2 and Gaq  (Brunk et al., 2006a, Brunk et al., 2006b).  
Leaky Stores 
  Regulated release from chromaffin cells and sympathetic nerves is an important 
facet of catecholaminergic pathways.  The classical interpretation of release in this setting 
is that catecholamines are packaged into vesicles, and exist in a “static environment”, 
awaiting appropriate stimuli to induce exocytosis.  However, a contemporary theory of 
constant vesicular leakage and sequestration within the same cell in catecholamine 
synthesis occurs is emerging (Eisenhofer et al., 2004a).  In this paradigm, neuronal and 
extra-neuronal catecholamines exist in a “dynamic equilibrium” (Eisenhofer et al., 2004a), 
and passively leak from vesicular stores into the cytosol whereby they are recycled back 
into vesicles by VMATs.  Additionally, since VMATs have a greater affinity for 
catecholamines than the enzyme MAO, more of the leaked substrate (upto 90%) is 
recaptured than is metabolised or released by exocytosis (Eisenhofer et al., 1992, 
Eisenhofer et al., 2004a). In situations requiring prolonged increases in cardiovascular 
workload and sympathetic nerve activation the concept of vesicular leakage is an important 
factor in how catecholaminergic systems have adapted to meet the demands of prolonged 
stress.  Using distance running as a model, it has been calculated that exercise at 50% of   43 
maximal capacity causes a 10-fold increase in noradrenaline output from sympathetic 
nerves compared to baseline levels.  However, despite the large noradrenaline output from 
cardiac nerves, catecholamine biosynthesis is only increased 3-fold compared to baseline 
levels.  Since the contribution of biosynthesis in this setting is modest compared to output, 
if the ability to replenish catecholamine stores was reliant on synthesis, demand would 
rapidly outstrip availability and the ability of the organism to maintain the cardiovascular 
workload would be rapidly abated as catecholamine stores rapidly depleted.  However, 
because within this context, leakage from vesicular stores is unchanged, the net loss of 
catecholamines due to exocytosis is around 3-fold which can be compensated for by the 
accompanying 3-fold increase in catecholamine biosynthesis (Eisenhofer et al., 2004a).  
The system of leakage and recycling has implications for the pathophysiology of diseases 
such as heart failure and orthostatic intolerance. 
VI.  Chromaffin Granule Cargo Proteins 
 
Introduction 
  While catecholamines make up a large proportion of the chromaffin granule cargo 
other proteins and peptides are co-stored and co-released with catecholamines.  
Neuropeptide Y (NPY) and chromogranin A (CGA) are highly abundant in chromaffin 
granules and have been implicated as playing a localised role within the adrenal gland, 
including modulating catecholamine release, in addition to other more diffuse hormonal 
roles such as inducing vasoconstriction within the periphery.  In addition, elevated NPY   44 
and CGA concentrations are found in a number of pathologic conditions, including 
phaeochromocytoma and hypertension. 
Neuropeptide Y 
  Neuropeptide Y (NPY) is a tyrosine rich 36 amino acid peptide, first discovered in 
the pig brain (Tatemoto et al., 1982), and then subsequently cloned from 
phaeochromocytoma cDNA (Minth et al., 1984).  The peptide belongs to the pancreatic 
polypeptide hormone family (PP), which also includes the members peptide YY and 
pancreatic polypeptide (Cerda-Reverter & Larhammar, 2000).  All three PP family 
members contain 36 amino acid residues and demonstrate strong sequence homology, with 
70% homology between NPY and PYY, and 50% homology between NPY and PP.  There 
is also strong interspecies NPY sequence homology, in which 22 of 36 (61%) amino acids 
are identical in all species examine thus far, suggesting that NPY is one of the most 
evolutionary conserved proteins known (Cerda-Reverter & Larhammar, 2000). 
Neuropeptide Y has been referred to as a promiscuous peptide due to the array of functions 
in which it has an implicated role including feeding behaviour (Bailer & Kaye, 2003, Arora 
& Anubhuti, 2006), sexual behaviour (Kalra & Kalra, 2004), alcohol sensitivity (Thorsell 
et al., 2005), thermogenesis and energy metabolism (Levine et al., 2004), circadian rhythms 
(Yannielli & Harrington, 2004) and cardiovascular homeostasis. 
In humans, NPY is found at chromosomal position 7p15.1 (Baker et al., 1995), and is 
composed of four exons.  The first exon encodes the 5’ – untranslated region, the second 
encodes a signal peptide and mature NPY sequence, while exon three encodes a dibasic site 
and the main portion of the C-terminal part of NPY (C-PON) and exon four encodes the 
end portion of the C-PON and the 3’ – untranslated region (Silva et al., 2002). The NPY   45 
peptide is synthesised as a larger pre-pro-NPY molecule and translocated to the 
endoplasmic reticulum where the signal peptide is removed generating pro-NPY.  Pro-
NPY1-69 is cleaved at the dibasic site by prohormone convertase yielding NPY1-39 and C-
PON.  The mature amidated NPY is then produced by the sequential truncations of 
carboxypeptidase (NPY1-37) and peptidylglycine α-amidating monooxygenase (NPY1-36). 
The amide moiety on the mature NPY prevents further degradation by carboxypeptidases.  
However, mature NPY can be further truncated to NPY2-36 or NPY3-36 by the actions of 
aminopeptidase P or dipeptidylpeptidase IV (Silva et al., 2002).  The tissue distribution of 
NPY is vast, including numerous brain regions such as the hippocampus, amygdala and 
locus coeruleus (Eva et al., 2006) and abundant expression in sympathetic nerves and 
chromaffin cells.  Other minor populations of NPY occur in the liver (Ding et al., 1997), 
heart, spleen (Lundberg et al., 1989), within a sub-population of parasympathetic nerves 
(Lacroix et al., 1990, Gray et al., 2004) and in endothelial cells of blood vessels (Pernow, 
1989).  
Neuropeptide Y receptors 
  The effects of NPY are mediated by a specific G-protein coupled NPY receptor 
family, which includes six members: Y1 – Y6.  The Y1 receptor is localised predominantly 
in blood vessels and the central nervous system, and the effects of Y1 are mostly post-
synaptic vasoconstriction (Wahlestedt & Hakanson, 1986, Grundemar et al., 1992, 
Wahlestedt et al., 1993).  The Y2 receptor is largely presynaptic and is thought to be 
involved in the inhibition of neurotransmitter release (Potter & Tripovic, 2006) and the Y2 
receptor is localised in the central and peripheral nervous systems, intestines and blood 
vessels (Michel et al., 1998, Caberlotto et al., 2000, Stanic et al., 2006).  The Y3 receptor   46 
is localised to the adrenal medulla where it is thought to regulate catecholamine release 
from chromaffin cells (Cavadas et al., 2001), nucleus tractus solitarius (Lee & Miller, 
1998) and cardiac membranes in the rat (Balasubramaniam et al., 1990).  The Y4 receptor 
does not bind NPY in humans and has a low affinity for NPY in the rat (Lundell et al., 
1995, Lundell et al., 1996), while the Y5 receptor is thought to be involved in feeding and 
regulation of food intake (Kanatani et al., 2000), and is localised centrally in the 
hypothalamus, and peripherally is localised to tissues including the intestines, ovaries, liver 
heart and spleen (Silva et al., 2002).  A sixth NPY receptor has been cloned, termed y6, but 
it’s functional role in humans is yet to be determined (Bromee et al., 2006). 
  All NPY receptors utilise similar signal transduction pathways, generally either via 
Gi or Go G proteins (Silva et al., 2002).  The archetypal responses of NPY receptors involve 
either inhibition of adenylate cyclase (Michel, 1991, Silva et al., 2002), or by regulation of 
intracellular calcium concentrations by mobilizing intracellular stores via inositol 
dependent and independent pathways (Perney & Miller, 1989, Silva et al., 2002).  Other 
pathways which NPY can act on include calcium signaling through Ca
2+ channels, (Michel 
& Rascher, 1995), activation of phospholipase A2 (Martin & Patterson, 1989) or nitric 
oxide (Nilsson et al., 2000).  
  The N- and C-termini of NPY are important for proper binding of NPY to its 
receptors, with the NPY isoforms, NPY2-36 and NPY3-36  (which are truncated at the N-
terminal end), showing decreased affinity and biological activity.  Peptides with C-terminal 
modifications show full activity for Y1 but reduced activity for Y2 (Krause et al., 1992, 
Rose et al., 1995).  Thus, the N-terminal region determines Y1 receptor binding and   47 
activity, whereas, the Y2 receptor binding is dictated by the C-terminus region of NPY 
(Silva et al., 2002).   
Neuropeptide Y: is a sympathetic co-transmitter and a vasoactive 
peptide 
  Sympathetic transmission was originally thought to be driven by noradrenaline as 
the sole sympathetic transmitter, however this process is now known to be governed by by 
at least three transmitters:  noradrenaline, NPY and adenosine triphosphate (ATP) 
(Huidobro-Toro & Donoso, 2004). The peptide is abundant in central and peripheral 
sympathetic nerves, especially in nerve endings surrounding blood vessels, in addition to 
chromaffin cells where it is stored and released with catecholamines and ATP (Huidobro-
Toro & Donoso, 2004).  Neuropeptide Y is a powerful and long-lasting vasoconstrictor 
(Lundberg & Tatemoto, 1982) and important modulator of cardiovascular homeostasis.  
Elevated NPY levels have been detected in a number of diseased states, including 
congestive heart failure  (Kaye et al., 1994), hypertension and in phaeochromocytoma 
patients (Ullman et al., 2002). Circulating NPY released from chromaffin cells or 
sympathetic nerves bind to NPY receptors and in its role as a sympathetic transmitter, NPY 
binds to the Y1 or Y2 receptors.  The Y1 receptor is located post-synaptically, particularly 
at the surface of vascular smooth muscle where it potentiates noradrenaline evoked 
vasoconstriction (Huidobro-Toro & Donoso, 2004).  Pre-synaptic effects of NPY 
modulated by the Y2 receptors are inhibitory, reducing noradrenaline release from 
sympathetic nerves (Wahlestedt & Hakanson, 1986, Malmstrom, 2001).  However, NPY is 
also suggested to modulate haemodynamic effects though interactions with histamine, 
vasopressin, ATP and angiotensin II (Silva et al., 2002).   Neuropeptide Y can also act as   48 
a secretogogue, which modulates catecholamine release from the adrenals, however 
whether the effects of NPY are stimulatory or inhibitory is controversial, with plentiful data 
supporting each response (Higuchi et al., 1988, Hexum & Russett, 1989, Hexum et al., 
1994, Zheng et al., 1997, Hahn & Blakely, 2007).  Functional expression of the Y1, Y2, Y4 
and Y5 receptors has been detected in human chromaffin cells (Cavadas et al., 2001).  The 
NPY evoked catecholamine release in humans has been postulated to occur via the Y3 
receptor (Cavadas et al., 2001), while in mice, catecholamine release is mediated by the Y1 
receptor (Cavadas et al., 2006).  
Chromogranin A 
  Chromogranin – secretogranin or ‘granin’ family members are a unique group of 
acidic, soluble secretory proteins (O'Connor & Frigon, 1984) found ubiquitously in the 
soluble matrix of dense-core secretory vesicles in endocrine tissues and neurons (Iacangelo 
& Eiden, 1995).  The three “classic” granins are chromogranin A (CGA), chromogranin B 
(CGB) and secretogranin II (SG2; also known as chromogranin C [CGC]).   
  Chromogranin A is the best described and most abundant of the granins, 
representing between 7 – 10% of the total cellular protein in adrenal chromaffin cells 
(O'Connor & Frigon, 1984, Eiden et al., 1987).  Located on chromosome 14q32 in humans 
(Modi et al., 1989), CGA was first purified from chromaffin cells (Banks & Helle, 1965, 
Helle, 1966).  Ultrastructural and biochemical studies have since demonstrated that CGA is 
packaged into chromaffin granules in chromaffin cells and into large dense core vesicles in 
sympathetic nerves (Smith & Kirshner, 1967, O'Connor et al., 1991).  
  The physiologic role of CGA is complicated, multifaceted and the source of much 
speculation.  Intensive research over the last two decades has demonstrated that CGA may   49 
perform one or many tasks.  Firstly, CGA has been implicated as a helper or chaperone 
protein during the packaging of secretory granules (Huttner & Natori, 1995) and secondly, 
it is implicated in the regulation of intracellular Ca2
+ levels.  Up to 60% of intracellular 
calcium is stored in secretory granules (Haigh et al., 1989), and more than 99% of 
intracellular calcium within the granule is bound to chromogranins (Bulenda & Gratzl, 
1985).  The chromogranins (A and B) are known to interact with, and activate, the inositol 
1,4,5-triphosphate receptor (IP3R)/Ca2
+ channel, allowing mobilisation of intracellular Ca
2+ 
(Huh et al., 2005).  Subsequent studies have demonstrated that the suppression of CGA/B, 
and the resulting reduction in the number of secretory granules, also decreased the amount 
of IP3 induced intracellular Ca2
+ release (Huh et al., 2005).  Therefore CGA, via its 
interaction with the IP3R, has been identified as a potential modulator of intracellular 
calcium, particular in endocrine and neuroendocrine cells where storage granules are 
present.  A third, and very controversial proposed role for CGA is in secretory granule 
biogenesis.  Kim et al (2001), demonstrated that the downregulation of CGA in 
neuroendocrine PC12 cells caused a pronounced decrease in dense core granules, and also 
that transfecting CGA mRNA into non-neuroendocrine fibroblast cells induced the 
development of CGA immunoreactive dense core granules (Kim et al., 2001), thus the 
authors implicated CGA as a “master on/off switch” in granule biogenesis, sufficient to 
induce granule formation.  However, the possibility that CGA itself is a potential master 
switch of granule biogenesis is difficult to reconcile with the other available data.  For 
instance, CGB has also been shown to possess similar granulogenic capabilities (Huh et al., 
2005) and further, dense core granules can exist in the absence of CGA, and CGA synthesis 
can occur in the absence of dense core granules (Day & Gorr, 2003).  Subsequent studies   50 
have also suggested that the granule formation observed when non-neuroendocrine cells are 
transfected with CGA, is due to the sorting of CGA to lysosomes (Malosio et al., 2004).  
However, work on CGA knockout or transgenic animals or cell lines have demonstrated 
that in the absence of CGA expression, there is also a loss in the number of secretory 
granules (Kim et al., 2005, Mahapatra et al., 2005, Courel et al., 2006).  Thus while it 
appears highly unlikely that CGA alone can commandeer the formation of secretory 
granules, it appears certain that CGA is highly important in granule biosynthesis.   
CGA, chromaffin cells and hypertension. 
  The role of CGA as a “pro-hormone” or “pro-protein” is well established.  Several 
biologically active peptides are cleaved from the parent CGA protein, including 
pancreastatin (human CGA249 – 303) which elevates blood glucose (Tatemoto et al., 1986); 
the vasostatins (vasostatin I [human CGA1 – 76] and vasostatin II [human CGA1-113] which 
cause vasorelaxation (Aardal et al., 1993); chromofungin (bovine CGA47 – 77) and the 
chromomacins (chromomacin I [bovine173 – 194] and chromomacin II [bovine195 – 221] with 
antifungal and bacteriolytic functions (Lugardon et al., 2000, Lugardon et al., 2001) and 
parastatin (porcine CGA347 – 419) which inhibits parathyroid hormone secretion from 
parathyroid chief cells (Fasciotto et al., 1993).  Another CGA derived fragment with 
special implications for chromaffin cells is catestatin (human CGA352-372) (Taupenot et al., 
2000).  In addition to inducing histamine release from mast cells (Kruger et al., 2003) and 
possessing antimicrobial capabilities (Briolat et al., 2005), catestatin also inhibits the 
release of catecholamines from chromaffin cells by acting as a nicotinic receptor 
antagonist, thus potentially acting as an autocrine negative feedback mechanism with the 
capacity to modulate catecholamine from the adrenal (Mahata et al., 1997, Mahata et al.,   51 
2000). Elevated CGA levels have been detected in conditions in which hypertension is a 
presenting feature, including essential hypertension and phaeochromocytoma.  Whether, 
elevations in CGA in the context of essential hypertension or phaeochromocytoma are an 
artefact of increased catecholamine release, or whether they contribute to pathogenesis of 
disease is unclear.  However, alterations to CGA have been implicated as playing a 
modulating role.  Patients with established hypertension, in addition to augmented 
circulating CGA levels, also have reduced plasma catestatin concentrations (O'Connor et 
al., 2002).  Similarly, CGA
-/- mice also have elevated blood pressure relative to normal 
controls, and demonstrate diminished plasma catestatin pools, and hypertension in 
knockout animals can be rescued by the administration of catestatin (Mahapatra et al., 
2005).  Given the specificity of catestatin on chromaffin cells, could this novel braking 
system represent an extra-layer of protection against excessive sympathoadrenal activation 
with special relevance to hypertension in phaeochromocytoma?   
 
Part B – Phaeochromocytoma: Clinical 
characteristic & genetics 
 
VII.  Perspectives on a clinical enigma 
Introduction 
  Phaeochromocytomas are a rare but clinically important neuroendocrine tumour 
arising from chromaffin cells.  Most tumours arise as a sporadically occurring neoplasia.  
However, the development of phaeochromocytoma is also associated with at least four   52 
hereditary endocrine syndromes, including those associated with multiple endocrine 
neoplasia type 2 (MEN 2; due to mutations in the RET proto-oncogene), von Hippel-Lindau 
(VHL; due to mutations in the VHL tumour suppressor gene), the phaeochromocytoma-
paraganglioma syndrome (due to mutations in the succinate dehydrogenase subunits B 
(SDHB), and D (SDHD) and neurofibromatosis Type 1 (NF1; due to mutations of the 
neurofibromin gene) (Neumann et al., 2002b, Bryant et al., 2003).   
The prevalence of the phaeochromocytoma is unknown, but it thought to occur in 0.05 – 
0.2% of individuals with sustained diastolic hypertension (Manger, 2006).  Between 5 – 
25% of phaeochromocytomas are thought to possess metastatic potential, although this 
figure is higher for extra-adrenal tumours or those associated with hereditary forms of the 
tumour (Ahlman, 2006). 
  Phaeochromocytomas are a functional tumour capable of the synthesis, storage and 
release of excess quantities of catecholamines and other components of chromaffin cells, 
including vasoactive intestinal peptide, NPY, adrenocoticotropic hormone, CGA, CGB, 
enkephalins, atrial natriuretic factor, growth hormone releasing hormone, somatostatin, 
parathyroid hormone related peptide, calcitonin and serotonin.  One or many of these 
proteins and peptides may or may not contribute to the signs and symptoms of the tumour 
(Manger, 2006).   
Phaeochromocytomas are said to be ‘often searched for but rarely found’, in part due to the 
constellation of signs and symptoms attributed to the tumour.  In general, most tumours 
produce excess noradrenaline, while tumours which produce exclusively adrenaline are rare 
(Ito et al., 1992, Eisenhofer et al., 2001b).  The primary clinical feature of 
phaeochromocytoma is hypertension, which may occur as sustained or paroxysmal with   53 
these differences suggested to reflect the type of catecholamine released (Aronoff et al., 
1980, Page et al., 2004).  However, hypertension may be absent altogether.  Other common 
clinical features which may, or many not, be present in patients with phaeochromocytoma 
include severe headaches, heart palpitations, anxiety, nausea and constipation and generally 
these signs and symptoms are attributed to the effects of excess circulating catecholamines. 
Phaeochromocytoma have been described as a ‘pharmacologic time bomb’ due to the 
unpredictable nature of the tumour, in which stimuli ranging from trauma, fear and pain, to 
intubation and induction of anaesthesia can provoke catecholamine release and 
hypertensive attacks with potentially lethal results.  The presence of phaeochromocytoma is 
also linked to other cardiovascular complications, which can lead to sudden death including 
myocardial infarction (without any underlying coronary atherosclerosis), arrhythmias, heart 
failure, hypertensive encephalopathy and dissecting aortic aneurysm (Zelinka et al., 2007).  
 Nomenclature defined 
  According to the World Health Organisation (2004) classification of endocrine 
tumours, phaeochromocytomas “arise in the adrenal medulla, are derived from chromaffin 
cells of neural crest origin”, and are “an intra-adrenal sympathetic paraganglioma”, whereas 
paragangliomas are “extra-adrenal and arise from chromaffin cells in the sympathoadrenal 
and parasympathetic ganglia” (DeLellis, 2004).  Thus, the nomenclature defining 
phaeochromocytomas and paraganglioma largely distinguishes between an intra- or extra-
adrenal location respectively.  For the purposes of this thesis, the term phaeochromocytoma 
will be applied to intra-adrenal lesions, and paraganglioma will be used to describe extra-
adrenal chromaffin cells lesions.   54 
Paragangliomas are derived from either the sympathetic or parasympathetic paraganglion.  
Parasympathetic derived paragangliomas are generally found adjacent to structures of the 
head and neck, commonly at the site of the carotid bifurcation, but also as vagal or jugulo-
tympanic tumours (Bryant et al., 2003, Benn et al., 2006). The parasympathetic derived 
paragangliomas are often non-functional, and almost exclusively benign, whereas, 
sympathetic derived paragangliomas are generally found within the abdomen 
(retroperitoneum) and thoracic regions, and are often functionally active, as indicated by 
excess catecholamine production (Bryant et al., 2003, Benn et al., 2006). 
  Despite the differing nomenclature, it is important to note that in many ways 
phaeochromocytomas and paragangliomas of sympathetic origin are more similar than 
different.  Both show similar or identical morphology and histologic features, a near 
identical neuroendocrine phenotype and have similar genetic backgrounds (Tischler et al., 
2006).  However, the malignant potential in sympathetic derived paragangliomas is 
reportedly higher than phaeochromocytomas (Linnoila et al., 1990, Brouwers et al., 2006a, 
Benn et al., 2006) and paragangliomas tend not to express the enzyme PNMT or secrete 
adrenaline (Tischler et al., 2006). 
Diagnosing the ‘Great Mimic’ 
  Phaeochromocytoma represents a diagnostic challenge as it can ‘mimic’ numerous 
other conditions (Table 1.1).  As indicated many of the signs and symptoms of 
phaeochromocytoma are not specific to the tumour. Thus, as with any other conditions, the 
diagnosis of phaeochromocytoma relies on balancing the specificity and sensitivity of 
diagnostic tests available.   55 
Biochemistry 
  Measurements of plasma and urine catecholamines are commonly used in the 
biochemical diagnosis of phaeochromocytomas, however, the sensitivity and specificity of 
these tests are approximately 92% and 72% for sporadic phaeochromocytoma, and 
approximately 68% and 89% in hereditary phaeochromocytomas (Manger & Eisenhofer, 
2004). While catecholamines are often elevated in a patient suspected to be harbouring a 
phaeochromocytoma, many other disorders may also induce increases in plasma and urine 
catecholamines.  Consequently, as discussed previously the role of catecholamine 
metabolism, has important implications for clinical diagnosis.    56 
Table 1.1  Conditions mimicking the symptoms of phaeochromocytoma. 
Adapted from Manger & Gifford (1996). Italics indicate conditions in which plasma and/or 
urinary catecholamines and their metabolites may also be elevated. 
1.  Anxiety, panic attacks with labile blood pressure 
2.  Migraine 
3.  Paroxysmal atrial tachycardia 
4.  Hyperdynamic β-adrenergic circulatory state 
5.  Preeclampsia (eclampsia with convulsions) 
6.  Unexplained shock 
7.  Unexplained multi-system organ failure and lactic acidosis 
8.  Cardiomyopathy (with failure) 
9.  Baroreflex failure 
10.  Familial dysautonomia (Riley-Day syndrome) 
11.  Carcinoid 
12.  Neuroblastoma 
13.  Drug-induced hypertension 
14.  Cushings syndrome 
15.  Postural tachycardia syndrome (POTS) 
16.  Acute infectious disease 
17.  Autonomic hyperreflexia 
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  The role of intratumoural metabolism of catecholamines was recognised early, with 
the discovery that phaeochromocytomas produce COMT and contain high concentrations of 
the O-methylated metabolites, metanephrine and normetanephrine (Kopin & Axelrod, 
1960).  Soon after, it was identified that the presence of catecholamine metabolites in the 
urine of phaeochromocytoma patients is due to intratumoural catecholamine metabolism 
(Crout et al., 1961, Crout & Sjoerdsma, 1964) with between 70 – 75%, of the endogenous 
catecholamine metabolism of occurs within the same cell of synthesis (Maas et al., 1970, 
Eisenhofer et al., 2004a).  Subsequently, several studies have demonstrated that 
metanephrines provide superior diagnostic sensitivity over other methods with up to 100% 
sensitivity in the detection of phaeochromocytoma (Raber et al., 2000, Lenders et al., 2002, 
Davidson, 2002, Sawka et al., 2004, Guller et al., 2006).  Additionally, due to the strong 
relationship between tumour diameter and plasma metanephrine concentration, 
measurements of plasma metanephrines as a diagnostic marker have the added clinical 
utility of indicating tumour size (Eisenhofer et al., 2005).  Since plasma metanephrine 
measurements can predict the biochemical phenotype of the tumour, this provides valuable 
information regarding the location of the lesion.  Findings have shown that when 
metanephrine is elevated above 15% of the combined increase in total metanephrines, this 
strongly indicates the presence of an adrenal tumour (Eisenhofer et al., 2005).  This 
information can aid in the clinical management of patients with the tumour.  According to 
recommendations from the First International Symposium on phaeochromocytoma 
(ISP2005; Bethesda, Maryland, USA, October 2005) plasma and urinary metanephrines 
should be considered the test of choice in the biochemical diagnosis of 
phaeochromocytoma (Grossman et al., 2006).   58 
Malignant phaeochromocytoma 
  In most cases, phaeochromocytoma develop as benign localised adrenal lesions (to 
one or both adrenals), and less often, as benign paragangliomas.  Malignant forms of 
phaeochromocytoma are currently defined by the presence of metastases at sites where 
chromaffin tissue should not be present such as liver, lungs, bones and lymph nodes (Lack 
et al., 2003).  Currently, the metastatic potential of phaeochromocytoma or paraganglioma 
cannot be determined histologically, and consequently all tumours possess a theoretical 
potential for malignancy (Tischler et al., 2006).  The malignant potential of sporadically 
occurring and hereditary phaeochromocytomas is relatively low, suggested to be <5% in 
phaeochromocytomas arising in MEN 2, SDHD and/or VHL disease, and higher (11 %) in 
phaeochromocytoma associated with NF1.  However data is emerging that the malignant 
potential for tumours derived from SDHB mutations is much higher, with reports 
suggesting that up to 50% of patients with SDHB will develop malignant disease (Lenders 
et al., 2005, Brouwers et al., 2006a). 
The current prognosis for patients with malignant phaeochromocytoma and metastatic 
disease is dismal, and the average 5-year survival rate for these patients’ ranges from 20 – 
50% (Edstrom Elder et al., 2003).  The therapeutic options available for combating 
malignant disease are also extremely limited, and often strategies are directed at palliative 
management, with a major therapeutic objective comprising tumour debulking and 
management of symptoms.   59 
Localisation 
  Appropriate localisation of tumour lesions is important in the clinical management 
of phaeochromocytoma patients, as it can provide important data including the size and 
location of the tumour, and can also identify the presence of metastatic lesions.    
Anatomical localisation 
  Typical anatomical techniques include contrast enhanced computerised tomography 
(CT) which is between 90 – 95% sensitive (Francis & Korobkin, 1996, Goldstein et al., 
1999), especially in the detection of adrenal lesions ≥1 cm, or metastatic lesions of at least 
1.0 – 2.0 cm  (Bravo, 1994, Grossman et al., 2006).  Magnetic resonance imaging (MRI) 
has a similar sensitivity to CT, and is particularly useful in detecting extra-adrenal 
phaeochromocytoma (Quint et al., 1987, Maurea et al., 1996). 
Functional Localisation 
  Functional localisation is a physiology-based imaging modality, which relies on the 
selective binding and/or uptake and retention of radiopharmaceuticals by tumour tissues.  
Radiolabelled iodine scintigraphy with [
123I]-metaiodobenzylguanidine of [
131I]-
metaiodobenzylguanidine (I-MIBG) is the most commonly utilised test of choice for the 
functional imaging of phaeochromocytoma.  This tracer was developed by (Wieland et al., 
1980), as an analogue of the adrenomimetic guanethidine, with structural similarities to 
noradrenaline. Benzylguanidine was originally developed as a guanethinidine derivative for 
the potential use as an anti-hypertensive agent (Short & Darby, 1967) and 
metaiodobenzylguanidine (MIBG) tagged with radioactive iodine, 
131I or 
123I, was   60 
developed in the 1980’s for detecting phaeochromocytoma (Wieland et al., 1980, Sisson et 
al., 1981).  MIBG is a structural analogue of noradrenaline, and the delivery of radioactive 
I-MIBG into target cells or tissues is mediated via the noradrenaline transporter (Sisson et 
al., 1981, Jaques et al., 1984, Mairs, 1999). Once in the cell, I-MIBG is then sequestered 
from the cytosol into storage vesicles via the actions of vesicle membrane bound vesicular 
monoamine transporters (Kolby et al., 2003). Following previous discussion of the dynamic 
equilibrium in which catecholamines exist, expression of both NAT and the VMATs are 
crucial to prevent the leaky catecholamines and labelled pharmaceuticals from passively 
leaking out of cells into the bloodstream.   
While I-MIBG is highly specific (95 – 100%) for adrenal and extra-adrenal 
phaeochromocytoma, it is much less sensitive (77 -90%) (Pacak & Goldstein, 2001), 
especially in the detection of hereditary tumours (Taieb et al., 2004). 
Other physiology-based methods of imaging which utilise NAT and VMATs for 
sequestration include positron emission tomography (PET) with the dopamine analogue 6-
[
18F]-Fluorodopamine (F-FDA)(Pacak et al., 2001), in addition to other compounds which 





(Shulkin et al., 1999, Pacak et al., 2001, Hoegerle et al., 2002, Trampal et al., 2004, Mann 
et al., 2006).  However, the latter are thought to have limited diagnostic utility due to 
imperfect sensitivity and/or specificity for phaeochromocytoma (Ilias et al., 2003, Ilias & 
Pacak, 2005).   
  Comparisons of I-MIBG and F-FDA have suggested F-FDA is a superior imaging 
agent primarily due to its ability to detect phaeochromocytoma, including metastatic   61 
lesions, with a greater sensitivity than I-MIBG (Ilias et al., 2003).  Imaging with F-FDA 
also allows a lower dose of radiation than I-MIBG to be delivered to the patient, has less 
adverse affects on the thyroid and allows scanning immediately following F-FDA 
administration, compared to the 24- to 48-hour delay in I-MIBG scintigraphy.  Moreover, 
F-FDA provides better spatial resolution and image quality compared to the planar images 
acquired with I-MIBG (Ilias et al., 2003).  However, F-FDA PET is currently available 




  The definitive treatment of phaeochromocytoma is surgery.  The success of surgical 
intervention is dependent upon suitable pre-operative management of the patient to 
circumvent a catecholamine-related crisis before and during surgery.  Due to the 
unpredictable nature of phaeochromocytomas, the patient may be at risk of hypertensive 
crisis, thus pharmacologic measures to control the effects and/or synthesis of 
catecholamines must be implemented.  The preoperative drug regimen of choice often 
includes alpha adrenoceptor antagonists such as phenoxybenzamine or doxazosin (Bravo, 
1997, Prys-Roberts, 2000) as they can improve haemodynamic stability, reduce peripheral 
vascular resistance, decrease blood pressure (Mannelli, 2006).  The use of beta-
adrenoceptor antagonists to ablate the cardiovascular effects mediated by beta-
adrenoceptors and calcium channel antagonists to prevent NPY mediated vasoconstriction 
may also be indicated (Bravo, 2002).  Drugs that inhibit the synthesis of catecholamines by   62 
acting on the rate-limiting enzyme of the catecholamine biosynthetic pathway, such as 
methyltyrosine, may also be useful especially in patients with extensive metastatic disease 
(Steinsapir et al., 1997).   
Emerging concepts in treatment 
  The radionucleotide
 131I-MIBG was originally developed as a compound for 
detecting phaeochromocytomas (Sisson et al., 1981), however soon after its development it 
was applied as a therapeutic agent in patients with metastatic phaeochromocytoma.  The 
first application of 
131I-MIBG in the treatment of metastatic phaeochromocytoma occured 
in 1984 at the University of Michigan (Sisson et al., 1984) and since this date, numerous 
other patients with metastatic disease have been treated with 
131I-MIBG at several other 
centres worldwide.  Due to the rarity of phaeochromocytoma, and the even smaller 
prevalence of metastatic phaeochromocytomas, clinical studies on the efficacy of 
131I-
MIBG are limited.  However, data generated from a series of trials is promising.  
Forsell-Aronsson and colleagues reviewed the present literature on 
131I-MIBG treatment of 
phaeochromocytoma and paragangliomas in 176 patients in over 10 countries.  The 
cumulative data demonstrated showed symptomatic improvement in 76 -100% of patients, 
hormonal improvement in 45 – 89% and tumour responses in 30 – 83%.  The diverse range 
of responses, may relate to the large range of specific activity administered, in which 
patients received from 96 to 870 mCi of 
131I-MIBG (Loh et al., 1997, Mukherjee et al., 
2001, Rose et al., 2003, Safford et al., 2003, Forssell-Aronsson et al., 2006).  Fitzgerald 
and colleagues also conducted a phase 2 study of the efficacy of high dose (557 – 1185 
mCi) 
131I-MIBG in a cohort of 30 patients with metastatic phaeochromocytoma and 
paraganglioma, the results demonstrating that 67% of patients obtained complete remission   63 
(4/30), partial remission (15/30) or stable disease (1/30; (Fitzgerald et al., 2006).  Given the 
almost certain lethality of malignant phaeochromocytoma and paragangliomas, and distinct 
lack of therapeutic options available to patients with this form of metastatic disease, these 
figures are promising, if only in allowing extension and/or improvement in the quality of 
life.   
Other alternatives for treatment of metatstatic PC or PG 
  Other alternatives for the treatment of metastatic phaeochromocytoma and 
paraganglioma are in development, including the combination 
131I-MIBG therapy with 
other radionucleotide compounds such as 
177Lu-DOTATOC or 
90Y-DOTATOC, which are 
analogues of the somatostatic receptor, SSTR (Forrer et al., 2005) and have showed 
promise in the treatment of other neuroendocrine tumours such as carcinoid.  The value of 
combining multiple radionucleotids is two-fold.  First through acting on different ligands, 
cells with poor NAT/VMAT expression but suitable SSTR may be targeted, and secondly 
due to an ability to target large populations of cells through a range of emitted particles.   
Treatment of phaeochromocytoma with combined radionucleotide therapy and 
chemotherapy has also been proposed.  While very few clinical trials have been conducted, 
some success has been achieved in the treatment of neuroblastoma, a childhood cancer 
derived from similar pregenitor cells as phaeochromocytoma. 
VIII.  Hereditary phaeochromocytoma:  
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Introduction 
  Phaeochromocytomas were originally described as the “10% tumour”, for the 
approximate frequency of malignancy, presentation during childhood, extra-adrenal 
location and familial occurrence.  Recent studies however have challenged these 
proportions, and it is now accepted that the frequency of heritable phaeochromocytomas is 
up to 29% (Neumann et al., 2002b, Bryant et al., 2003, Bornstein & Gimenez-Roqueplo, 
2006).  Hereditary phaeochromocytomas have been linked to several heritable endocrine 
tumour syndromes and germline-mutations in at least 5 phaeochromocytomas susceptibility 
genes (Table 1.2), including those associated with multiple endocrine neoplasia type 2 
(MEN 2) due to mutations in the RET proto-oncogene, von Hippel-Lindau (VHL) 
syndrome due to mutations in the VHL gene, and the phaeochromocytoma-paraganglioma 
syndrome due to mutations in the succinate dehydrogenase subunits B (SDHB), and D 
(SDHD), and neurofibromatosis Type 1 (NF1) due to mutations of the neurofibromin gene 
(Neumann et al., 2002b, Bryant et al., 2003). Although other phaeochromocytoma 
susceptibility genes may also exist, thus far the role of RET, VHL, NF1, SDHB, and SDHD 
genes in phaeochromocytoma development are unequivocal (Opocher et al., 2005). 
The von Hippel-Lindau syndrome   
The VHL phenotype 
  The von Hippel-Lindau (VHL) syndrome is a dominantly inherited familial cancer 
syndrome with an incidence of approximately 1 in 36 000 live births.  By 60 years of age, 
97% of individuals with VHL syndrome will show some form of clinical   65 




  VHL  MEN 2  NF1  SDHB  SDHD 
Gene mutated  VHL  RET  NF1  SDH  SDH 
Gene locus (humans)  3p26-25  10q11.2  17q11.2  1p35-36  11q23 
Disease Prevalence 
(general population) 
1:36 000 - 
1:85 000 
1:30 000  1:3 000  Unknown  Unknown 
Proportion of cases with 
phaechromocytoma (%) 
20 - 25  50  0.1 – 5.3  Unknown  Unknown 
Mean age of diagnosis  29  36  42  20 – 30  20 – 30  
  Phaeochromocytoma 
location (%): 
•  Adrenal  >90  90  84  Rare  Rare  
•  Extra-adrenal  Rare  Rare  Rare  Common  Common  
•  Bilateral  40  50 – 80   10  Unknown  Unknown  
Biochemical Phenotype  NA  A + NA  Unknown  NA  NA 
Malignant Potential  Low  Low  Low  High  Low   66 
manifestations associated with the VHL syndrome (Opocher et al., 2005).  The syndrome 
predisposes the individuals to an array of malignant and benign multicentric neoplasms, 
including haemangioblastoma (retinal, cerebellar and/or spinal), renal cell carcinoma, 
pancreatic endocrine tumours, endolymphatic sac tumours and phaeochromocytoma.  Less 
frequently renal, pancreatic and epididymal cysts are encountered (Ong et al., 2007). 
  The VHL syndrome can be classified as VHL type 1, where phaeochromocytoma is 
not (or very rarely) observed, or VHL type 2, in which phaeochromocytoma is observed 
(Neumann & Wiestler, 1991).  VHL type 2 can also be classified as 2A, 2B or 2C, 
depending on the tumours which develop: VHL type 2A is associated with a high risk of 
developing haemangioblastomas and phaeochromocytoma, but a low risk of renal cell 
carcinoma, whereas VHL type 2B is associated with a high risk of developing 
haemangioblastoma, renal cell carcinoma and phaeochromocytoma (Bryant et al., 2003). 
The VHL type 2C phenotype is characterised by a high risk for developing 
phaeochromocytoma only (Hoffman et al., 2001). 
  Between 7 – 20% of patients with VHL type 2 disease will develop 
phaeochromocytoma and of these patients approximately 40% will develop bilateral 
phaeochromocytomas.  Extra-adrenal or malignant phaeochromocytomas are rare in the 
VHL syndrome and the diagnosis of phaeochromocytoma within this syndrome occurs 
earlier than seen with sporadic forms of the disease (Opocher et al., 2005).  Although 
typical symptoms such as hypertension are present in VHL phaeochromocytomas, the 
frequency of symptoms is lower in this patient group than in other forms of the tumour 
(Eisenhofer et al., 2001b) and this has been suggested to reflect the tendency of 
phaeochromocytomas from VHL to continuously discharge catecholamine contents leading   67 
to a possible down-regulation of adrenoceptors (Eisenhofer et al., 2001b).  
Phaeochromocytoma due to the VHL syndrome are also characterised as almost exclusively 
producing noradrenaline, and having little or no PNMT expression or adrenaline synthesis 
(Eisenhofer et al., 2001b). 
VHL genotype 
  Mutations in the VHL tumour suppressor gene underlie the development of VHL 
syndrome (Latif et al., 1993).  Located on chromosome sub-band 3p25-26, the VHL gene 
contains merely 3 exons, and can be transcribed into two splice variants, which differ 
depending on the presence or absence of exon two (Richards et al., 1996).  Tissue specific 
expression of the VHL gene is apparent during embryogenesis but in the adult, expression 
appears ubiquitous (Richards et al., 1996, Opocher et al., 2005).  The progression of VHL 
disease demonstrates a classic “two-hit” mode of tumorigenesis (Prowse et al., 1997), in 
which both alleles of the VHL gene must be inactivated in order for the syndrome to 
manifest.  The first inactivation mutation is inherited, and the second inactivating event 
occurs as a somatic mutation. The VHL gene contains two domains, a β-domain consisting 
of a 100-residue amino terminal domain rich β sheet, and a α-domain, containing a carboxy 
terminal and helical domain (Clifford et al., 2001).  Disruptions within these domains are 
particularly important in the development of VHL disease. 
VHL and oxygen sensing pathways 
  A major macromolecular binding site mapping to the VHL gene is within the β-
domain, which targets the oxygen sensing alpha subunits of the hypoxia inducible 
transcription factors (HIF1- and HIF2α) (Ohh et al., 2000, Kamura et al., 2000). The VHL   68 
protein operates as the substrate recognition component of an E3 ligase complex, which 
under normoxic conditions facilitates the ubiquitination of hydroxylated HIF-α.  The HIF-α 
hydroxylation process occurs though a triad of oxygen-dependent prolyl-hydroxylases 
(PHD1 – 3).  The reaction also requires 2-oxoglutarate, Fe
2+ and ascorbate, and generates 
succinate and CO2. (Jaakkola et al., 2001).  This effect of hydroxylation of the HIF-α 
protein is destabilisation, ubiquitination and ultimately proteasomal degradation (Maxwell 
et al., 1999, Jaakkola et al., 2001).  However, under hypoxic conditions, PDH activity is 
restrained, binding to VHL is hindered, the HIF-α protein is stabilised and able to 
translocate to the nucleus where it binds to the HIF-β subunit and transcriptionally activates 
an array of genes involved in energy metabolism, angiogenesis and apoptosis (Maxwell et 
al., 1999, Kaelin, 2005).   
  In the absence of a functional VHL protein, such as in the setting of the VHL 
syndrome, HIF-α activation can occur under normoxic conditions, resulting in the 
upregulation of genes normally induced by hypoxia (Maxwell et al., 1999, Cockman et al., 
2000, Clifford et al., 2001).  Disregulation of hypoxia inducible pathways are a prominent 
feature in the pathogenesis of VHL-associated tumours, especially haemangioblastoma and 
renal cell carcinoma (Clifford et al., 2001).  However, mutations underlying the VHL type 
2C phaeochromocytoma-only clinical phenotype are distinct from other VHL mutations, 
and do not impair the HIF-α/VHL interaction. Thus it appears that VHL has other critical 
functions, which are involved in phaeochromocytoma development (Clifford et al., 2001, 
Hoffman et al., 2001).  Studies have also identified an effect of VHL mutations on 
fibronectin assembly/deposition, thus this may represent an additional target of the VHL   69 
protein with a potential role in phaeochromocytoma tumourigenesis (Ohh et al., 1998, 
Hoffman et al., 2001).    
Neurofibromatosis Type 1 
The NF1 phenotype 
  Neurofibromatosis Type 1 (NF1), or von Recklinghausen disease, is a common 
familial disease which affects approximately 1:30 000 – 40 000 individuals (Opocher et al., 
2005), manifesting as an array of peripheral nervous system tumours including 
neurofibromas, café-au-lait spots, malignant gliomas and phaeochromocytoma (Bryant et 
al., 2003).  The prevalence of phaeochromocytoma within the setting of NF1 disease is 
reportedly 0.1 – 5.7%.  When discovered in NF1 patients at autopsy, this figure is markedly 
higher (3.3 – 13.0%) (Heim et al., 1995).  Hypertension is a frequent feature of NF1, and 20 
– 50% of hypertensive NF1 patients will also harbour a phaeochromocytoma (Walther et 
al., 1999a).  According to a recent review of 148 patients with phaeochromocytoma and 
NF1, the mean age of phaeochromocytoma diagnosis was 42; 84% of patients presented 
with a unilateral solitary adrenal mass, 9.6% with bilateral adrenal masses and 6.1% with 
extra-adrenal phaeochromocytoma.  The review also determined 11.5% of patients (17/148) 
had malignant phaeochromocytoma, a figure similar to the frequency of malignant 
transformation in sporadic phaeochromocytomas (Walther et al., 1999a). 
The NF1 genotype 
  The NF1 gene encodes for a protein called neurofibromin, a product thought to act 
as a Ras-GTPase activating protein, a negative Ras regulator, which promotes Ras-GTP   70 
conversion to Ras-GDP (Shen et al., 1996, Reed & Gutmann, 2001). The NF1 gene is 
located at 17q11.2 and spans over 300 kb of genomic DNA with at least 11 kb of coding 
sequence situated on 60 exons.  Due to the enormous size of the NF1 gene, comprehensive 
analysis of any genotype-phenotype relationships between specific mutations and NF1 
disease have not been conducted (Opocher et al., 2005). 
Multiple Endocrine Neoplasia Type 2 
The MEN 2 phenotype 
  Multiple Endocrine Neoplasia type 2 is a rare hereditary autosomal dominant 
endocrine disorder associated with the occurrence of medullary thyroid carcinoma, primary 
hyperparathyroidism and unilateral or bilateral phaeochromocytoma.  Multiple Endocrine 
Neoplasia type 2 is classified into two sub-types MEN 2A and MEN 2B, according to the 
clinical manifestations present (Marini et al., 2006).  MEN 2A is associated with the 
development of medullary thyroid carcinoma, primary hyperparathyroidism and 
phaeochromocytoma, while MEN 2B is associated with the development of medullary 
thyroid carcinoma, phaeochromocytoma, ganglioneuromas and marfinoid habitus (Hoff et 
al., 2000).  The prevalence of MEN 2 is reportedly 1: 30,000 with MEN 2A representing 
approximately 75 – 80% of all diagnosed MEN 2 cases.  Phaeochromocytoma is present is 
50% of individuals with MEN 2A and MEN 2B, and 90% of phaeochromocytomas within 
the framework of MEN 2A and 2B are benign and located on the adrenals, but extra-
adrenal MEN 2 tumours have been reported (Brandi et al., 2001).  Between 50 – 80% of 
MEN 2 phaeochromocytomas are bilateral.  The development of signs and symptoms such 
as hypertension in patients with phaeochromocytomas arising due to MEN 2 is less than in   71 
patients with sporadic forms of the disease (Zelinka et al., 2007), however hypertension is 
observed in approximately 50% of patients, and the incidence of hypertension in MEN 2 
patients is greater than in patients with phaeochromocytoma due to VHL disease 
(Eisenhofer et al., 2001b).  Phaeochromocytomas arising due to MEN 2 demonstrate an 
adrenergic biochemical phenotype, classified as producing adrenaline and this has been 
suggested to explain the appearance of paroxysmal hypertension observed in this patient 
group (Zelinka et al., 2007). 
The MEN 2 genotype 
  The discovery that MEN 2 is due to mutations of the RET (Rearranged during 
Transfection) proto-oncogene was brought about by an association between polymorphisms 
in chromosome 10 in pedigrees affected by MEN 2 discovered in the mid 1980’s (Mathew 
et al., 1987, Simpson et al., 1987).  Shortly after, RET was sequenced and localised to 
chromosome 10q11.2 and found to cover 60 kb of genomic DNA, contain 21 exons and 
encoding a 1,100 amino acid protein (Kwok et al., 1993). 
  The RET gene encodes for a membrane tyrosine kinase receptor also called RET 
that is composed of an intracellular portion with two tyrosine kinase domains, an 
extracellular portion with six domains; a calcium binding site, four cadherin-like domains 
and a cysteine rich domain, a single pass transmembrane domain (Kwok et al., 1993). The 
tyrosine kinase receptor is essential for the proper development of the kidneys and adult 
nervous system, including motorneurons and a population of enteric, sympathetic and 
dorsal root ganglionic neurons (Pachnis et al., 1993).  Mice lacking the RET gene die early 
postnataly, and do not develop an enteric nervous system and display kidney agenesis 
(Schuchardt et al., 1994).  RET expression is also seen in early progenitor chromaffin cells   72 
prior to their migration to the adrenal, thus RET has been implicated as an essential factor 
required for the normal migration and development of chromaffin cells. While adrenal 
chromaffin cells show normal migration and differentiation in RET deficient mice, the 
animals display chromaffin cell abnormalities such as reduced adrenaline content and 
PNMT expression indicating that RET may be an indirect or direct requirement for the 
induction of an adrenergic phenotype in chromaffin cells (Allmendinger et al., 2003). The 
RET tyrosine kinase receptor binds to growth factors of the glial derived neurotrophic 
factor (GDNF) family. When bound to GDNF family receptor alpha proteins (ligand 
binding co-receptors), GDNF-family ligands are then able to bind to, and activate RET 
(Arighi et al., 2005).  However, as is the case in MEN 2 syndrome, germline mutations of 
the RET gene causing ligand independent activation of the tyrosine kinase receptor, and 
induction of downstream pathways.  Almost all (93 – 98%) cases of MEN 2A are due to 
missense mutations at one of six cysteine residues within the extracellular domain, 
specifically at codons 609, 611, 618, 620 and 630 within exon 10, and codon 634 on exon 
11 (Marx, 2005, Marini et al., 2006).  Codon 634 mutations occur in upto 85% of MEN 2A 
patients, and this mutation is strongly associated with the development of 
phaeochromocytoma (Neumann et al., 2002a, Punales et al., 2003)  
The phaeochromocytoma – paraganglioma syndrome 
Succinate Dehydrogenase 
  Adenosine triphosphate (ATP) is generated in the mitochondria via the interaction 
of two fundamental biochemical pathways: the Krebs cycle and oxidative phosphorylation.  
The molecular link between these two pathways is the electron transport chain, which is   73 
composed of a heterotetrameric complex and generates a proton gradient between the inner 
and outer mitochondrial membranes (Pawlu et al., 2005).  Succinate dehydrogenase (SDH), 
owing to its role in the Krebs cycles, also represents mitochondrial complex II within the 
electron transport chain.  The SDH enzyme consists of four subunits, referred to as SDHA 
– D respectively.  
Clustering of paragangliomas within family lines prompted suspicions that a hereditary 
factor may underlie the development of some paragangliomas.  This led to the mapping of 
two paraganglioma susceptibility loci: PGL1 on 11q23 (Heutink et al., 1994) and PGL2 
(Mariman et al., 1995) and subsequently to the discovery that PGL1 corresponded to the 
SDHD gene (Baysal et al., 2000).  Soon thereafter, germline mutations corresponding to 
other paraganglioma susceptibility loci were characterised, including SDHC (PGL3) on 
1q21 and SDHB (PGL4) at 1p36 (Niemann & Muller, 2000, Astuti et al., 2001).  
  Genotype – phenotype correlations linking specific SDH mutations to the 
development of a particular clinical presentation have emerged since the discovery that the 
development of phaeochromocytoma – paraganglioma syndrome are linked to germline 
mutations in the SDHB and SDHD genes.  It appears certain that SDHD mutations are 
associated with a greater frequency of head and neck paragangliomas, but a lower 
frequency of abdominal or thoracic paraganglioma than in patients with SDHB (Heutink et 
al., 1992, Benn et al., 2006).  Conversely, the frequency of malignant disease is much 
greater in patients with SDHB mutations (Gimenez-Roqueplo et al., 2003, Benn et al., 
2006) than in patients with SDHD mutations (Pawlu et al., 2005, Benn et al., 2006).  
Mutations to the SDHC gene appears to be linked to the development of head and neck   74 
paragangliomas, but not adrenal phaeochromocytomas (Baysal et al., 2004, Muller et al., 
2005). 
IX.  Five genes and one disease:  Development along a 
common pathway of pathogenesis? 
   
  Germline mutations in at least five phaeochromocytoma susceptibility gene have 
been identified as playing a major role in the pathogenesis of phaeochromocytomas.  
However, it remains unanswered how mutations in five functionally and spatially distinct 
genes can lead to the development of the same kind of tumour.   
  The adverse effects of VHL mutations on O2-sensing and hypoxia inducible 
pathways are known to play a major role in the pathogenesis of phaeochromocytomas in 
VHL disease.  However, a relationship between mutations in the SDHB and D subunits and 
impaired O2-sensing and hypoxia inducible pathways is also emerging.  As discussed, 
mutations in the VHL gene authorise the activation of hypoxia inducible pathways during 
normoxia by preventing ubiquitination and thus degredation of HIF-α proteins.  However, a 
similar hypoxic trait has also been noted in phaeochromocytomas associated with mutated 
SDHB and D genes, hinting that mutations in the SDHD and D subunits also have an 
ability to modulate O2-sensing and hypoxia inducible pathways, and that alterations within 
these pathways may play a major role in the pathogenesis of SDH related tumours 
(Gimenez-Roqueplo et al., 2002, Dahia et al., 2005a, Selak et al., 2005).  Unlike VHL 
mutations, which allow HIF-α stability through flawed ubiquitination, it appears likely that 
SDH mutations activate hypoxia inducible pathways by an alternative pathway.  Loss of 
function of the SDH enzyme results in succinate accumulation, and due to product   75 
inhibition, of PDH activity is also impaired, triggering a cascade of events which give rise 
to the aberrant activation of hypoxia induced genes (Gottlieb & Tomlinson, 2005, Selak et 
al., 2005).  Consistent with this hypothesis, increased succinate levels have been detected in 
phaeochromocytoma and paraganglioma tumour tissue (Pollard et al., 2005).  Other work 
also suggests that the HIF protein can down regulate the expression of SDHB but how and 
what triggers this novel function of HIF remains undecided (Dahia et al., 2005b, Dahia, 
2006).  Regardless of the mechanism, the potential ability of HIF to suppress SDHB may 
feasibly initiate a positive feedback loop of further activation of hypoxic pathways.  
Increased levels of reactive oxygen species (ROS), through undefined means, have also 
been suggested as a factor linking SHD and VHL mutations to depressed PDH activity, and 
enhanced HIF stability and availability (Gerald et al., 2004).  While no 
phaeochromocytoma or paraganglioma models have been tested thus far, defective or 
absent SDHC in in vitro and C. elegans models respectively both demonstrate increased 
ROS (Ishii et al., 1998, Ishii et al., 2005).   
Developmental culling – Linking the five distinct phaeochromocytoma 
susceptibility mutations to a common pathway 
  Apoptosis is a normal part of cellular programming and development.   A recent 
publication by Lee and colleagues (2005) has provided compelling evidence linking all five 
phaeochromocytoma susceptibility genes along a common pathway of pathogenesis, by 
suggesting that the failure of progenitor cells to undergo apoptosis following NGF-
withdrawal during development triggers tumorigenesis (Lee et al., 2005).  Neurotrophins 
including nerve growth factor (NGF) regulate neuronal function, development and survival 
during embryogenesis and are thought to be particularly critical for the divergence of   76 
sympathetic nerves from sympathoadrenal progenitors.  However, NGF may also have an 
important function during maturity (Huang & Reichardt, 2001, Kreusser et al., 2006).  
Disruptions to the normal NGF pathways in sympathetic nerves are also observed in the 
disease pure autonomic failure, a condition in which there is a profound and unexplained 
loss of sympathetic nerves in patients manifesting clinically as severe postural hypotension 
and recurrent syncope (Goldstein et al., 1997).  Patients with pure autonomic failure have 
almost undetectable levels of circulating NGF and impaired NGF release from cardiac 
nerves.  It has been suggested that impaired neurotrophic support presents a mechanism of 
pathogenesis (Esler et al., 2003, Esler & Kaye, 2006).  During embryogenesis, NGF is 
important for the maintenance but not induction of sympathoadrenal progenitor cells along 
a pathway of sympathetic nerves (Partlow & Larrabee, 1971, Coughlin & Collins, 1985).  
In the setting of sympathoadrenal programming, as NGF concentrations become limiting, 
sympathetic nerves undergo apoptosis, in a process mediated by the activation of c-Jun, a 
member of the Jun family (Eilers et al., 2001).  Additionally, a massive induction of 
apoptosis occurs following the activation of the NGF receptor TrkA, due to the depletion of 
NGF.  According to recent reports by Lee and co-workers (2005), the ability of mutations 
in five spatially separate and functionally distinct genes to lead to the development of a 
single tumour phenotype – phaeochromocytoma – can be explained by the failure of cells to 
undergo apoptosis or developmental culling in a process linked to NGF signalling.  The 
authors suggest that mutations in the RET and NF1 genes are able to cause the development 
of phaeochromocytoma in the setting of MEN 2 and NF1 disease through impaired 
interactions with the NGF receptor TrkA (Lee et al., 2005).  In the setting of NF1 disease, 
the NF1 gene would normally inhibit downstream signalling with TrkA.  When NF1 is   77 
mutated, such is the case with NF1 disease, the NF1-TrkA interaction is disrupted and cells 
are not targeted for apoptosis despite diminishing NGF concentrations (Vogel et al., 1995).  
TrkA also interacts with JunB, another member of the Jun family, that similar to c-Jun is 
also important in activation apoptosis (Lee et al., 2005).  In the setting of MEN 2, RET, 
which is the receptor for another neurotrophin GDNF (glial cell-line derived neurotrophic 
factor) can “cross-talk” with TrkA.  Thus, mutations of the RET gene impair the ability of 
Trk A to interact with JunB, and c-jun, and thus attenuates JunB/c-jun mediated apoptosis 
following NGF-withdrawal (Dechant, 2002, Peterson & Bogenmann, 2004).  Defects in 
oxygen-sensing pathways been implicated as a key component of tumorigenesis in VHL 
disease.  A unique feature of the von Hippel-Lindau syndrome as a collection of tumours, is 
that the syndrome can be divided into two forms relating to whether phaeochromocytoma is 
present or not (Neumann & Wiestler, 1991, Bryant et al., 2003, Opocher et al., 2005).  
Further, the type of mutation associated with VHL disease appears to be a critical 
determinant of the level of risk of developing phaeochromocytoma.  Missense (gain-of-
function) mutations associated with VHL type 2 confer a greater risk of 
phaeochromocytoma development than null VHL (loss-of-function) mutations associated 
with VHL type 1, which carry a low risk of phaeochromocytoma development.  A subset of 
VHL type 2 patients are characterised by a phaeochromocytoma only phenotype (VHL 2C) 
(Hoffman et al., 2001).  It has been demonstrated that unlike all other types of VHL, where 
the underlying mutations disrupt the ability of VHL to bind to target HIF-α for 
ubiquitination, in VHL 2C, the ability of VHL target HIF-α is not impaired (Clifford et al., 
2001, Hoffman et al., 2001), suggesting that at least in the setting of VHL 2C, that an 
alternative pVHL target is associated with the pathogenesis.  According unifying theory of   78 
Lee and colleagues linking all five phaeochromocytoma susceptibility genes to a common 
pathway, they propose that VHL mutations are also linked to a failure of progenitor cells to 
undergo apoptosis.  In the context of VHL, inactivating VHL mutations cause increased 
JunB expression, which as an antagonist of c-Jun, attenuates c-Jun mediated apoptosis (Lee 
et al., 2005).  Moreover, the authors point to findings where PC12 cells treated with NGF 
down regulate JunB expression following NGF withdrawal, and undergo apoptosis.  The 
authors further demonstrate that all know disease associated VHL mutations, including 
those that do not have impaired HIF binding, do not down regulate JunB, suggesting a 
central mechanism of pathogenesis in VHL disease (Lee et al., 2005).  But how do SDH 
mutations and the development of phaeochromocytoma and paraganglioma fit into this 
convoluted pathway?  According to the hypothesis presented by Lee et al, SDHB and 
SDHD mutations, which cause an accumulation in succinate, have tumourigenic potential 
due to an ability to impair the enzyme EglN3 (also known as prolyl hydroxylase 3) which is 
a paralog of EglN1, the primary prolyl hydroxlylase that functions in normoxia as the 
enzyme which hydroxylates HIF-α in the presence of VHL.  The authors suggest that the 
accumulation of succinate inhibits EglN3 activity, which subsequently allows progenitor 
cells to escape apoptosis, as NGF concentrations become limiting (Lee et al., 2005).     
Through a novel explanation centred on the failure of progenitor cells to undergo apoptosis 
as a normal part of development once NGF levels become limiting, the authors go to great 
lengths to weave a common thread linking mutations to five phaeochromocytoma-
susceptibility genes to the development of a single tumour phenotype.  A central caveat of 
the “developmental culling” theory is that because chromaffin cells and sympathetic nerves 
are (thought to be) derived from a common precursor, the effects of NGF withdrawal on   79 
sympathetic nerves also translate to an effect on chromaffin cells.  Possibly, an emerging 
theme is that in the setting of hereditary phaeochromocytoma, disease-causing mutations 
exert their erroneous effects at a critical point in chromaffin cell development.  The idea 
that tumourigenesis occurs within a critical window of opportunity may explain the variable 
penetrance of phaeochromocytoma as a presenting feature in these hereditary forms of the 
disease.   
X.  Differences between VHL and MEN 2  
 
  In 1999, Eisenhofer et al, made the serendipitous discovery that 
phaeochromocytomas from MEN 2 and VHL possess significant differences in the 
production of O-methylated catecholamine metabolites, metanephrine and 
normetanephrine.  Specifically, patients with MEN 2 were consistently found to have 
elevated plasma metanephrine levels, in contrast to VHL patients, which demonstrated 
nearly universal increases in plasma normetanephrine levels (Eisenhofer et al., 1999).  This 
finding set the stage for the subsequent discovery that phaeochromocytomas associated 
with MEN 2 and VHL possess numerous differences, with the most striking related to 
catecholaminergic phenotype:  VHL tumours, almost exclusively, produce noradrenaline, 
whereas MEN 2 tumours produce both adrenaline and noradrenaline (Eisenhofer et al., 
2001b), the latter discovery supported by previous data suggesting patients with MEN 2 
have a higher incidence of adrenaline-producing tumours (Sato et al., 1975, Hamilton et al., 
1978, Vistelle et al., 1991).  A lack of PNMT expression by VHL tumours has since been 
found to underscore the appearance of a noradrenergic phenotype in this group (Eisenhofer 
et al., 2001b), and while attempts to explain why PNMT is negligible in VHL tumours have   80 
been made (Huynh et al., 2006), the factor(s) precipitating changes in PNMT are 
unresolved.   
Subsequently, other salient differences relating to clinical presentation and tumour biology 
have emerged.  For instance, patients with MEN 2 are more likely to be symptomatic, and 
show a higher incidence of hypertension (Eisenhofer et al., 2001a).   Catecholamine release 
from VHL tumours occurs more avidly than their MEN 2 counterparts, as demonstrated by 
higher total plasma catecholamine levels in VHL relative to MEN 2 patients.  This 
divergence in release has been suggested to explain the paroxysmal hypertension 
encountered in MEN 2 patients compared to the sustained hypertension presented by VHL 
patients (Eisenhofer et al., 2001b).  Other aspects of chromaffin cell and/or tumour biology 
contrast between VHL and MEN 2 phaeochromocytomas, including the expression of the 
noradrenaline and vesicular monoamine transporters (Huynh et al., 2005), chromogranin B 
(Brouwers et al., 2007) and erythropoietin (Vogel et al., 2005).  Ultrastructural, differences 
are also apparent, including abundance of chromaffin granules (Eisenhofer et al., 2001b, 
Huynh et al., 2005) and histopathologic features (Koch et al., 2002). 
XI.  Summary, Aims and Objectives 
 
  The autonomic nervous system is divided into two major branches, the 
parasympathetic and sympathetic nervous, which provide divergent but complementary 
signals, allowing internal homeostasis to be regulated.  The sympathetic nervous system, 
including its two major components, sympathetic nerves and the adrenal medulla, provide a 
fundamental function to the maintenance of blood pressure, through the measured release 
of catecholamines and other bioactive peptides and proteins.  Chromaffin cells, of the   81 
adrenal medulla, are a modified post-ganglionic sympathetic neuron, which synthesise and 
secrete catecholamines.  The neoplastic transformation of chromaffin cells is demonstrated 
by the tumour phaeochromocytoma, a functional tumour that recapitulates the normal role 
of chromaffin cells by synthesising, storing and releasing excess catecholamines.  
Phaeochromocytoma is a clinical enigma, characterised by clinical and biological 
heterogeneity, manifesting as a constellation of signs, symptoms and genotypic profiles.   
Given the heterogeneity observed in phaeochromocytoma, our hypothesis was that many 
aspects of tumour biology must be altered in these tumours.  Therefore, in this study, we 
aimed to clarify the expression of several key proteins and peptides in sporadic and 
hereditary forms of phaeochromocytoma, especially tumour samples obtained from patients 
with MEN 2 and VHL syndrome.   
  Specifically, we sought to characterise the expression of the noradrenaline 
transporter (NAT) in sporadic and hereditary phaeochromocytoma compared to the normal 
human adrenal, including the association between NAT and the catecholamine biosynthetic 
enzyme, PNMT, and with the chromaffin granule marker chromogranin A (CGA).  Given 
the importance of NAT expression for the uptake of radiolabelled catecholamine analogues 
in clinical imaging and diagnosis of these tumours, we also examined whether NAT 
expression is related to the findings of 6-[
18F]-Fluorodopamine studies in the diagnosis of 
patients with phaeochromocytoma.  We examined ways of manipulating NAT expression 
with the aim of augmenting NAT expression to allow greater uptake of 
131I-MIBG and thus 
the efficacy of this compound in the treatment of patients with metastatic 
phaeochromocytoma.  To test this hypothesis, we used the rat phaeochromocytoma PC12   82 
cell line to examine whether pretreating cells with the chemotherapy drug Cisplatin can 
increase NAT expression.    
Phaeochromocytoma arising due to germline mutations in the RET and VHL genes are 
associated with marked differences in clinical presentation, biochemical phenotype and 
underlying tumour biology.  We sought to elucidate whether some of the differences 
observed between these two patient groups are due to the differential expression of 
chromaffin granule constituents, neuropeptide Y (NPY) and CGA.   
Finally, we examined the expression of a set of sympathoadrenal markers (NPY, NAT, 
Leu-Enkephalin, vesicular monoamine transporters type 1 & 2) relative to the enzyme 
PNMT in normal mouse adrenal glands and in an experimental model of 
phaeochromocytoma.  In this study we set to validate this animal model as a tool for 
studying phaeochromocytoma metasteses and adrenal lesions, and explore whether this 
model represents a viable animal model for the study of human disease.   
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Chapter 2 – Materials and Methods 
 
I.  Ethics Approval 
 
Human Samples 
The results presented in this thesis were from 83 patients with histologically 
confirmed phaeochromocytomas.  These patients were recruited into clinical research 
protocols at the National Institutes of Health Clinical Research Centre in Bethesda, 
Maryland, USA.   
All tumour and plasma samples were obtained under clinical protocols through the 
National Institutes of Child Health and Human Development (NICHD) or National Cancer 
Institute (NCI) and were approved by an Institutional Review Boards, with informed 
consent from all patients.  Human phaeochromocytoma samples analysed at Murdoch 
University were assessed with the approval of the Murdoch University Human Ethics 
Committee.  
Animals 
  The animals from which positive control sections in Chapter 3 and 5 were 
performed with the approval of the Murdoch University Animal Ethics Committee. 
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  The animal experiments conducted in Chapter 7 were performed with the approval 
of the National Institutes of Health (NIH) Institutional Animal Care and Use Committee. 
II. Patient and sample details 
Patients 
Patients were classified according to whether tumour development was related to 
hereditary factors (n=50) or occurred as a sporadically arising tumour (n=33; Table 2.1).  
Genetic testing was employed to confirm the diagnosis of patients with hereditary 
phaeochromocytoma by the detection of germline mutations to the VHL tumour suppressor 
gene (VHL syndrome; n=30) or RET proto-oncogene (Multiple Endocrine Neoplasia Type 
2A; n=20).  
 
Table 2.1  Patient details 
  MEN 2  VHL  No Hereditary 
Syndrome 
N  20  30  33 
Gender (F/M)  13/7  14/16  17/16 
Age (mean, range)  40.2 (25 – 75)  31.9 (10 – 60)  51.8 (21 – 75) 
 
Plasma Procurement 
Blood samples were obtained from patients by using an in dwelling iv catheter in 
the forearm vein.  Patients were supine for at least 20 minutes before collections of blood.    85 
Samples were transferred into heparinised tubes and immediately placed on ice, and then 
centrifuged at 4°C to separate plasma from other blood components.  The plasma was 
collected and stored at -80°C until the time of assaying. 
Tumour Procurement 
Phaeochromocytoma samples were obtained within 90 minutes of surgical removal 
of phaeochromocytomas at the NIH Clinical Center (Bethesda, MD, USA).  Tumours were 
place on ice immediately after surgical removal and the tumour dimensions were recorded.  
Small samples (5 – 100 mg) were dissected from surrounding tissues and treated in several 
ways.  Firstly, samples were taken for histopathology, and were fixed in formalin, mounted 
into paraffin blocks to allow routine H&E staining of the tissues to confirm the diagnosis of 
phaeochromocytoma.  The paraffin block containing the sample(s) were then archived 
within the Pathology department.  The remaining tissue samples recovered from surgical 
removal of the tumour were both placed on dry ice, or into OCT (Optimal Cutting 
Temperature) blocks and stored at -80°C.  The stored frozen samples were used for 
calculating tissue catecholamine content (HPLC), RNA extraction (Q-PCR), protein 
extraction (Western Blot, ELISA).   
 
Procurement of normal human adrenal tissue 
Paraffin-embedded 5 µm slices of human adrenal mounted onto glass slides (n=9) 
used for immunohistochemistry were obtained commercially (Biocompare, San Francisco, 
CA, USA), however no details regarding the age or gender of these individuals was   86 
available.  For Q-PCR studies, wherever possible, samples of normal adrenal were obtained 
when surgically resected tumours contained margins of normal tissue. 
Plasma and Tissue Catecholamine Measurements 
Plasma and tissue concentrations of catecholamines (adrenaline, noradrenaline and 
dopamine) were measured by high performance liquid chromatography with 
electrochemical detection.  Tumour samples were weighed and homogenized in 5 – 10 
volumes of 0.4 mol/L percholric acid containing 0.5 mmol/L EDTA.  Homogenates were 
centrifuged, supernatant collected and store at -80°C until time of assaying.  Catecholamine 
concentrations were determined after extraction from plasma or perchloric acid tissue 
supernatants using alumina absorption (Eisenhofer et al., 1986). 
Animals 
Sections of rat adrenal gland were processed concurrently alongside all human 
samples serving as positive control samples.  Sections were obtained from Wistar-Kyoto 
rats (6 – 12 weeks, both sexes).  Animals were anaesthetized with sodium pentobarbital 
(Nembutal; 100 mg/kg i.p.) and transcardially perfused with 0.9% NaCl solution containing 
0.001% sodium nitrate (w/v) and 0.25% (v/v) heparin (1000 U/ml), followed by perfusion 
with 4% (v/v) formaldehyde in PBS (0.1 M, pH 7.4).  The adrenal glands were removed, 
the surrounding fatty tissue detached and the glands were paraffin embedded and cut into 5 
µm sections and processed according to the same methods described for the human 
samples.   87 
I.  Extraction of RNA and Reverse Transcription  
 
Extraction of RNA and Reverse Transcription: Human Samples 
Small (5 – 100 mg) frozen samples of surgically resected phaeochromocytoma 
tumour tissue were homogenized in TRIzol (Invitrogen, Carlsbad, CA, USA) reagent for 30 
seconds.  Chloroform was then added to the homogenate mixture and the solutions mixed 
vigorously for 15 seconds and left to stand for 3 minutes so that the RNA, DNA and protein 
components could be separated.  The homogenate was then centrifuged for 15 minutes at 
12 000 g, and supernatant containing the concentrated RNA was transferred to a new 
centrifuge tube with 0.5 volumes of 100% ethanol.  To purify the RNA, the solution was 
then added to an RNeasy column (RNeasy Maxi Kit, Qiagen, Valencia, CA, USA) 
centrifuged for 5 minutes at 4 000 g and the resulting flow-through was discarded.  This 
process was repeated twice.  Another 15 mL of RW1 Buffer was added to the column and 
the sample centrifuged for 5 minutes at 4,000 g, and subsequent flow-through again 
discarded.  Ten mL of RPE Buffer was added to the column, which was centrifuged for 10 
minutes at 4 000 g and the flow-through discarded. This process was repeated twice.  The 
column was then removed from the centrifuge tube and transferred to a fresh tube, and 1 ml 
of RNAase-free water was added to the column.  The tubes were left to stand for 1 minute 
at room temperature, and then finally centrifuged for 5 minutes at 4 000 g.  This process 
was repeated twice. 
A 400 µl sample containing the concentrated RNA was transferred to a new tube, 
and the RNA was precipitated with the addition of 1 ml of 100 % ethanol and 40 µl of 3M   88 
sodium acetate (pH 6.0) to each new tube.  The samples were then either stored at – 80 °C 
for 15 minutes, or overnight.  Samples were then spun for 15 minutes at 15 000 g at 4 °C to 
pellet the RNA.  The supernatant was discarded, and the RNA pellet was washed in 75 % 
ethanol, and the samples again centrifuged for 5 minutes at 12 000 g.  Finally the pellet was 
air dried for 10 minutes at room temperature, and resuspended in RNAse-free water and the 
concentration and purity of the RNA in the samples was determined using a 
spectrophotometer.  Any contaminating genomic DNA was removed using a 
deoxyribonuclease (DNAse) according to the manufacturers instructions (Gene Hunter, 
Nashville, TN, USA).  The DNAse treated samples were quantified with a 
spectrophotometer and 2 µg of RNA was reverse transcribed by mixing with 50 ng/µl 
random hexamers (Qiagen), 10mM dNTP mix and DEPC-treated water.  The samples were 
incubated for 5 minutes at 65 °C and then immediately placed on ice to allow primers to 
anneal.  The samples were then added to fresh tubes and the RNA was reverse transcribed 
into cDNA in a reaction containing 10X RT buffer, 25 mM MgCl2, 0.1 M DTT, 
RNaseOUT and SuperScript III RT enzyme (SuperScript III First-Strand Synthesis System, 
Invitrogen) and incubated for 10 minutes at 25 °C followed by 50 minutes at 50°C.  
Reactions were terminated by incubating samples for 5 minutes at 85 °C.  Finally, RNase H 
was added to each sample, and incubated for 20 minutes at 37 °C.  The concentrated cDNA 
was then either stored at - 20 °C or diluted and used for quantitative real time PCR. 
Extraction of RNA and Reverse Transcription: Cell Culture 
  Variations of the RNA extraction and reverse transcription protocol described above 
used for PC12 cell cultures are provided in Chapter 4.    89 
II. Quantitative Polymerase Chain Reaction (Q-PCR) 
 
TaqMan Q-PCR:  Human tissues 
Quantitative PCR was performed on an ABI 7000 Sequence detector (Applied 
Biosystems, Foster City, CA, USA) using PCR conditions consisting of 40 cycles of 15 
seconds at 95°C and 1 minute at 60°C.  Each Q-PCR reaction contained 20 ng cDNA 
template, 1 x TaqMan Universal PCR mastermix (Applied Biosystems), forward and 
reverse primers and a TAMRA labelled probe for the target genes (specific primer 
concentrations and sequence details for the target genes can be found in individual 
chapters).  Each Q-PCR reaction was normalised against the 18sRNA housekeeping gene, 
which consisted of 0.15 µmol/L of forward and reverse primers, and 0.25 µmol/L of VIC 
labelled probe (TaqMan Endogenous Controls, Applied Biosystems).   
SYBR Green Q-PCR:  Cultured PC12 cells 
The methodology for Q-PCR using SYBR Green dye on the cultured PC12 cells is 
provided in Chapter 4.   
TaqMan vs SYBR Green Q-PCR 
  Both TaqMan and SYBR Green technologies are based on the detection and 
quantification of a fluorescent reporter dye that increases in signal intensity relative to the 
amount of PCR product present in the reaction.  However, TaqMan Q-PCR involves a 
sequence-specific oligonucleotide that is tagged with a fluorescent probe (e.g., TAMRA) on   90 
the 5’ end of the sequence, which hybridizes to the internal region of the PCR product.  In 
comparison, SYBR Green is a double-stranded DNA specific dye, which upon excitation 
emits light.  A limitation of SYBR Green technology is that because the dye binds to any 
double stranded DNA, non-specific product such as primer dimer may be detected.  To 
determine non-specific products or primer dimmers have occurred, a melt cure analysis is 
performed.  In contrast, TaqMan will only hybridise to the specific sequence, and unlike 
SYBR Green, can be used for multiplex reactions where two separate sets of primers and 
probe can be used in a single reaction tube (providing the two probes are labeled with 
fluorescent dyes with sufficiently different emission spectra).  Within this thesis, multiplex 
reactions with TaqMan labeled probes were only conducted once prior validation 
confirmed that all reactions were primer limited and primer concentrations were optimized. 
Q-PCR Data Analysis 
  For both TaqMan and SYBR Green Q-PCR, the method of data generation was 
according to the comparative Ct method.  In order to convert the raw Q-PCR data into units 
of relative mRNA expression the threshold (Ct) data, which indicates the fractional cycle 
number at which the amount of amplified target reaches a fixed threshold were obtained for 
both the target (gene of interest e.g., NAT, CGA or NPY) and reference (endogenous 
control e.g., 18sRNA, GAPDH) genes.  The ΔCt could then be calculated by subtracting the 
Ct value of the reference gene from the Ct value of the target gene.  A sample (either 
normal adrenal or untreated PC12 cells) is designated the ‘calibrator’ forming the basis for 
comparative results, whereby the calibrator becomes the “1x” sample, and all other 
quantities are expressed as an n-fold difference relative to the calibrator.  A ΔΔCt value is   91 
then generated by subtracting the ΔCt of the calibrator, from the ΔCt of the unknown 
sample (a ΔΔCt equaling zero is also generated for the calibrator).  The fold difference 
between unknown samples and the reference is then calculated by putting the ΔΔCt into the 
formula 2
-(ΔΔCt) where for the reference sample, by definition, 2
-(ΔΔCt) = 0, therefore, the fold 
difference = 2
-0 = 1.  Thus, unknown samples were expressed as a proportion (or fold 
change) of 1.   
Protein extraction for ELISA  
 
Small samples of frozen phaeochromocytoma tumour tissue were boiled in 750µl of 
0.1M Acetic Acid for 10 minutes, homogenized for 30 seconds and centrifuged for 15 
minutes at 4 000x g (4°C).  Supernatants were then collected and lyophilised.  Dried 
residues were reconstituted in 250µl assay buffer and diluted to allow the concentration of 
plasma and tissue protein levels using commercially available ELISA kits.  Final plasma 
and tissue concentrations of peptide/protein were calculated relative to a standard curve 
generated using Graph Pad Prism 4 software, and converted into ng per ml for plasma 
samples and µg per g of tumour tissue for tumour samples. 
Western Blot 
 
  Western blot analysis was used to compare CGA protein expression in MEN 2 and 
VHL tumour samples.  The specific details of the methodology, including the primary and 
secondary antibodies (and manufacturers information) will be provided in Chapter 6.    92 
III.  Immunohistochemistry 
 
General immunohistochemistry protocol: Paraffin embedded tissue 
sections 
  A  basic  protocol  was  used  throughout  with  modifications  made  according  to 
whether immunohistochemistry was on paraffin embedded or free floating tissueus or on 
cultured  cells.    The  primary  and  secondary  antibodies  used  for  immunohistochemistry 
experiments within this thesis (including manufacturer information) are outlined in Table 
2.2, however the specific details for each type of sample, such as the duration of incubation 
or antibody concentration, will be provided in the individual chapters.   
Two types of blocking solution were used, referred to as either Blocking Solution A or B.  
Both contained 0.1M PB with 10 mM Tris (TPBS), 0.3% Triton X-100, 0.1% (w/v) sodium 
azide  and  normal  donkey  serum  (Jackson  Immuno,  Westgrove  Pennsylvania,  USA).  
Blocking  Solution  A  containing  10%  (v/v)  donkey  serum  was  used  as  a  preblotting 
incubation  serum  and  for  incubating  primary  antibodies,  whereas  Blocking  Solution  B 
contained 1% (v/v) donkey serum and was used for incubating secondary antibodies. 
  Formalin  fixed  sections  of  normal  human  adrenal  gland,  and  human 
phaeochromocytoma were deparaffinized and rehydrated by washing twice for 10 min with 
xylene, followed by 2 x 2 min washes in 100%, 95% and 70% (v/v) ethanol.  Due to the 
potential  erroneous  effects  of  formalin  fixation  on  antigens  within  tissues,  an  antigen 
retrieval process was then performed on the samples whereby the slides were rinsed with 
distilled water and placed into warmed citrate buffer (0.01M, pH 6.0) for 5 min, followed   93 
by immersion in hot citrate buffer (58 ºC). Sections were then heated at 50% power for 5 x 
5 min in a 1100 W microwave oven and allowed to cool to room temperature prior to 
performing the immunohistochemistry procedure.  The glass slides were washed in PB for 
3 × 10 min placed incubated for 1 hour at room temperature in Blocking Solution A in a 
humidified chamber.  Primary antibody, diluted in Blocking Solution A, was applied to the 
slides and incubated at 4 °C for 24 – 48 hours.  The primary antibody was removed by 
washing the slides in TPBS for 3 × 10 min and then the slides were placed back in the 
humidified chamber and secondary antibody, diluted in Blocking Solution B was applied.  
The  humidified  chamber  was  sealed  and  protected  from  the  light,  and  the  secondary 
antibody incubated for 4 hours at room temperature.  Finally, slides were washed for 3 × 10 
min in TPBS before being mounted in ProLong Antifade (Molecular Probes, Eugene, OR 
USA) reagent.       94 
Table 2.2  List of Primary and Secondary Antibodies used within thesis for 
immunohistochemistry experiments   95 
 
Free-floating tissue sections 
  Mouse adrenal slices were washed twice for 30 mins in PB solution and then 
incubated for 30 minutes in 50% ethanol, and again washed in PB solution (2 × 15 min).  
Adrenal slices were then incubated for one hour in Blocking Solution A, and primary 
antibodies, diluted in Blocking Solution A, were added to the tissue slices and incubated on 
a shaker for 48 – 72 hours at room temperature. After washing in TPBS (3 × 30 min), 
Blocking Solution B containing secondary antibodies was added, the tray containing the 
slices was covered to protect from light, and the slices were incubated in species-specific 
secondary antibody on a shaker for 24 hours at room temperature.  Finally, slices were 
washed in TPBS (3 × 30 min) prior to being placed on silanised slides and mounted with 
antifade reagent. 
Cultured PC12 cells 
Cultures of PC12 cells were split into 12-well tissue culture trays containing sterile 
coverslips coated with Poly-L-lysine (0.01% w/v) and incubated for 24 hours in Cisplatin.  
The cells were then washed in 0.1M PB and fixed in 4% (v/v) formalin solution (10 min) at 
4 °C.  The cells were then washed again in PB and incubated for 1 hour at room 
temperature in Blocking Solution A.  Cells were then incubated for 4 hours at room 
temperature with the primary antibodies diluted in Blocking Solution A. Unbound primary 
antibody was removed by washing cells with TPBS (3 x 10 min), and species-specific 
secondary antibody diluted in Blocking Solution B was applied for 1 hour at room   96 
temperature.   Finally, cells were washed in TPBS  (3 x 10 min), and mounted onto glass 
slides with antifade reagent. 
 
IV.  Confocal Microscopy 
 
Confocal microscopy was performed on two seperate machines according to 
whether work was conduced at Muroch University or the National Institutes of Health. 
Sections processed at Murdoch University were examined on a Bio-Rad confocal dual 
laser-scanning TCS 4 D system (Nikon, Wetzlar, Germany) with excitation at 488 nm or 
568 nm and 522 DF35 or 585 EFLP emission filters respectively.  Images were acquired 
with confocal assistant software (BioRad).  Sections processed at the National Institues of 
Health were examined using a Zeiss LSM 510 “405” confocal microscope (Carl Zeiss, 
Oberkochen, Germany) at excitation wavelengths of 488 nm, 543 nm and 633 nm, and 
emission filters consisting of BP 505-550, BP 560-615 and LP 650 respectively.  Images 
were processed using Zeiss LSM Image Browser software (Carl Zeiss, Oberkochen, 
Germany) without modifications to subsequent images.  
All images, including negative controls, were taken with the confocal settings for iris, gain, 
blackness and power set at the same level to allow comparisons.  Staining was described as 
negligible, moderate or intense, and the distribution pattern of immunoreactive cells was 
noted.   97 
V. Statistical Analysis 
   
  The specific statistical tests will be described within each chapter.  Statistical tests 
were performed using the statistics package SPSS (Chicago, IL, USA) and significance was 
set at p < 0·05. 
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Chapter 3 – Expression of NAT & PNMT in the 
normal human adrenal medulla and 
phaeochromocytoma 
 
I.  Abstract 
 
The  noradrenaline  transporter  (NAT)  provides  an  important  mechanism  for 
inactivating  catecholamine-mediated  transmission,  and  is  also  an  important  clinical 
target for radiolabelled catecholamine analogues used in the imaging and detection of 
neuroendocrine tumours including phaeochromocytoma.  In this study we examined 
NAT expression in the normal human adrenal medulla (n=9) and in two groups of 
patients  with  phaeochromocytoma  (n=31),  including  samples  from  patients  with 
hereditary  and  sporadically  occurring  tumours.    Using  immunohistochemistry  and 
confocal microscopy, the enzymes tyrosine hydroxylase (TH) and phenylethanolamine 
N-methyltransferase (PNMT) were used as catecholamine biosynthetic markers and 
chromogranin A (CGA) was used as a marker for secretory granules. In human adrenal 
medulla (n=5), all cells were immunoreactive for TH and PNMT indicating that the 
human adrenal medulla is composed entirely of adrenergic chromaffin cell.  Staining 
for PNMT and NAT were also co-localized, and punctate NAT staining was located 
within  the  cytoplasm.    In  the  first  cohort  of  human  phaeochromocytomas  samples 
(n=8), all demonstrated strong TH expression but variable PNMT expression.  NAT 
immunoreactivity was also variable ranging from absent (n=1) to weak (n=3) and   99 
strong (n=4) and, in some cases, occupied an apparent nuclear location.  In general, 
the level of NAT immunoreactivity did not appear to relate to whether patients had 
positive or negative 6-[
18F]-Fluorodopamine (F-FDA) PET scans.  Furthermore, unlike 
the expression seen in normal human adrenal medullary tissue, NAT expression was 
not consistently co-localized with PNMT.  In the normal adrenal medulla, NAT was 
associated with CGA (n=4). However, in the phaeochromocytoma samples in which 
we examined NAT and CGA, the two proteins did not consistently colocalise.  In the 
phaeochromocytoma  samples  from  patients  with  hereditary  phaeochromocytoma 
associated  with  von  Hippel-Lindau  (VHL;  n=8)  syndrome  and  multiple  endocrine 
neoplasia  type  2  (MEN  2;  n=8),  NAT  expression  was  variable,  but  no  consistent 
difference in NAT immunoreactivity between the two groups of patients were noted.  
The altered pattern of expression for both NAT and PNMT in phaeochromocytoma 
indicates a significant disruption in the regulation and possibly in the function of these 




In many species, the adrenal medulla is a composite of two sub-populations of 
adrenergic and noradrenergic chromaffin cells: ranging from approximately 10 – 20% 
noradrenaline containing cells in the rat, cat, dog and horse, to 100% adrenergic chromaffin 
cells in the rabbit and chipmunk adrenal medulla (Suzuki & Kachi, 1996).  Catecholamine 
transporters, including the noradrenaline transporter (NAT), provide an important 
mechanism for the reuptake of catecholamines following their release from catecholamine   100 
secreting cell populations such as central noradrenergic neurons and postganglionic 
sympathetic nerves. In the peripheral and central nervous systems, NAT is expressed 
predominantly in noradrenergic neurons (Lorang et al., 1994) however, in 2001, Phillips et 
al made the serendipitous discovery that within the rat adrenal medulla NAT expression is 
confined to adrenergic (PNMT-positive) chromaffin cells (Phillips et al., 2001) of the 
adrenal medulla.  Furthermore, in contrast to other transporters such as the serotonin 
transporter (SERT), which is expressed at the cell membrane in chromaffin cells (Schroeter 
et al., 1997), only a minor fraction of NAT is expressed at the cell surface, with most NAT 
expression occurring within the cytosol (Comer et al., 1998, Kippenberger et al., 1999, 
Schroeter et al., 2000), where it has been suggested that NAT is associated with secretory 
granules (Kippenberger et al., 1999).  However, the physiologic role of NAT within 
chromaffin cells is unknown. 
 
In addition to the predominant role of NAT in terminating catecholamine-mediated 
signalling, NAT is also utilised in clinical imaging studies for neuroendocrine tumours 
including phaeochromocytoma (Castellani et al., 2000, Pacak et al., 2001, Ilias et al., 
2003), neuroblastoma (Claudiani et al., 1995, Howman-Giles et al., 2007) and carcinoids 
(Macfarlane et al., 1996).  The clinical utility of NAT is derived from the ability of the 
transporter to act as “molecular gateway”, and facilitate uptake of radiolabelled 
catecholamine analogues including the noradrenaline structural analogue iodo-  101 
metaiodobenzylguanidine (I-MIBG)
1 (Maurea et al., 1993, Shapiro et al., 1995, Sisson & 
Shulkin, 1999) and the dopamine analogue 6-[
18F]-Fluorodopamine (F-FDA) (Pacak et al., 
2001, Pacak & Goldstein, 2001, Ilias et al., 2003).  These compounds are frequently used 
for the detection of phaeochromocytoma.   
 
Although the pattern of NAT expression in adrenergic chromaffin cells of the rat 
has been established (Phillips et al., 2001), we sought to determine in patients with tumours 
arising sporadically whether this pattern replicates that in the human adrenal medulla. We 
also examined whether NAT is associated with secretory granules, using the secretory 
granule marker CGA.  Similarly, given the importance of NAT as a clinical target for 
imaging studies, we examined NAT expression and correlated the level of NAT staining in 
sporadic phaeochromocytoma with F-FDA PET scanning data. NAT expression was also 
examined in phaeochromocytoma samples from patients with tumours arising due to 
hereditary reasons such as germline mutations giving rise to the von Hippel-Lindau 
syndrome (VHL) and Multiple Endocrine Neoplasia type 2 (MEN 2).    
                                                 
1 I-MIBG in text refers to parent MIBG molecule radiolabelled with either the 
123iodine or 
131iodine isotope.   102 
 
III.  Materials and Methods 
 
Tissue procurement and patient samples 
This study included 9 normal human adrenal glands acquired commercially 
(Biocompare) and 31 patients with histologically-confirmed phaeochromocytoma (Table 
3.1).  Phaeochromocytoma samples were divided into two groups depending on whether or 
not they had a hereditary basis.  A subset of the samples from 15 patients with no evidence 
of a hereditary basis for tumour development (which were considered sporadic tumours) 
were divided into Group 1A (n=8; samples 1 – 8) and Group 1B (n=7; samples 9 – 15).  
The second group of samples consisted of 16 patients with a proven hereditary cause of 
disease, including patients with MEN 2 (n=8; samples 16 – 23) and patients with VHL 
(n=8; samples 24 – 31).   
 
Table 3.1  Patient information 
  Sporadic  VHL  MEN 2 
N  15  8  8 
Gender (F/M)  6/9  4/4  5/3 
Age (mean, range)  49.5 (21 – 75)  34.0 (10 – 59)  40.8 (32 – 75) 
   103 
6-[
18F]-Fluorodopamine PET scanning 
  For PET scanning, the patients in Group 1A (samples 1 – 8) were studied fasting 
and were asked to avoid caffeine, tobacco and alcohol for at least 12 h before the scan (to 
avoid any interference with the imaging process because caffeine is a weak adrenergic 
stimulant, and tobacco and alcohol are known to influence gastrointestinal motility).  The 
6-[
18F]-Fluorodopamine (1.0 mCi; 37 MBq) in 10 ml of normal saline was infused over 3 
min via an antecubital iv catheter. Attenuation-corrected images were obtained (from the 
neck to the pelvis in 13 patients and from the head to the midthighs in three patients, the 
latter being patients no. 2, 4, and 9), starting immediately after injection (15 min per 
position). 6-[
18F]-FDA PET scanning was performed using an Advance scanner (General 
Electric) with a 15-cm field of view. Images where initially obtained in 3-dimensional 
mode (with filtered backprojection reconstruction algorithm; 11 studies) and later in two-
dimensional mode (with an iterative reconstruction algorithm; seven studies). The duration 
of emission scanning was 8–15 min at each level. At least one transmission scan of 3- to 5-
min duration was obtained at each level.  All 6-[
18F]-FDA PET scans were performed in the 
NIH Nuclear Medicine Department at the NIH Clinical Center (Bethesda, MD, USA).   
Immunohistochemistry 
  Immunohistochemistry was performed on 5 µm sections of paraffin embedded 
normal human adrenal or phaeochromocytoma specimens.  The slides were deparaffinised, 
antigen retrieval was performed and the immunohistochemistry procedure was conducted 
according to the methods described previously in Chapter 2.  The primary antibodies 
consisted of a polyclonal rabbit anti-NPY (1:100), mouse anti-CGA (1:500), mouse anti-  104 
TH (1:250) and sheep anti-PNMT (1:500).  Antibody labelling was detected using species-
specific secondary antibodies.   
 
  Dual-labelling experiments were performed for the respective groups of patients 
using the following primary antibody combinations (specific secondary antibody indicated 
in parentheses).  Samples from Group 1A were stained for TH/PNMT (anti-mouse 
FITC/anti-sheep Alexa-Fluor 594) and NAT/PNMT (anti-rabbit Cy3/anti-sheep Cy2).  
Samples from Group 1B were stained with antibodies for NAT/CGA.  Samples from Group 
2 were stained with antibodies for NAT/TH (anti-rabbit Cy3/anti-mouse FITC).   
Confocal microscopy 
  Sections were examined using a Zeiss LSM 510 “405” confocal microscope 
according to methods described in Chapter 2.  Staining was described as negligible, 
moderate or intense, and the cellular localisation of staining and distribution pattern of 
immunoreactive cells was noted. 
IV.  Results 
 
TH, PNMT and NAT expression in normal human adrenal samples 
  Dual-labelling experiments were performed on five samples of normal human 
adrenal medulla with antibodies against TH and PNMT.  Strong cytoplasmic staining for 
TH was observed in all medullary cells from the five normal adrenal samples analysed 
(Figure 3.1a).  Strong cytoplasmic staining for PNMT was also encountered in medullary   105 
cells in the five normal adrenal samples analysed (Figure 3.1b).  Cells expressing TH also 
co-stained with PNMT, indicating that the human adrenal medulla is composed of 
adrenergic chromaffin cells. 
  Along side experiments for TH and PNMT, dual-labelling experiments were 
simultaneously conducted with antibodies against PNMT and NAT to determine the 
phenotypic pattern of expression of NAT in the normal human adrenal medulla.  Results 
demonstrated strong punctate NAT staining in the cytoplasm of the normal human adrenal 
glands examined (Figure 3.1c).  NAT expression was consistently co-localised with PNMT 
(Figure 3.1d).   
TH, PNMT and NAT expression in sporadic phaeochromocytoma 
tumour samples 
  Dual labelling experiments were performed for TH/PNMT, and NAT/PNMT 
expression in sporadic phaeochromocytoma samples (n=8; Table 3.2).  Strong TH staining 
was observed in all samples analysed.  PNMT expression was variable (Figure 3.2a-d) 
ranging from strong (n=3 samples) to diffuse weak (n=2 samples) to overall negligible 
(n=2 samples).  In another two samples, isolated clusters of PNMT immunoreactivity were 
observed.   
  We examined whether NAT expression was colocalised with PNMT in the 
phaeochromocytoma tumours, to determine whether the pattern of expression of these two 
markers was the same as in the normal adrenal.  However, the association between the two 
markers was highly variable (Figure 3.3a-d), as NAT staining was observed in PNMT-
positive cells (n=3 samples), in PNMT-negative cells (n=3 samples) and in both PNMT-
positive and PNMT-negative cells within the same tumour sample (n=2 samples).     106 
Additionally, the level of NAT immunoreactivity detected was also inconsistent, ranging 
from strong (n=4 samples) to weak (n=3 samples) to negligible (n=1 sample) NAT 
expression.   
  Results of 6-[
18F]-Fluorodopamine PET scans are presented in Table 3.2.  Among 
the seven patients in whom PET scan data was available, four patients had a positive scan, 
whereas the remaining three patients had negative scans.  Although there was no clear 
direct relationship between the level of NAT immunoreactivity and the PET scan data, 
there was a trend and one isolated case where lack of NAT immunoreactivity correlated 
with a negative PET scan.  In 3 of the 4 patients who had positive PET scans, strong NAT 
immunoreactivity was detected in tumour samples. In 2 of the 3 patients with negative 
scans, the tumour samples from these patients showed either absent or weak NAT 
immunoreactivity. However, one patient, whose tumour sample possessed weak NAT 
immunonreactivity had a positive PET scan and another patient with a negative PET scan, 
had a tumour with strong NAT immunoreactivity.   
Relationship between NAT and CGA  
  To clarify the sub-cellular localisation of NAT, dual-labelling experiments of NAT 
and CGA were performed on normal human adrenal glands (n=4 samples) and in sporadic 
phaeochromocytoma samples (n=7 samples).   
  Strong immunoreactivity was seen for CGA in all samples analysed.  Staining for 
CGA was diffuse and localised to the secretory granules within the cytosol.  This staining 
was co-localised with NAT (Figure 3.4a-b).   
  In the sporadic phaeochromocytoma samples analysed, CGA staining (Table 3.3) 
ranged from weak (n=2 samples), to strong (n=5 samples).  In all samples assessed, CGA   107 
staining was present in the cytoplasm.  The expression of NAT was variable, ranging from 
strong staining (n=1 sample) to weak (n=5 samples) or negligible expression (n=1 sample). 
Within the samples analysed, NAT and CGA were colocalised within the cytoplasm in 4 
samples (Figure 3.4c-d), however in 3 of the samples NAT and CGA were not colocalised, 
either because NAT staining was not identified, or because NAT staining in the cytoplasm.   108 
Table 3.2  TH, PNMT and NAT expression in sporadic phaeochromocytoma.  
Immunoreactivity was described as strong (++), weak (+) or absent (–).  Immunoreactvity 
in parentheses indicates tumours in which the expression of PNMT was absent in the 
majority of the section apart from small clusters of cells possessing immunoreactivity.   
aNAT immunoreactivity was present in both PNMT-positive and PNMT-negative cells 
within same sample. † PET scan data for this patient was not available. 
 






1   ++  ++  ++  +
a  Positive 
2   ++  +  ++  +  Positive 
3   ++  –  –  –  Negative 
4   ++  (+)  +  +
a  Negative 
5   ++  ++  ++  +  Negative 
6   ++  ++  +  +  N/A† 
7   ++  (+)  +  –  Positive 
8  ++  +  ++  –  Positive 
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Figure 3.1  The human adrenal medulla is composed of adrenergic chromaffin cells and 
NAT is colocalised with adrenergic cells.     110 
 
Figure 3.2  Human phaeochromocytoma tumour samples demonstrate variable PNMT 
expression   111 
 
Figure 3.3  Variable colocalisation of NAT and PNMT in human phaeochromocytoma 
tumour samples   112 
 
Table 3.3  NAT & CGA expression in sporadic phaeochromocytoma.  
Immunoreactivity was described as strong (++), weak (+) or absent (–).  Immunoreactvity 
in parentheses indicates tumours in which the expression of NAT was absent in the 
majority of the section apart from small clusters of cells possessing immunoreactivity.  * 
indicate that NAT immunoreactivity was not co-localised with CGA in the cell nucleus. 
 
Sample  NAT  CGA  NAT/CGA co-
localisation 
9  (+)  +   – * 
10  +  +  + 
11  +  ++  +* 
12  +  ++  + 
13  +  ++  +* 
14  ++  ++  + 
15   –   ++   –  
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Figure 3.4  Colocalisation of CGA and NAT in normal human chromaffin cells and in 
phaeochromocytoma   114 
 
NAT expression in hereditary phaeochromocytomas from VHL and 
MEN 2 
In a parallel study, we examined the expression of NAT in hereditary 
phaeochromocytomas from VHL and MEN 2 patients.  Staining for TH was detected in all 
the samples analysed (VHL; n = 8, MEN 2; n = 8).  TH was always detected in the 
cytoplasm, and ranged from weak (n=4 samples) to strong (n=12 samples) staining (Table 
3.4).   
Expression of NAT in the hereditary phaeochromocytomas was highly variable. No 
NAT staining was observed in a subset of samples (n=3 samples) and strong NAT staining 
was observed in the majority of samples (n=8 samples), however the pattern of this staining 
ranged from diffuse strong immunoreactivity (n=4), to only being present in a small 
proportion of cells within the section (n=3 samples) or in the nucleus as compared to the 
nucleus (n=1 sample).  Generalised weak staining was present in the remainder of the 
samples examined (n=5 samples).  In the majority of sections, NAT and TH were 
colocalised (n=10 samples), while in the remaining sections where NAT and TH did not 
colocalise, this was either because NAT was not detected (n=3 samples) or was not in a 
cytoplasmic location (n=3 samples). 
Control sections 
Positive control sections from rat adrenal glands were processed concurrently 
alongside human tissues with each experiment (data not shown).  Immunoreactivity for TH 
was strong in all rat chromaffin cells, and strong PNMT staining was also encountered in a   115 
sub-population of the chromaffin cells, representing the adrenergic population.  Staining for 
NAT was punctate, cytoplasmic and co-localised with PNMT.  No NAT staining was seen 
in the PNMT negative (noradrenergic) cells.  Samples processed in the absence of primary 
antibody showed no immunostaining.  Pre-absorption of the anti-NAT antibody with excess 
GST-NATM2 fusion protein caused a significant reduction of NAT immunoreactivity in 
both normal rat (data not shown) and human adrenal medulla (Fig. 3.5a, b) and human 
phaeochromocytoma (Fig. 3.5c, d). The peptide block significantly diminished both 
cytoplasmic and nuclear NAT immunoreactivity.  Unlike the work of Tischler et al (1998), 
negative controls treated with normal rabbit serum did not show any preferential staining of 
adrenergic chromaffin cells but instead demonstrated weak non-punctate cytoplasmic 
staining of all cells in both the adrenal medulla and cortex of normal rat, normal human 
adrenal and human phaeochromocytoma samples. These results indicated that the staining 
patterns obtained with the rabbit anti-NAT antibody were not attributable to 
immunoreactivity against any unknown adrenaline cell-specific protein(s).   116 
 
Table 3.4  Expression of NAT & TH in hereditary phaeochromocytomas from VHL and 
MEN 2 syndrome.  
Parentheses indicate that staining was only detected in limited clusters of cells.* indicates 
that staining was restricted to nuclear region. 
a indicates that  when NAT staining was 
present, NAT and TH were co-localised 
 
Sample  TH  NAT  NAT/TH co-
localisation 
16   ++  ++ *   –  
17   +  –    –  
18   ++  –   – 
19  ++  ++  + 
20  ++  ++  + 
21   +   +  + 
22   +   ++  +  
23   ++  + *  + 
24   +  (++)  + 
a 
25   ++  (++)  + 
a 
26   ++  ++  +  
27   ++  +  +  
28   ++   –    –  
29)  ++  (++)  + 
a 
30   ++  +   –  
31   ++  +    –  
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Figure 3.5  Variable expression of NAT in human phaeochromocytoma tumour samples. 
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Figure 3.6  Control sections indicating the specificity of the anti-NAT antibody 




  The major findings of this study are that unlike the rat adrenal gland, which is 
composed of two sub-populations of adrenergic and noradrenergic chromaffin cells, the 
human adrenal medulla appears completly composed of adrenergic chromaffin cells.  
However similar to the findings in the rat, NAT expression within the human adrenal is 
localised to the cytoplasm of adrenergic chromaffin cells and is associated with the 
secretory granule marker CGA.  In contrast, NAT expression in phaeochromocytoma, from 
patients with sporadic and hereditary forms of the disease is highly variable and suggests 
that the pattern of NAT expression within some phaeochromocytomas is disrupted relative 
to normal chromaffin cells, including the relationship between NAT and PNMT, the 
association with CGA and also the level of NAT staining detected.  
PNMT expression.   
  Unlike other species that demonstrate specific sub-populations of chromaffin cells 
based on the expression of PNMT, the normal human adrenal gland is composed primarily, 
if not exclusively, of a homogenous population of PNMT positive cells.  In the present 
study we report that in sporadic phaeochromocytoma samples PNMT expression is 
disrupted and although in some samples expression of the enzyme is retained, in other 
samples, PNMT expression is lost.   Our findings of strong TH expression and altered 
PNMT expression in phaeochromocytoma samples is consistent with a recent animal model 
of phaeochromocytoma which also possess high levels of TH but variable PNMT (Hill et   120 
al., 2003).  Our data are also consistent with other studies in human phaeochromocytoma, 
which have also reported altered PNMT levels (Isobe et al., 1998), including findings 
showing that phaeochromocytoma due to the VHL syndrome express negligible levels of 
PNMT and subsequently synthesise minimal amounts of adrenaline (Eisenhofer et al., 
2001b).  Several factors have been shown to modulate PNMT expression including steroid 
associated factors including cortisol, glucocorticoid receptors and steroidogenic factor-1 
(Luo et al., 1994, Finotto et al., 1999, Isobe et al., 2000, Gut et al., 2005).  Other factors 
including the immediate early gene transcription factor Egr-1 (Isobe et al., 2000), neural-
crest associated developmental transcription factor, AP2 (Ebert et al., 1998) and the 
pituitary adenylate cyclase-activating polypeptide and the pituitary adenylate cyclase-
activating polypeptide (Isobe et al., 2003).  An alteration in any of these factors may play a 
role in the variable PNMT expression in sporadic phaeochromocytoma described herein.  
Our present finding that the human adrenal gland is primarily composed of PNMT positive 
cells is at odds with our findings of variable PNMT expression some sporadic 
phaeochromocytomas and hereditary phaeochromocytomas, especially those associated 
with VHL disease (Eisenhofer et al., 2001b).  How and why the loss of PNMT occurs is 
unclear.  Given that the induction of PNMT expression occurs relatively late in 
embryogenesis, and only once progenitor chromaffin cells have migrated to the adrenal 
(Teitelman et al., 1979, Verhofstad et al., 1979, Souto & Mariani, 1996), the absence of 
PNMT in some phaeochromocytomas may reflect a population of cells which either never 
acquired PNMT expression, or have regressed to a cell type incapable of supporting the 
expression of this enzyme.   121 
What is NAT doing in chromaffin cells? 
  In this study our findings show that in the human adrenal medulla NAT is expressed 
in adrenergic cells, similar to the rat where NAT and PNMT are also colocalised to the 
same cells (Phillips et al., 2001).  We also report that in phaeochromocytoma samples this 
relationship was not always so stringent, whereby NAT and PNMT were associated in 
some samples but not in others.  Adrenomedullary chromaffin cells respond to autonomic 
signals prompting the release of catecholamines into the interstitial space where they enter 
the circulation and behave as an endocrine hormone by acting on distant targets.  Several 
studies thus far, including the data presented in this chapter, have identified NAT 
expression in chromaffin cells (Comer et al., 1998, Kippenberger et al., 1999, Schroeter et 
al., 2000, Phillips et al., 2001).  However, it is yet to be determined why NAT expression 
occurs in chromaffin cell given that the catecholamines released from this gland are 
destined to enter the circulation.  Pioneering experiments by Kent and Coupland (1981) 
demonstrated that uptake of exogenous catecholamines occurs in chromaffin cells.  The 
authors also demonstrated that [
3H]-dopamine and [
3H]-noradrenaline were accumulated at 
the highest concentration (with greater accumulation of [
3H]-dopamine) in adrenergic cells.  
While [
3H]-adrenaline accumulation was also observed, it was to a much lesser extent than 
either dopamine or noradrenaline (Kent & Coupland, 1981).  These findings agree with the 
data presented here, and the work of Phillips et al (2001) showing NAT expression in 
adrenergic cells.  The fact that [
3H]-dopamine and [
3H]-noradrenaline were accumulated at 
a higher concentration than [
3H]-adrenaline is likely in keeping with notion that NAT 
sequesters dopamine more effectively that noradrenaline, and adrenaline approximately 2-  122 
fold less efficiently than noradrenaline (Eisenhofer, 2001).  Other data also show that NAT 
can transport all catecholamines (Lorang et al., 1994, Paczkowski et al., 1999).   
  The catecholamine transporters are an important mechanism for catecholamine 
inactivation.  However, what is responsible for adrenaline uptake?  With the exception of 
the bullfrog, Rana catesbiana (Apparsundaram et al., 1997), a specific adrenaline 
transporter has not been identified.  Adrenaline uptake can occur through the organic cation 
transporters (OCTs), particularly OCT1 and OCT3 (EMT) (Breidert et al., 1998, 
Grundemann et al., 1998a, Martel et al., 1999), particularly in non-neuronal cells including 
the liver, intestines and kidney (Eisenhofer, 2001).  However, with the exception of OCT3, 
these transporters have not been detected in the adrenal gland (Verhaagh et al., 1999, 
Eisenhofer, 2001).  Thus, it seems unlikely that any reuptake of adrenaline in the adrenal 
occurs along this pathway. Given the endocrine role of the adrenal medulla and lack of 
studies demonstrating catecholamine reuptake in this tissue, it seems plausible that the 
OCTs and NAT at distant sites in non-neuronal tissues provide an adequate mechanism for 
catecholamine recapture and inactivation.   
Association between NAT and secretory granules  
  Cell surface biotinylation and subcellular fractions of chromaffin cells have 
revealed that the majority of NAT is associated with secretory granules, while only a minor 
fraction of NAT is present at the cell membrane (Kippenberger et al., 1999), findings 
consistent with other reports in PC12 cells, rat adrenal and noradrenergic neurons of 
multiple brain regions (Comer et al., 1998, Kippenberger et al., 1999, Schroeter et al., 
2000, Phillips et al., 2001) where NAT expression is similarly described as cytoplasmic.  
Therefore, we performed dual-labelling experiments with NAT and the secretory granule   123 
marker CGA in order to ascertain the cellular localisation of NAT in normal chromaffin 
cells and phaeochromocytomas.  In normal human chromaffin cells NAT and CGA were 
co-localised, supporting existing evidence of a relationship between NAT and secretory 
granules (Kippenberger et al., 1999). The association with NAT and secretory granules 
appears to contrast with the widely accepted paradigm of NAT as a “plasma membrane” 
transporter and is dissimilar to the serotonin transporter, which is expressed at the plasma 
membrane (Schroeter et al., 1997).  However, numerous finding support the notion of a 
dynamic process in which transporter molecules are recycled to and from the cell surface. 
Trafficking of NAT between vesicular and plasma membrane pools has been implicated as 
a possible means of regulating the activity of the transporter (Blakely et al., 1998, 
Kippenberger et al., 1999, Renick et al., 1999), and the association between NAT and 
secretory vesicles may be important for this (Kippenberger et al., 1999).  Trafficking ability 
may be mediated by either direct or indirect phosphorylation of the transporter, a theory 
supported by the presence of putative phosphorylation sites on the genes encoding SLC6 
transporters, and also through experimental data showing phosphorylating agents such as 
phorbol esters can modulate transporter trafficking and activity (Zahniser & Doolen, 2001, 
Melikian, 2004).  The secretion of transmitter involves the fusion of secretory vesicles with 
the plasma membrane (see Chapter 1) in a process facilitated by interactions between 
vesicular components such as vesicular SNAREs (soluble N-ethymaleimide-sensitive 
attachment factor attachment protein receptor) and the plasma membrane (Kippenberger et 
al., 1999).  Interestingly, a direct interaction between the SNARE protein syntaxin 1A, a 
key component of vesicular trafficking and docking, and the N-terminal portion of NAT 
have been reported (Sung et al., 2003, Sung & Blakely, 2007).  Findings by Sung et al   124 
(2003) also suggest that PKC activation alters cell-surface NAT/syntaxin 1A interaction 
causing a decrease in NAT activity.  Expression of C – terminal variants of human NAT 
have also been shown to cause loss of function and intracellular retention of the variant 
protein (Bauman & Blakely, 2002). 
 
  In contrast to the normal adrenal where NAT and CGA were colocalised, within the 
phaeochromocytoma samples examined, we found that this relationship was not so 
exclusive.  Whereas CGA was consistently observed wtithin the cytoplasm, the site of NAT 
expression was variable, and in some cases the transporter appeared to be located in an 
apparent nuclear location.  The appearance of NAT at the nucleus was highly unusual, 
however, perinuclear expression of the hNET C-t var 1 splice variant of the human NAT 
was detected in COS-7 cells transfected with hNET (Kitayama et al., 2001).  The antibody 
utilised in our experiments is known to recognise all splice variants, thus the unique nuclear 
staining seen in our study may represent a hitherto unseen splice variant.  While this 
remains to be examined, differential subcellular localisation of splice variants has been 
demonstrated for other members of the SLC6 family of Na
+/Cl
- - dependent monoamine 
transporters, including the glycine transporter (Geerlings et al., 2002).  
A future direction for this study could include the further analysis of the relationship 
between NAT and secretory granules using methods such as immunolabelled-electron 
microscopy.  While we attempted to conduct these experiments, the NAT antibody used 
within this study was found to be unsuitable for this experimental procedure.      125 
Is aberrant NAT expression clinically significant? 
The clinical significance of the differing patterns of NAT expression between 
normal and neoplastic chromaffin cells is undetermined but given the importance of NAT 
in the uptake of I-MIBG and F-FDA, we questioned whether these difference in NAT 
expression but may be sufficient to alter the functional activity of the transporter and 
consequently effect the uptake of radiolabelled compounds.  Should this be the case, it may 
partly explain the insensitivity of I-MIBG and F-FDA for the detection of some 
phaeochromocytomas (Pacak & Goldstein, 2001).  A comparison of I-MIBG and F-FDA 
has shown that F-FDA is a superior functional localising agent in the detection of 
phaeochromocytoma (Ilias et al., 2003).  Both I-MIBG and F-FDA utilise NAT for entry 
into tumour cells, however as an analogue of dopamine, which is a better substrate for NAT 
than noradrenaline (Eisenhofer, 2001), it is tempting to speculate that the superiority of F-
FDA is due to a greater affinity for NAT than I-MIBG.  In a study by Carlin et al (2003) 
NAT mRNA and I-MIBG accumulation are highly related in neuroblastoma tumours and 
cell lines (Carlin et al., 2003).  In this study we also looked at the relationship between 
NAT immunoreactivity and whether patients, from whom the tumour samples were 
procured, received positive or negative results in clinical imaging studies using F-FDA.  
When comparing these two factors, the intensity of NAT immunoreactivity was not always 
a reliable indicator of whether a patient would have a positive PET scan. In all of the 3 
patients in whom PET scans were positive, NAT was also detected (strong to weak 
staining). In one of the 4 patients with a negative PET scan, NAT staining was absent.  
However, in two of the patients in whom PET scans were negative, NAT staining was 
detected.  In this comparison, only seven patients/tumour samples were analysed, so   126 
possibly if this number was increased, more obvious trends will emerge.  Another future 
direction is to compare I-MIBG and F-FDA test results with NAT expression (i.e., mRNA 
using Q-PCR) as another means of determining whether a relationship exists.  
 
In a study comparing NAT expression in phaeochromocytomas samples from 
patients with MEN 2 and VHL syndrome it was demonstrated that tumour tissue extracts 
from MEN 2 patients have greater NAT mRNA (6-fold) and protein expression than 
samples from VHL patients (Huynh et al., 2005). Although VHL and MEN 2 patients were 
not compared, a recent study by Kaji et al (2007) suggests that F-FDA is more sensitive 
than I-MIBG in for phaeochromocytoma localisation in patients with VHL syndrome than 
in other forms of the disease (Kaji et al., 2007).  While we also examined NAT expression 
in phaeochromocytomas from patients with MEN 2 and VHL in parallel to the study 
performed by Huynh et al, we did not detect any significant difference in level of NAT 
staining between the two groups.  
But don’t forget the VMATs 
A major issue associated with physiology-based imaging with radionucleotide-
labelled substrates is distinguishing between poor signal intensity due to the absence of a 
lesion versus poor signal intensity due to poor expression of key factors necessary for 
accumulation of the substrate.  Within this chapter we present data demonstrating that in 
phaeochromocytoma tumour tissue from patients with sporadic and hereditary forms of the 
tumour NAT expression varies considerably between samples.  We also speculate that 
variable NAT expression is a major factor determining why the imaging modalities, I-
MIBG and F-FDA, which utilise NAT as an entry point into the tumour cells, can fail to   127 
detect some phaeochromocytomas.  Given that we failed to report a relationship between 
NAT staining in tumour samples and the results of F-FDA imaging studies suggest 
otherwise.  A critical, but often overlooked factor relating to the clinical efficacy of agents 
such as I-MIBG and F-FDA is the retention, active accumulation and recycling of I-MIBG 
or F-FDA into secretory vesicles once they have been sequestered into the cytoplasm in 
process facilitated by VMATs (Kolby et al., 2003, Kolby et al., 2006).  In the case of F-
FDA, a dopamine analogue, once it has been transported into the cytosol, the F-FDA is 
translocated into storage vesicles where it may undergo further conversion by DBH into 6-
fluoronoradrenaline (Eisenhofer et al., 1989).  Reduced F-FDA PET image quality due to 
poor storage by VMAT can be differentiated from reduced uptake (Eisenhofer, 2001) 
indicating that the VMATs play an equally if not more important role in determining the 
ability of F-FDA or I-MIGB to detect phaeochromocytoma.  While in this chapter we did 
not explore the expression of the VMATs in our patient cohorts, this is an important factor 
to be considered in the future.  
 
In summary, the results of this study reveal that while the majority of human 
phaeochromocytoma tumour samples analysed demonstrate NAT immunoreactivity, in 
contrast to the normal rat and human adrenal medulla, NAT expression is not consistently 
colocalised with PNMT or CGA.  The pattern of NAT expression observed in our samples 
varied markedly both in the level of detection and cellular distribution pattern.  Similarly, 
PNMT expression was also altered in some of the phaeochromocytoma samples examined.  
This study indicates that the transformation of normal neuroendocrine chromaffin cells to 
phaeochromocytoma tumour cells is associated with changes in the expression of NAT and   128 
the catecholamine biosynthetic enzyme PNMT.  In comparison, the expression of TH and 
CGA both appeared relatively unchanged. 
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Chapter 4 – Effects of Cisplatin on the activity and 
expression of NAT in PC12 cells 
 
I.  Abstract 
 
Patients with metastatic phaeochromocytoma have limited options for treatment.  An 
emerging concept in the treatment and clinical management of these patients is by 
combining chemotherapy compounds with the imaging agent 
131Iodo-
metabenzylguanidine (
131I-MIBG) based on the rationale that increasing the 
expression and/or activity of the noradrenaline transporter (NAT) allows the active 
accumulation of a greater dose of the 
131I-MIBG radionucleotide to be incorporated 
into the tumour, thus providing greater therapeutic value.  In this study, we examined 
NAT expression in the rat phaeochromocytoma PC12 cell line following 24-hour pre-
treatment with the chemotherapy drug Cisplatin at a range of concentrations (0.1 µM 
to 0.001 µM), to determine whether this compound may represent a novel drug which 
could be administered to metastatic phaeochromocytoma patients in order to prime 
them for further treatment with 
131I-MIBG.  Functional [
3H]-noradrenaline uptake 
assays, quantitative PCR and immunohistochemistry were performed to assess NAT 
expression following Cisplatin treatment.  The results of this study did not 
demonstrate any appreciable upregulation of NAT activity following Cisplatin 
treatment, and while NAT mRNA expression was 2-fold greater in cells treated with 
Cisplatin, this difference was not statistically different.  Immunohistochemistry using   130 
an antibody for NAT also failed to show any major impact on the level or pattern of 
NAT expression in treated versus untreated cells.  The data generated in this study do 
not support a priming role for Cisplatin as a drug with the capacity to augment NAT 
expression in phaeochromocytoma. 
 
II.  Introduction 
 
  Although the prevalence of phaeochromocytoma has been suggested to be between 
0.05 – 0.2% of individuals with sustained diastolic hypertension (Manger, 2006), up to 
36% of patients with sporadic phaeochromocytoma (John et al., 1999, Ahlman, 2006) have 
been suggested to develop the metastatic form of the disease. The management of patients 
with metastatic phaeochromocytoma is complicated and therapeutic options are limited.  
Furthermore, the prognosis for these patients is poor and the overall 5-year survival rate for 
these individuals ranges from 20 – 50% (Edstrom Elder et al., 2003). While developed 
primarily as a localising agent, the potential therapeutic value of 
131I-MIBG has also been 
recognised (Wieland et al., 1980, Sisson et al., 1981, Sisson et al., 1984).  The active uptake 
of 
131I-MIBG is mediated via the noradrenaline transporter (NAT) (Sisson et al., 1981, 
Jaques et al., 1984, Mairs, 1999), a monoamine transporter expressed by chromaffin and 
phaeochromocytoma tumour cells (Kippenberger et al., 1999).  Once 
131I-MIBG is 
transported into the cell a concentrated dose of radiation, primarily via emitted β-particles 
(Tepmongkol & Heyman, 1999) can be delivered to the tumour lesion(s).  Since the 
development of this radionucleotide, several papers espousing the therapeutic value of 
131I-  131 
MIBG have been published in which varying doses of 
131I-MIBG were administered and 
the observed patient responses varied considerably (Sisson et al., 1984, Loh et al., 1997, 
Mukherjee et al., 2001, Safford et al., 2003, Rose et al., 2003, Fitzgerald et al., 2006, 
Forssell-Aronsson et al., 2006).  A possible reason for the variable responses to 
131I-MIBG 
therapy may relate to NAT expression within tumour cells.  
  Neuroblastoma arise from cells derived from the neural crest which, progress along 
the sympathoadrenal lineage (Mora & Gerald, 2004, Maris et al., 2007).  Neuroblastoma is 
an aggressive childhood cancer, which accounts for about 8 – 10% of all childhood cancers 
(Riley et al., 2004) and is the most common extra-cranial solid tumours observed in 
children under four years (Mora & Gerald, 2004, Maris et al., 2007).  Although localised 
forms of neuroblastoma are generally highly treatable (Maris et al., 2007), the outlook for 
patients with advanced metastatic forms of neuroblastoma continue to be dismal 
(Mastrangelo et al., 1998, Brodeur, 2003, Pajic et al., 2005).  Malignant neuroblastomas 
are often composed of heterogeneous and phenotypically diverse sub-populations of cells 
that can possess differing chemosensitivities.  Therefore treating disseminated 
neuroblastoma with chemotherapy alone can be met with poor outcomes due to the 
appearance of drug-resistant clones within the tumour(s), which following initial therapy 
may continue to expand and proliferate (Mastrangelo et al., 1998, Pajic et al., 2005, de 
Cremoux et al., 2007).  Radiation therapy of the tumour with 
131I-MIBG is also often 
advocated on the basis that neuroblastoma lesions (primary and metastates) are radiation 
sensitive and can accumulate 
131I-MIBG which will selectively delivery of large doses of 
radiation to the lesions while minimising the adverse affects on adjacent tissues 
(Tepmongkol & Heyman, 1999, Garaventa et al., 2003).  However, large doses of 
131I-  132 
MIBG can be associated with hematopoietic toxicity (Maris et al., 2007) and because 
uptake of 
131I-MIBG into neuroblastoma lesions can be heterogeneous this therapy alone is 
unlikely to provide a definitive treatment option (Mairs, 1999).  Given the limitations of 
chemotherapy or radiotherapy alone, the use of multiple non-cross resistant therapies 
including chemotherapy and 
131I-MIBG radiotherapy in combination have been suggested a 
as means of maximising long-term survival (Mastrangelo et al., 1998).  Pilot clinical trials 
in patients with malignant neuroblastoma in which 
131I-MIBG was combined with the 
chemotherapy drug Cisplatin have provided promising results, and these data suggest that 
when administered prior to 
131I-MIBG, Cisplatin may have a ‘radiosensitiser’ role whereby 
the compound can influence the noradrenaline transporter and hence promote greater 
uptake of 
131I-MIBG.  
  Given that neuroblastomas are derived are from the same neural crest progenitor 
cells as chromaffin cells (Maitra & Kumar, 2003, Mora & Gerald, 2004), 
phaeochromocytomas and neuroblastomas possess many similarities, including the ability 
to accumulate 
131I-MIBG.  Therefore, in this study, we examined the impact of Cisplatin 
pre-treatment in vitro on NAT expression and activity in the PC12 rat phaeochromocytoma 
cell line, to establish pre-clinical data on the efficacy of this compound as a putative 
treatment strategy for phaeochromocytoma.      133 
 
III.  Materials and Methods 
 
Cell Culture 
The PC12 cell line was obtained from the American Type Culture Centre CRL 1721 
(ATCC, Manassas, VA).  Cells were grown in Dulbecco modified medium (DMEM) 
supplemented with 0.03% (w/v) L-glutamine, 0.03% pyruvate, 0.03% non-essential amino 
acids, 5% (v/v) foetal calf serum, 10% (v/v) horse serum, and 25 U/ml penicillin-
streptomycin, and maintained at 37 °C with 7.5% CO2. 
Cells were treated with varying concentrations of Cisplatin diluted in media, 
ranging from 0.1 µM to 0.001 µM, and incubated for 24 hours prior to experimental 
regimes.  Control cells were not treated with Cisplatin were cultured and processed 
concurrently.  
[
3H]-Noradrenaline Uptake Assays 
To determine the effects of Cisplatin on the functional activity of NAT, PC12 cells were 
plated grown to 80% confluence and split into 12-well tissue culture trays pre-coated with 
0.01% w/v Poly-L-lysine (Sigma-Aldrich, Castle Hill, NSW, Australia) and incubated for 
24 hours in the presence (or absence) of Cisplatin.  The media was aspirated, and the cells 
were then washed with Krebs-Ringer-N-2-hydroxyethylpiperazine-N’-2-ethane sulphonic 
acid (KRH) buffer to remove any traces of media.  Cells were incubated for 12 minutes at 
37 °C in 1 ml of KRH buffer containing 10 nm of [
3H]-Noradrenaline ([
3H]-NA; NET-678:   134 
49.7 Ci/mmol, Perkin Elmer, Boston, MA USA).  For each Cisplatin concentration, each 
tray contained a matching well with untreated PC12 cells.   Cisplatin treated and untreated 
cells were also matched with wells incubated in the presence (or absence) of 10 µM 
desipramine (DMI), a non-selective monoamine transporter antagonist used to inhibit 
catecholamine reuptake (Kitayama et al., 2006).  Following incubation, supernatant 
containing [
3H]-NA ± DMI was aspirated, and the cells were washed twice in ice-cold 
KRH buffer.  Cell contents were then lysed with 0.5% Triton X-100, and aliquots taken for 
measurement in a scintillation spectrometer (Beckmen LS6500 Liquid Scintillation 
Counter) to measure the [
3H]-NA decays per minute (dpm).  To measure the content of total 
protein in each well, a Bradford Assay (Bio-Rad Laboratories, Hercules, CA) was 
performed according to the manufacturers instructions.  
[
3H]-Noradrenaline uptake experiments statistical analysis 
  To determine the effect of the different Cisplatin (± DMI) concentrations on the 
uptake of [
3H]-NA ± DMI was compared using a one-way ANOVA followed by post-hoc 
testing by Sheffe's method.   This analysis was performed under the assumption of equal 
variance and significance set at P<0·05.  
Ribonucleic acid isolation and reverse transcription 
To assess the effect of Cisplatin on mRNA expression of NAT in PC12 cells, cells 
were grown in tissue culture flasks to 80% confluence, and incubated for 24 hours in the 
presence of Cisplatin (0.1 µM to 0.001 µM).  Cells were trypsinised and washed in 0.1 M 
phosphate buffered saline and centrifuged to produce a pellet.  Total RNA was then 
extracted from cells using the Total RNA Isolation System (Promega, Madison, WI)   135 
according to the manufacturers instructions.  Cell pellets were suspended in equal volumes 
of Denaturing solution and Phenol:Chloroform:Isoamylalcohol (Promega), mixed 
thoroughly and incubated on ice for 15 minutes.  The samples were then centrifuged at 4 °C 
at 10 000 g for 20 minutes.  The aqueous phase was removed and transferred to fresh 
microcentrifuge tubes. 2M Sodium Acetate (pH 4.0) and isopropanol (Promega) were 
added to the aqueous layer, mixed thoroughly and centrifuged at 10,000x g for 5 minutes at 
4 °C.  The resulting RNA pellet was air-dried and then resuspended in 20 µl of RNase-free 
water. Purity and quantity of RNA was measured using a spectrophotometer (NanoDrop, 
ND-1000, Wilmington, DE, USA).  
Genomic DNA was removed from 20 µg samples of RNA by incubating a 1x buffer 
containing 5U of RQ1 deoxyribonuclease (Promega) and 80 U of ribonuclease inhibitor 
(RNasin; Promega) for 20 minutes at 37 °C. RNA was then re-extracted with 
Phenol:Chloroform:Isoamyl alcohol and Phase Lock Gel tubes (Eppendorf; Brinkman 
Instruments, Westbury, NY), and precipitated in 100% ethanol and 0.3 M sodium acetate 
(pH 4.0).  Deoxyribonuclease treated total RNA (5 µg) was then reverse transcribed in a 50 
µl volume using Superscript III (200 U, Invitrogen) in 1 x RT buffer, containing 2.5 ng/µl 
random primers, 1 mM deoxynucleoside triposphate (dNTPs), 10 mM dithiotreitol, and 40 
U RNAsin.  The reverse transcription reaction consisted of 50 °C for 45 minutes, 55 °C for 
30 minutes and final enzyme inactivation step of 90 °C for 5 minutes. 
Quantitative real-time reverse transcriptase-polymerase chain 
reaction 
Quantitative PCR was conducted using the double-stranded DNA intercalating dye, 
SYBR Green 1 (Applied Biosystems).  Each reaction contained SYBR Green dye, cDNA,   136 
0.1 µmol/L of NAT primers (Fwd: CCTGCACCACCAACTGCTTAGC, Rev: 
GCCAGTGAGCTTCCCGTTCAGC) and 0.2 µmol/L of GAPDH primers (Fwd: 
TCTCCATCCTTGGTTACACTGG, Rev: AGGACCTGGAAGTCATCAGC) and water.  
Negative control samples contained either water alone, or RNA samples in which reverse 
transcription was not conducted).  Amplification was performed on a Corbett RotorGene 
real time PCR Detection System (Corbett Life Science, Sydney, NSW, Australia) at the 
following conditions; one cycle of 95 °C for 10 minutes, 40 cycles of 15 seconds at 95 °C, 
and 1 minute at 60 °C.  Dissociation curve analysis was performed consisted of 95 °C for 
15 seconds, 60 °C for 20 seconds. To finish the temperature was gradually increased for 20 
minutes back up to 95 °C for 15 seconds.   
Immunofluorescence 
Three replicated cultures of PC12 cells were split into 12-well tissue culture trays 
containing sterile coverslips coated with Poly-L-lysine (0.01% w/v) and incubated for 24 
hours in Cisplatin.  The cells were then stained with rabbit anti-NAT (1:400) and mouse 
anti-TH (1: 500) primary antibodies followed by donkey anti-rabbit Cy3 and donkey anti-
mouse FITC according to the methods described in Chapter 2.  Control experiments where 
primary antibodies were omitted were also run in parallel.     137 
 
IV.  Results 
 
Effect of Cisplatin on NAT mRNA levels 
  Examining NAT mRNA in untreated PC12 cells relative to Cisplatin treated cells 
with revealed that at a concentration of 0.1 mM Cisplatin had a negative effect on NAT 
expression (Table 4.1, Figure 4.1).   At greater concentrations, Cisplatin treatment 
increased NAT mRNA modestly.  However, when examined for statistical significance, the 
difference between untreated and treated (at all concentrations) failed to reach significance.    
 
Table 4.1  Effects of Cisplatin pre-treatment on NAT mRNA expression in PC12 cells 
 
  Δ Ct (mean ± SEM) for NAT at 
each Cisplatin concentration 
(normalized to GAPDH Ct) 
Untreated   4.46 ± 0.42 
0.1 mM  6.80 ± 0.09 
0.01 mM  5.74 ± 1.16 
0.001 mM  4.30 ± 0.44 
0.1 µM  5.01 ± 0.61 
0.01 µM  3.76 ± 0.51 
0.001 µM  4.14 ± 0.31 
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Figure 4.1  Effect of 24-hour Cisplatin pre-treatment on the relative expression of NAT 
mRNA in PC12 cells.   
   139 
 
Effect of Cisplatin on NAT cellular expression 
Incubating PC12 cells did not appear to cause major changed to the NAT, or TH 
expression (Figure 4.2).  All cells, regardless of treatment, demonstrated cytoplasmic TH 
expression. Cisplatin pre-treatment did not affect the cellular localisation of NAT in PC12 
cells, and punctate NAT staining was also detected in the cytoplasm of all cells, treated or 
untreated.  When comparing the level of intensity of staining, cells treated with Cisplatin 
appeared to have less intense NAT staining than the untreated cells, with the exception of 
cells treated with 0.001mM, which appeared possess NAT staining similar to the untreated 
cells.  Treating cells with Cisplatin did not impair cell growth characteristics, and the 
morphology of the PC12 cells was not changed following treatment.  Negative control 
experiments failed to show any immunoreactivity.     140 
 
Figure 4.2  Effect of 24-hour Cisplatin pre-treatment on NAT staining in PC12 cells   141 
 
Effect of Cisplatin on NAT functional activity 
In our [
3H]-NA uptake experiments we found that the wildtype PC12 cells 
demonstrated only marginal noradrenaline uptake, indicated by our finding of very little 
difference between [
3H]-NA uptake between wildtype PC12 cells compared to those treated 
with DMI.  Similarly, there was also very little difference between [
3H]-NA uptake from 
the Cisplatin PC12 cells incubated in the presence or absence of DMI.  When examining 
the effect of the drug on uptake [
3H]-NA uptake between wildtype and treated cells, there 
was a weak positive effect of Cisplatin on [
3H]-NA uptake, however, when we examined 
this effect for statistical significance by ANOVA, the effect of the drug was not statistically 
valid.   
 
Table 4.2  Effects of Cisplatin pre-treatment on NAT functional activity in PC12 cells 
(DMI; desipramine). 
 








0.1 mM  2.607 ± 0.679  3.360 ± 0.817  2.977 ± 0.107  3.587 ± 0.302 
0.01 mM  2.997 ± 1.802  3.617 ± 1.738  2.560 ± 1.482  5.612 ± 3.502 
0.001 mM  2.390 ± 0.640  5.377 ± 1.311  2.318 ± 0.590  5.412 ± 1.061 
0.1 µM  3.280 ± 1.035  16.763 ± 5.374  4.457 ± 2.056  25.770 ± 2.266 
0.01 µM  1.660 ± 0.105  4.520 ± 1.858  1.663 ± 0.435  4.697 ± 0.983 
0.001 µM  2.835 ± 0.878  2.371 ± 0.323  2.617 ± 0.258  3.594 ± 0.419 
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V. Discussion 
 
  Despite the promising results from studies in neuroblastoma cell lines, where 
Cisplatin pre-treatment increased NAT functional activity and/or expression, in our study 
we observed a marginal, but statistically invalid, effect of Cisplatin on NAT expression 
(mRNA) and [
3H]-NA uptake in PC12 cells treated with Cisplatin.  
131I-MIBG and NAT expression 
The treatment of malignant phaeochromocytoma with 
131I-MIBG has been in effect 
since the early 1980’s, and despite more than two decades of use, few detailed guidelines 
for the use of 
131I-MIBG have been implemented.  Further, due to the extreme rarity of 
malignant phaeochromocytoma, very few detailed clinical studies with the compound have 
been conducted. However of the data collected, promising results have demonstrated that in 
some groups of patients, complete or partial tumour and hormonal responses may be 
achieved (Sisson et al., 1984, Loh et al., 1997, Mukherjee et al., 2001, Safford et al., 2003, 
Rose et al., 2003, Fitzgerald et al., 2006, Forssell-Aronsson et al., 2006).  The underlying 
reason for such a vast range of responses to the therapy may be due to the dose of 
131I-
MIBG administered (96 – 1185 mCi), extent of the disease or the site of the metastatic 
lesions.  Another factor may also be related to the intrinsic capacity of the tumours to 
accumulate the compound via NAT.  Several lines of evidence have shown a strong 
correlation between NAT expression and 
131I-MIBG accumulation in neuroblastoma cells 
lines (Mairs et al., 1994, Lode et al., 1995, Carlin et al., 2003) and previous data on 
neuroblastoma patients treated with 
131I-MIBG and the chemotherapy drug Cisplatin have   143 
shown improved tumour and hormonal responses (Mastrangelo et al., 1995, Mastrangelo et 
al., 1997, Mastrangelo et al., 1998).  Similar data in phaeochromocytoma are lacking, 
however, while 
131I-MIBG accumulation was not examined directly, variable levels of NAT 
expression in phaeochromocytoma tumour samples have been described elsewhere 
including in Chapter 3 and in phaeochromocytoma cell lines (Dixon et al., 2005).  
Combined, one may extrapolate from these findings that the poor patient responses to 
131I-
MIBG may be, atleast in part, due to inadequate expression of NAT.  
Why combine 
131I-MIBG and chemotherapy, and why chose Cisplatin? 
The rationale for combining chemotherapy and radiation therapy is to maximise the number 
of cancer cells effectively targeted and destroyed.  Metastatic neuroblastoma and 
phaeochromocytoma are both composed of heterogeneous sub-populations with differing 
sensitivities to radiation and chemotherapy (Spengler et al., 1986).  Therefore following 
initial therapy, aggressive chemo- and radiation resistant clones may continue to proliferate 
and be responsible for relapses with poor responses to follow up therapy (Mastrangelo et 
al., 1998, Tepmongkol & Heyman, 1999, Mastrangelo et al., 2001).  Thus, to improve long-
term results, it is necessary to destroy resistant cells and prevent their development.  
According to the Goldie-Coldman hypothesis (Mastrangelo et al., 1998), the risk of 
tumour-cell cross-resistance is decreased by rapid cytoreduction, and the use of non-cross 
resistant drugs.  Further, greater benefit may also be derived from the early combination of 
chemotherapy and radiation therapy (Mastrangelo et al., 1998, Tepmongkol & Heyman, 
1999).  Cisplatin is deemed complementary to radiation therapy due to its known activity 
against neuroblastoma, mild myelotoxicity and the known synergism between Cisplatin and 
radiation (Dewit, 1987).  In vitro analysis has also demonstrated that Cisplatin pre-  144 
treatment augmented 
131I-MIBG uptake (Armour et al., 1997, Meco et al., 1999) and also 
increased NAT expression (Armour et al., 1997). Signal transduction mechanisms such as 
protein kinase A (PKA) and protein kinase C (PKC) are known to modify the activity 
catecholamine transporters, including NAT, by altering transporter phosphorylation.  The 
effects on transporter function are due to changes in the cell surface expression, and ability 
of the transporter to interact with substrate, rather than altering the catalytic capacity of the 
molecule (Apparsundaram et al., 1998, Pristupa et al., 1998, Melikian & Buckley, 1999).  
Reports in macrophages, suggest an interaction between Cisplatin and PKC (Shishodia et 
al., 1998) thus a possible explanation for the finding of increase uptake of 
131I-MIBG into 
the neuroblastoma cells is that Cisplatin has an effect on NAT phosphorylation by 
interacting with PKC resulting in increased activity of NAT.  The data generated in our 
study with PC12 cells pre-treated with Cisplatin did not replicate the findings from 
neuroblastoma cell lines.  We found that while Cisplatin pre-treatment augmented [
3H]-NA 
uptake and NAT mRNA slightly these findings were not statistically significant. Possibly, 
had we incubated cells in Cisplatin for longer (i.e., 48-hours) or at different range of 
concentrations this may have had a different effect.  While other reports have demonstrated 
an ability to down regulate NAT expression in phaeochromocytoma-derived cell lines or in 
other cell types expressing the transporter (Zhu & Ordway, 1997, Zhu et al., 2000, Ikeda et 
al., 2001, Ordway et al., 2005), few reports have demonstrated an ability to increase NAT 
activity, although in bovine chromaffin cells prolonged exposure to ketamine has been 
shown to cause NAT upregulation (Hara et al., 2002).  Thus the search for a compound 
with the ability to enhance 
131I-MIBG accumulation continues however, recent data in 
neuroblastoma cell lines using the topoisomerase I inhibitor topotecan suggest that this   145 
drug may improve 
131I-MIBG accumulation (McCluskey et al., 2005).  Whether this 
compound affects NAT activity and/or expression, or represents a viable option for patients 
with metastatic phaeochromocytoma is yet to be discovered. 
Different responses due to different cells 
Could the different responses observed in the current study on PC12 cells versus the 
previous findings in neuroblastoma cells be due to the intrinsic differences between the two 
cell types?  According to the classic theory of neural crest – sympathoadrenal cell 
development, pluripotent cells arise from a common progenitor and diverge into distinct 
cell types (Huber et al., 2002, Huber, 2006). Unlike chromaffin cells, which represent a 
fully differentiated and specialised cell, neuroblasts appear to represent an immature cell, 
which have a greater pluripotent potential than chromaffin cells (Mora & Gerald, 2004).  
This is highlighted by the capacity of neuroblastoma cell lines to differentiate into 
chromaffin cells, melanocytes, Schwann cells or neurons (Ciccarone et al., 1989, Cooper et 
al., 1990, Thiele, 1991, Gestblom et al., 1999). This has led many to suggest that that 
neuroblastomas are blocked in different stages of neural crest differentiation (Molenaar et 
al., 1990, Cooper et al., 1990) and exist along a biological continuum.  The level of tumour 
differentiation and the cell type from which tumours are derived has also been suggested to 
have an impact on prognosis (Hoehner et al., 1998). In vitro models of neuroblastoma can 
be divided into three types:  neuroblastic, substrate adherent and intermediate and these 
three sub-types have been suggested to represent different neural crest phenotypes (Ross et 
al., 2003).  The PC12 cells used in this study possess a fully differentiated neuroendocrine 
phenotype (Dixon et al., 2005), however, the phenotype of the neuroblastoma cells used in 
the previous in vitro studies by Armour and Meco is unclear.  Potentially, the divergent   146 
results obtained between out study on PC12 cells and the work of Armour and Meco is 
derived from differing sensitivities of the different cell lines to Cisplatin.  Conversely, the 
fact that our PC12 cells are derived from a rat phaeochromocytoma, the neuroblastoma cell 
lines were all generated from human neuroblastomas could also have in impact on the 
results we obtained.   
  
  In summary, in this study despite promising previous work in which treating 
neuroblastoma cell lines with Cisplatin led to an increase in NAT activity and/or 
expression, using the rat phaeochromocytoma PC12 cell culture model we failed to 
replicate these findings.   Based on this work, it seems that Cisplatin was limited clinical 
utility as a radiosensitiser in the treatment of patients with metastatic phaeochromocytoma 
using
131I-MIBG radiotherapy.   
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Chapter 5 – NPY expression in 
phaeochromocytomas: Relative absence 
in tumours from patients with VHL 
syndrome  
 
I.  Abstract 
 
In addition to producing excess  catecholamines  phaeochromocytomas also secrete 
numerous other secretory proteins and peptides, including neuropeptide Y (NPY), a 
vasoactive  peptide  with  influences  on  blood  pressure.  The  production  of 
catecholamines  and  NPY  by  phaeochromocytomas  is  highly  variable.  This  study 
examined the influence of hereditary factors, differences in catecholamine production 
and PNMT expression on tumour NPY expression, as assessed by quantitative PCR, 
enzyme  immunoassay  and  immunohistochemistry.  Phaeochromocytomas  included 
hereditary adrenaline-producing tumours (adrenergic phenotype) from patients with 
multiple  endocrine  neoplasia  type  2  (MEN  2),  predominantly  noradrenaline-
producing tumours (noradrenergic phenotype) from patients with von Hippel-Lindau 
(VHL) syndrome, and other adrenergic and noradrenergic tumours where there was 
no  identified  hereditary  syndrome.    Tumours  from  VHL  and  non-syndromic 
noradrenergic patients showed significantly less (P<0.0001) PNMT expression and 
tumour  adrenaline  concentrations  that  samples  from  MEN  2  or  non-syndromic 
adrenergic patients.  NPY levels in phaeochromocytomas from VHL patients were   148 
lower  (P<0.0001)  than  in  those  from  MEN  2  patients  for  both  mRNA  (84-fold 
difference) and the peptide (99-fold difference). These findings were supported by 
immunohistochemistry. NPY levels were also lower in VHL tumours than in those 
where there was no identified hereditary syndrome.  Relative absence of expression 
of NPY in phaeochromocytomas from VHL patients compared to other groups is 
consistent with a unique phenotype in VHL syndrome. 
II. Introduction 
 
  The adrenals are thought to be a major source of circulating NPY and in animals 
lacking an adrenal medulla, plasma NPY concentrations are reduced by 35% (Evequoz et 
al., 1995).  Thus the adrenals represent a potential source of vast quantities of NPY.  
Elevated plasma NPY levels are observed in diverse range of conditions including chronic 
stress (Han et al., 1998) and during septic or haemorrhagic shock (Watson et al., 1988, 
Qureshi et al., 1998) and NPY is also produced in high quantities by phaeochromocytomas 
(Adrian et al., 1983, Lundberg et al., 1986, Grouzmann et al., 1989, O'Hare & Schwartz, 
1989, deS Senanayake et al., 1995, Bravo, 2002, Spinazzi et al., 2005).  In addition to its 
known roles in feeding, sexual behaviour and energy metabolism, the peptide is also a 
potent modulator of the cardiovascular system and blood pressure.  Neuropeptide Y has 
powerful vasoconstrictor effects causing significant increases in blood pressure at plasma 
concentrations reached in several pathological conditions, including heart failure and 
phaeochromocytoma (Ullman et al., 2002).  The vasoactive properties of NPY operate 
independently of adrenoceptor activation, and consequently the common pharmacological   149 
management of phaeochromocytoma by adrenoceptor antagonists are ineffective against 
hypertension instigated by NPY.  This has prompted discussion that the anti-hypertensive 
management of phaeochromocytoma should also account for the effects of NPY, in 
addition to catecholamines (Bravo, 2002). 
  Several aspects of NPY production by phaeochromocytomas are unclear, including 
why  NPY  production  by  these  tumours  is  so  highly  variable  (Lundberg  et  al.,  1986, 
Grouzmann  et  al.,  1989,  deS  Senanayake  et  al.,  1995).    Some  reports  suggests  that 
differences in NPY production may depend on whether tumours are malignant or benign 
(Grouzmann  et  al.,  1989),  or  alternatively  are  derived  from  adrenal  extra-adrenal 
chromaffin cells (Lundberg et al., 1986).  It is unclear why this would be the case, but 
possibly given that adrenal and extra-adrenal tumours are characterised by differing PNMT 
expression  (Tischler  et  al.,  2006),  we  questioned  whether  NPY  expression  in 
phaeochromocytoma  relates  to  differences  in  adrenaline  synthesis  and/or  PNMT 
expression.   
  Phaeochromocytomas from VHL and MEN 2 possess numerous differences, which 
range from differences in tumour biology, such as the expression of PNMT and synthesis of 
adrenaline,  to  divergent  clinical  characteristics  such  as  the  appearance  of  symptoms, 
especially hypertension (Eisenhofer et al., 1999, Eisenhofer et al., 2001b).  Thus, in this 
study our objectives were two fold:  firstly, due to the vasoactive properties of NPY and 
differences  in  symptoms  observed  in  the  respective  patient  groups,  to  examine  NPY 
expression between phaeochromocytoma from VHL and MEN 2; and secondly due to the 
differences  in  adrenaline  synthesis  expression  between  VHL  and  MEN  2  patients,  to 
explore whether NPY and PNMT expression are related.   150 
  In order to examine whether NPY and PNMT production in phaeochromocytomas are 
linked, we compared NPY and PNMT expression in four groups of tumours and compared 
this data to adrenaline production from these patients (i.e., tumours with an adrenergic 
versus  noradrenergic  phenotypes).    Furthermore,  we  also  examined  whether  NPY  and 
PNMT expression in adrenergic versus noradrenergic tumours was related to the presence 
or absence of a hereditary syndrome (VHL and MEN 2 versus non-hereditary tumours).    
III.  Materials and Methods 
Patients and tumour specimens 
  Tumour  specimens  were  from  56  patients  with  histologically-confirmed 
phaeochromocytomas, including 16 patients with VHL syndrome, 12 with MEN 2A and 28 
patients with phaeochromocytomas in who there was no evidence of hereditary syndrome 
(Table 5.1).   The 28 patients in whom there was no evidence of a hereditary syndrome are 
referred  to  as  having  non-syndromic  phaeochromocytoma.  All  hereditary  and  non-
syndromic adrenergic tumours had an adrenal location, whereas 5 of the 15 non-syndromic 
noradrenergic tumours had an extra-adrenal location.   151 
 
Table 5.1  Patient data 
 
  MEN 2  VHL  No Hereditary Syndrome 
N  12  16  28 
Gender (F/M)  8/4  9/7  13/15 
Age (mean, range)  40 (28 – 75)  30 (11 – 60)  52 (22 – 74) 
 
Quantitative Polymerase Chain Reaction (PCR) 
    Singleplex PCR reactions were performed with 0.9 µmol/L of forward and reverse 
primers  and  0.25  µmol/L  probe  for  NPY  (TaqMan  Gene  Expression  Assays,  Applied 
Biosystems) and with 0.15 µmol/L of forward and reverse primers and 0.25 µmol/L of 
probe for 18s RNA (TaqMan Endogenous Controls, Applied Biosystems).  
NPY peptide quantification and extraction 
  Protein  from  the  phaeochromocytoma  samples  was  extracted  using  a  protocol 
described  in  Chapter  2.    The  NPY  content  of  each  sample  was  calculated  using  a 
commercially  available  enzyme  immunoassay  (Bachem,  King  of  Prussia,  Philadelphia, 
USA). Concentrations of NPY were calculated relative to a standard curve generated using 
GraphPad Prism 4 software and converted into units of µg of NPY per g of tumour tissue 
according to sample dilution and the original wet weight of the sample of tumour tissue that 
was processed.   152 
Immunohistochemistry 
  Immunohistochemistry was performed on 5 µm sections of paraffin embedded normal 
human adrenal (n=5) or phaeochromocytoma specimens from patients with VHL syndrome 
(n=6), patients with MEN 2 (n=7), and patients with tumours where there was no obvious 
hereditary basis or syndrome (n=7) were used.  The slides were deparaffinised, antigen 
retrieval performed and the immunohistochemistry procedure was conducted according to 
the  methods  described  previously  in  Chapter  2.    Immunohistochemistry  for  NPY  was 
performed on the phaeochromocytoma tumour samples using a polyclonal rabbit anti-NPY 
antibody (1:100) and species-specific donkey anti-rabbit Cy3 (1:500) secondary antibody.  
For the normal human adrenal specimens dual labeling for NPY and the secretory granule 
marker, Chromogranin A (CGA) was undertaken to confirm the localization of NPY to 
chromaffin granules, thus staining with a monoclonal mouse anti-CGA antibody (1:500) 
and a species specific anti-mouse FITC secondary antibody (1:500) were also applied to 
these samples according to the same methodology.  Sections were examined using a Zeiss 
LSM  510  “405”  confocal  microscope  according  to  methods  described  in  Chapter  2. 
Staining was described as negligible, moderate or intense, and the distribution pattern of 
immunoreactive cells was noted. 
Statistics 
  NPY  mRNA  and  peptide  levels  showed  non-normal  distributions.    The  data  were 
therefore  logarithmically  transformed  before  statistical  analysis  and  are  presented  as 
geometric means with standard errors calculated for either side of mean values. Analysis of 
variance, with post-hoc tests by Sheffe's method, was used to assess for differences among   153 
all  4  groups  of  tumours.  Relationships  between  variables  were  examined  by  linear 
regression analysis, with significance determined using Pearson’s correlation coefficient.    154 
IV. Results 
Tumour Biochemical Phenotypes 
  Among the 28 patients with MEN 2 and VHL syndrome, tissue concentrations of 
adrenaline ranged widely over 4 orders of magnitude, from 0.36 to 16809.2 µg/g, while 
concentrations of noradrenaline showed less variability ranging from 291.82 to 19715.9 
µg/g.  Tumour tissue concentration of adrenaline in tumours from VHL patients were less 
than  1%  the  concentration  observed  in  tumours  from  MEN  2  patients,  whereas  tissue 
concentrations of noradrenaline in VHL tumours were a third of that in MEN 2 tumours 
(Fig 5.1a).  Among the 28 patients with non-syndromic tumours, the tumour concentrations 
of adrenaline also varied widely over 4 orders of magnitude, from 0.33 to 6619.8 µg/g, 
while concentrations of noradrenaline ranged from 17.75 to 17651.4  µg/g.  Fifteen of these 
tumours contained less than 5% adrenaline and more than 95% noradrenaline, and were 
therefore defined as having a noradrenergic phenotype.  The other 13 tumours contained 
more  than  11%  adrenaline  and  therefore  were  defined  with  an  adrenergic  phenotype 
(Graeme Eisenhofer, personal communication).   
    For the non-syndromic tumours, the proportion of adrenaline averaged 1.5 % (range 
0.02 – 4.5%) of the total catecholamine content, and was similar to that (2.1%, range 0.1 – 
9.8%)  for  the  tumours  from  patients  with  VHL  syndrome  (Fig  5.1b).  For  the  non-
syndromic tumours with an adrenergic phenotype, the proportion of adrenaline averaged 
44.8% (range 11 – 86.1%), similar to that seen in tumours from MEN 2 patients where the 
mean proportion of adrenaline was 43.2% (range 8.9 – 67.8%). 
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Figure 5.1  Proportion of adrenaline and noradrenline in phaeochromocytoma tumour 
samples from hereditary and non-hereditary patients   156 
PNMT mRNA levels 
Quantitative PCR indicated that MEN 2 tumours possessed 200-fold higher (P<0.0001) 
levels of PNMT mRNA than VHL tumours (Figure 5.2a). The PNMT mRNA levels in non-
syndromic adrenergic tumours were also 64-fold higher (P<0.0001) than in VHL tumours.  
Tumour  tissue  PNMT  mRNA  levels  were  50-fold  higher (P<0.0001)  in  non-syndromic 
adrenergic tumours than in non-syndromic noradrenergic tumours. Tumours from MEN 2 
patients  had  153-fold  higher  (P<0.0001)  PNMT  mRNA  levels  than  in  non-syndromic 
noradrenergic tumours. Linear regression analysis indicated a strong positive relationship (r 
= 0.815, P < 0.001) between tumour PNMT mRNA levels and tumour tissue adrenaline 
levels (Figure 5.2b). 
NPY mRNA levels 
    Phaeochromocytoma  tumour  tissue  levels  of  NPY  mRNA  varied  considerably 
among tumour samples, with mRNA expression varying four orders or more in magnitude 
among different tumour samples.  Quantitative PCR indicated an 84-fold higher (P<0.0001) 
level of NPY mRNA expression in samples from MEN 2 patients than in those from VHL 
patients (Fig 5.3a). NPY mRNA levels in adrenergic tumours, where there was no clear 
evidence of hereditary syndrome, were also 26-fold higher (P=0.003) than in VHL tumours.  
Tumour tissue NPY mRNA levels in non-syndromic adrenergic tumours also tended to be 
higher than in non-syndromic noradrenergic tumours (3-fold difference), but this difference 
did not reach significance (P=0.55) and was much less than the 84-fold difference between 
hereditary adrenergic and noradrenergic tumours.     157 
Figure 5.2  Expression of PNMT mRNA in tumour samples from each patient group, and 
the relationship between tumour PNMT mRNA and adrenaline concentrations.   158 
 
Figure 5.3  Expression of NPY mRNA and peptide levels in phaeochromocytoma from 
hereditary and non-hereditary patients, and the relationship between NPY 
mRNA and peptide levels.   159 
NPY peptide levels 
    Tumour tissue NPY levels varied considerably amongst the tumour types, ranging 
from 0.001 µg/g to 24.3 µg/g.  Similar to the results for levels of mRNA, tumour tissue 
NPY peptide levels were 99-fold higher (P<0.0001) in MEN 2 than in VHL tumours and 
83-fold higher (P<0.0001) in non-sydromic adrenergic tumours than in VHL tumours (Fig 
5.3b).  Tumour  tissue  NPY  peptide  levels  were  also  22-fold  higher  (P<0.001)  in  non-
syndromic noradrenergic tumours than in VHL tumours.  While NPY peptide levels were 
4-fold greater in non-syndromic adrenergic than noradrenergic tumors, this difference did 
not reach significance (P=0.34) and was much less than the 99-fold difference between 
hereditary adrenergic and noradrenergic tumours. 
  Expression  of  NPY  mRNA  correlated  positively  (r=0.73,  P<0.0001)  with  tumour 
tissue  concentrations  of  NPY  peptide  (Fig  5.3c).    Tumour  tissue  concentrations  of 
adrenaline  were  positively  related  to  both  tumour  levels  of  NPY  mRNA  (r=0.425, 
P=0.0045) and tumour concentrations of NPY peptide (r=0.603, P<0.0001) (Fig 5.4a, b). 
Relationships of tumour adrenaline concentrations with the peptide remained significant 
when examined independently for tumours in patients with MEN 2 and VHL syndrome 
(r=0.679, P=0.0007) and for tumours in non-syndromic patients (r=0.633, P=0.0016). There 
were  no  significant  relationships  between  tumour  levels  of  NPY  mRNA  and  tumour 
noradrenaline  concentration  (r=0.022,  P=0.889)  or  combined  tissue  concentrations  of 
noradrenaline and adrenaline (r=0.087, P=0.557).  Tumour tissue levels of NPY peptide 
were positively related to tumour tissue concentrations of noradrenaline (r=0.327, P=0.027) 
and combined tissue concentrations of noradrenaline and adrenaline (r=0.465, P=0.002).   160 
Figure 5.4  Linear regression analysis demonstrating the relationship between tumour 
tissue NPY levels (mRNA and peptide) and PNMT expression or adrenaline 
content   161 
 
NPY staining in normal human adrenal tissues 
  In normal human adrenal glands (n=4 samples), NPY staining was confined to the 
adrenal medulla, within the cytoplasm, and was present in all chromaffin cells (Fig 5.5a).  
Further, NPY was also colocalised with CGA confirming the storage of NPY in chromaffin 
granules (Figure 5.5b) 
NPY staining in phaeochromocytoma tumour samples 
    Immunohistochemical staining of phaeochromocytoma samples demonstrated clear 
differences between MEN 2 and VHL tumours, but no obvious differences between non-
syndromic adrenergic and noradrenergic tumours (Fig 5.6a-d).  
    All 6 VHL tumours examined showed negligible to moderate cytoplasmic staining 
in isolated clusters, with occasional clusters of intense staining (Fig 5.6a).  Intense staining 
for NPY was observed in all sections from the 7 MEN 2 tumours examined. Staining was 
uniformly distributed in 6 specimens from MEN 2 patients (Figure 5.6b), while intense 
staining of large numbers of clusters of cells was observed in the seventh specimen.  The 
staining pattern in noradrenergic tumours (Figure 5.6c; n=3 samples) staining ranged from 
moderate  to  intense  staining  in  clusters  of  cells  throughout  the  section,  to  intense 
immunoreactivity throughout the entire section.  In the non-syndromic adrenergic tumours 
(Figure 5.6d; n=4 samples) NPY staining was moderate to intense throughout all sections 
examined.  Overall no discernable differences were noted between these two groups of 
tumours.   162 
 
Figure 5.5  NPY staining in the human adrenal gland   163 
 
Figure 5.6  NPY staining in phaeochromocytoma samples from patients with hereditary 
and non-hereditary forms of the tumour   164 
 
V. Discussion 
     
  The  major  findings  of  this  study  are  (i)  the  near  absence  of  NPY  in 
phaeochromocytomas  from  patients  with  von  Hippel-Lindau  syndrome  compared  to 
tumours from other groups and (ii) that NPY is strongly correlated with PNMT expression 
and tumour adrenaline content.  These findings add to an increasing body of evidence that 
the phaeochromocytomas in VHL syndrome have a unique phenotype (Eisenhofer et al., 
2001b, Koch et al., 2002, Huynh et al., 2005, Vogel et al., 2005).   
Relationship between NPY and PNMT 
  An unresolved issue of phaeochromocytoma tumour biology is how the distinct 
adrenergic and noradrenergic biochemical phenotypes arise, especially given that the 
normal adrenal is composed entirely of PNMT-positive cells (Chapter 3).  The development 
of PNMT-positive (MEN 2) versus PNMT-negative (VHL) hereditary 
phaeochromocytomas has been suggested to reflect origins from different populations of 
PNMT-negative noradrenergic and PNMT-positive adrenergic chromaffin cells (Eisenhofer 
et al., 2001b, Eisenhofer et al., 2004b).  In this study we found that in the normal human 
adrenal, NPY is found in all chromaffin cells, and was consistently colocalised with CGA.  
Given the findings of Chapter 3, that all chromaffin cells contain PNMT, we interpreted 
this to mean that NPY and PNMT are also colocalised in the human adrenal.  Interestingly, 
NPY expression in the normal adrenal gland of several species of mammals including 
humans and rats is confined to PNMT-positive chromaffin cells (Lundberg et al., 1986,   165 
Henion & Landis, 1990, Wolfensberger et al., 1995), while others report that in the rat 
adrenal medulla an association exists between NPY and PNMT-negative (noradrenergic) 
chromaffin cells (Varndell et al., 1984, Lundberg et al., 1986).  Thus we speculated 
whether the differences in NPY expression observed between hereditary 
phaeochromocytomas are linked to PNMT.  This presumption was based on the spatial 
relationship between NPY and PNMT in chromaffin cells and our finding of a positive 
relationship between NPY expression and tumour adrenaline concentration. Should this be 
the case, a similar reduction in NPY expression in non-syndromic noradrenaline producing 
tumours would be expected. However, NPY expression between adrenergic and 
noradrenergic non-syndromic tumours was not significantly different.  The significantly 
lower levels of NPY in tumours from VHL patients than in all other groups examined, 
including non-syndromic noradrenergic tumours therefore strongly indicates that the near 
100-fold difference in NPY expression between the hereditary tumours examined reflects 
the influence of a VHL gene mutation rather than an influence of adrenaline content or 
production. 
  Analysis  of  genes  activated  in  hereditary  phaeochromocytomas  suggests  that 
development of these tumours can be explained by a single pathway linking mutations in 
disease-causing genes to a failure of progenitor cells undergo apoptosis after withdrawal of 
growth factors during chromaffin cell development (Lee et al., 2005). According to this 
proposal, inappropriate survival of embryonic chromaffin progenitor cells, arrested in their 
development, would lead later in life to a propensity for these cells to develop into tumours. 
The particular phenotype of the tumour would further depend on different susceptibilities of 
the  pathway  to  the  effects  of  mutations  of  specific  genes  during  particular  stages  of   166 
chromaffin cell maturation. During development of the embryonic adrenal gland, NPY is 
expressed in precusor chromaffin cells as they invade the adrenal mesodermal anlagen, and 
before those precursor cells begin to express PNMT (Henion & Landis, 1990). Differences 
in expression of PNMT and NPY in phaeochromocytomas might therefore reflect origins 
from different chromaffin cell precursors, with relative lack of expression of both PNMT 
and  NPY  in  VHL  tumours  explained  by  development  from  more  primitive  chromaffin 
progenitor cells (i.e. those that do not yet express PNMT or NPY) than those giving rise to 
tumours in MEN 2, where NPY and PNMT are both expressed, or those in non-syndromic 
cases, where NPY and PNMT are co-expressed more variably.  
Could NPY contribute to the differences in the clinical presentation 
observed between VHL and MEN 2 patients? 
  The  significant  variability  of  NPY  expression  in  phaeochromocytoma  samples  has 
potential clinical implications.  This was demonstrated at both the peptide and mRNA level 
amongst  all  samples  analysed,  irrespective  of  genotype  or  biochemical  phenotype,  and 
importantly, when NPY expression was compared between groups vast differences were 
detected, especially between VHL and all other groups.  Our findings are compatible with 
previous  reports  of  substantial  variability  in  NPY  expression  in  phaeochromocytoma 
tumour tissue and plasma NPY levels in patients with the tumour (Adrian et al., 1983, 
Lundberg et al., 1986, Grouzmann et al., 1989, O'Hare & Schwartz, 1989, deS Senanayake 
et al., 1995).  Variable NPY plasma and tumour levels have been suggested in other studies 
to  contribute  to  the  clinical  picture  of  phaeochromocytoma  including  the  presence  of 
hypertension and left ventricular hypertrophy (Connell et al., 1987, deS Senanayake et al., 
1995,  Eurin  et  al.,  2000,  Bravo,  2002,  Kuch-Wocial  et  al.,  2004).    This  possibility  is   167 
supported  by  findings  that  tumour  NPY  expression  in  phaeochromocytoma  tissue 
determines elevations in plasma NPY levels, which in some patients may reach 26 µg/L 
(6.16 nmol/L) (deS Senanayake et al., 1995).  Moreover, these plasma NPY levels are well 
in excess of those shown during i.v. infusion of NPY to cause signifcant increases in blood 
pressure (Ullman et al., 2002), indicating that release of NPY from phaeochromocytomas 
may easily contribute to increased blood pressure. 
  Among the slew of genotypic and phenotypic differences, the clinical presentation 
between  VHL  and  MEN  2  patients  is  also  divergent,  particularly  with  relation  to  the 
occurrence of symptoms such as hypertension.  During screening for phaeochromocytoma 
in VHL patients, Walther and colleagues (Walther et al., 1999b) observed that only 16% of 
patients with the tumour had hypertension and 8% had symptoms of catecholamine excess. 
Although hypertension in VHL patients with phaeochromocytoma was noted to be more 
prevalent (50%) when screening was not employed, this prevalence was still lower than in 
patients with other forms of phaeochromocytoma, where 92% were hypertensive (Walther 
et al., 1999b). Other comparisons of patients screened for hereditary phaeochromocytoma 
have also confirmed a lower prevalence of hypertension in VHL than in MEN 2 patients 
(18%  versus  40%),  and  showed  that  this  difference  was  independent  of  tumour  size 
(Eisenhofer et al., 2001b).  Furthermore, as a function of tumour size, VHL patients show 
larger increases in plasma catecholamines, yet have a lower prevalence of hypertension 
than MEN 2 patients with phaeochromocytoma.  These observations suggest that factors 
other than plasma catecholamines contribute to differences in clinical presentation between 
these tumour groups.  Thus, it is tempting to propose that based on our present finding of a 
relative lack of NPY expression in tumours from VHL patients reduced NPY represents an   168 
alternative factor contributing to the lower prevalence of hypertension in VHL patients 
relative  to  other  forms  of  the  disease.    However,  establishing  this  possibility  requires 
further  studies  with  measurements  of  plasma  concentrations  of  NPY  in  relation  to 
presentation of signs and symptoms. Since the plasma half-life of NPY is only about 12 
minutes  (Grouzmann  et  al.,  2001),  and  because  the  peptide  is  co-secreted  with 
catecholamines, such studies will also need to take into account the more episodic nature of 
catecholamine  secretion  in  MEN  2  tumours  compared  to  the  continuous  secretion  of 
catecholamines in VHL tumours (Eisenhofer et al., 2001b). 
 
  In  summary,  in  this  study  we  found  highly  variable  expression  of  NPY  in 
phaeochromocytoma  tumour  extracts  from  patients  with  sporadic  and  hereditary 
phaeochromocytoma, including samples from patients with MEN 2 and VHL syndrome.  
This  study  has  also  established  that  phaeochromocytomas  from  patients  with  VHL 
syndrome have significantly less NPY that phaeochromocytomas from patients with other 
forms of the tumour.  This difference supports the presence of a distinct phenotype of 
phaeochromocytomas  in  VHL  patients  and  may  suggest  that  phaeochromocytoma 
associated  with  the  VHL  syndrome  are  a  more  immature  chromaffin  cell  arrested  in 
development.   
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Chapter 6 – CGA expression in 
phaeochromocytomas associated with von 
Hippel-Lindau syndrome and multiple 
endocrine neoplasia type 2 
 
I.  Abstract 
 
Chromogranin A (CGA) is a major secretory protein present in the soluble matrix of 
chromaffin granules of neuroendocrine cells and tumours, such as 
phaeochromocytomas.  Improper CGA expression may contribute to the distinct 
phenotypic differences of phaeochromocytomas in patients with von Hippel-Lindau 
(VHL) syndrome compared to multiple endocrine neoplasia type 2 (MEN 2).  In this 
study, we therefore compared tumour and plasma levels of CGA in patients with 
phaeochromocytoma associated with the two syndromes. We show that 
phaeochromocytomas from MEN 2 patients express substantially more CGA than 
tumours from VHL patients at both the mRNA (3-fold greater) and protein (20-fold) 
level. We further show that relative to increases in plasma catecholamines, patients 
with phaeochromocytomas associated with MEN 2 have higher plasma 
concentrations of CGA than those with tumours in VHL syndrome. These data 
supplement other observations that phaeochromocytomas in VHL compared to MEN 
2 patients express lower amounts of catecholamines and other chromaffin granule 
cargo, such as chromogranin B and neuropeptide Y.  Possibly the differences in 
tumour CGA expression may contribute to differences in secretory vesicle formation   170 
and secretion in the two types of tumours. Alternatively the differences in expression 
in CGA and other secretory constituents may reflect down-regulation of the entire 
regulated secretory pathway in VHL compared to MEN 2 tumours. 
II. Introduction 
   
  Chromaffin cells are specialised and unique neuroendocrine cells characterised by the 
presence of secretory granules that are necessary for the storage and release of 
catecholamines and other granule cargo.  Chromogranin A is the major soluble protein in 
chromaffin cells, and is expressed very early in adrenal development, even prior to the 
migration of primordial chromaffin cells into the adrenal analgen (Ehrhart-Bornstein et al., 
1997).  In the adrenal medulla and sympathetic nerves, CGA represents a major protein co-
stored and co-released with catecholamines and in chromaffin cells CGA comprises 
between 7-10% of the total protein content of the cellular fraction (O'Connor & Frigon, 
1984, Eiden et al., 1987).  In Chapter 3 and 5 we reported that the pattern of CGA 
expression in the normal human adrenal is ubiquitous to all chromaffin cells.  In Chapter 3 
we also demonstrated strong CGA expression in the sporadic phaeochromocytoma samples 
analysed.  These findings are consistent with other documented reports of CGA in the 
human adrenal and phaeochromocytoma (Portel-Gomes et al., 2001, Montero-Hadjadje et 
al., 2002). 
  Elevated plasma CGA levels have been reported in a number of pathologic conditions 
including phaeochromocytoma.  Tumours associated with VHL disease and MEN 2 display 
distinct differences in the appearance and numbers of chromaffin granules and also in the   171 
kinetics and rate of tumour catecholamine release from tumour stores (Eisenhofer et al., 
2001b, Huynh et al., 2005).  In this study we therefore examined whether these phenotypic 
differences might be associated with differences in CGA expression, the major secretory 
protein in chromaffin granules. 
III.  Materials & Methods 
 
Patients 
  This study included 49 patients with histologically confirmed phaeochromocytoma, 
comprising 29 patients with VHL syndrome and 20 with MEN 2 (Table 6.1).  
 
Table 6.1  Patient information  
 
  VHL  MEN2 
N  29  20 
Gender (F/M)  13/16  12/8 
Age (mean, range)  31(10 – 47)  38 (25 – 54) 
 
Quantitative Polymerase Chain Reaction (PCR) 
  RNA was extracted from frozen phaeochromocytoma samples according to previously 
described methods (Chapter 2).  Multiplex PCR reactions were performed for CGA and 
18sRNA.  Primers for CGA consisted of 0.9 µmol/L of FWD: 5’ – GGA TAC CGA GGT   172 
GAT GAA ATG C – 3’, REV: 3’ – CTC GGA GTG TCT CAA AAC ATT CCT – 5’; 
Biosynthesis Inc, Lewisville, TX, USA) and 0.25 µmol/L TaqMan probe:  5’ (FAM) – 
TCG TTG AGG TCA TCT CCG ACA CAC TTT C – (TAMRA) 3’; Applied Biosystems).  
Primers for 18sRNA consisted of 0.15 µmol/L of forward and reverse primers and 0.25 
µmol/L of probe (TaqMan Endogenous Controls, Applied Biosystems). 
CGA Enzyme-Linked ImmunoSorbent Assay (ELISA) 
  Protein was extracted from phaeochromocytoma samples using the protocol described 
in Chapter 2.  The protein was then reconstituted in assay buffer and diluted to allow 
determination of tissue concentrations of CGA using a commercially available kit (Alpco 
Diagnostics, Windham NH, USA).  Plasma samples were also diluted in assay buffer.  The 
final plasma and tissue concentrations of CGA were then calculated relative to a standard 
curve generated using Graph Pad Prism 4 software (GraphPad Software, San Diego, CA, 
USA), and converted into ng per ml for plasma samples and µg per g of tumour tissue for 
tumour samples.  
Western Blot 
  Tumour samples (10 – 50 mg), from patients with VHL (n=7) and MEN 2 (n=7), 
were homogenized in lysis buffer at a 1:10 ratio of tumour to buffer.  Lysis buffer consisted 
of 0.1 M phosphate buffered saline (PBS; pH 7.4), 10 mM 3-(3-cholamidopropyl 
dimethylammonio 1-propane sulphate (CHAPS) and a Roche Minitablet protease inhibitor 
(1 tablet per 5 ml of PBS; Roche Applied Biosciences, Indianapolis, IN, USA). 
Homogenates were centrifuged at 10,000 g for 10 minutes, and supernatants were collected 
and stored at -80 °C until the time of assay.  The concentration of protein in each sample   173 
was calculated using a Quant It Protein Assay kit according to manufacturers instructions 
(Molecular Probes, Invitrogen).  Total protein (1 µg and 15 µg of protein/well for CGA and 
Actin, respectively) was loaded into a 12 % Nu-PAGE Bis-Tris gel (Invitrogen) and 
separated by electrophoresis. Protein was then transferred onto polyvinylidene fluoride 
(PVDF) membranes (Millipore, Billerica, MA, USA) and stained with Ponceau S (0.1 % 
(w/v) in 5 % (v/v) acetic acid; Sigma Aldrich, St Louis, MO, USA) in order to verify equal 
protein loads.  After reversing Ponceau S staining by washing the membrane in de-ionised 
water any unoccupied binding sites were blocked by incubating the membrane in a 
blocking buffer consisting of Tris Buffered Saline (50 mM Tris, pH 7.4, 0.9% (w/v) NaCl 
with 0.05 % (v/v) Tween-20 (TBS-T) and 5% (w/v) skim milk powder for one hour at room 
temperature, and then washed in TBS-T for 3 x 5 minutes.  The membranes were then 
incubated for one hour at room temperature in blocking buffer containing primary antibody 
which consisted of either mouse anti-CGA (1:15,000; Chemicon) or goat anti-Actin (I-19; 
1:500; Santa Cruz Biotechnology).  Membranes were then washed (3 x 5 minutes) with 
TBS-T and incubated for one hour at room temperature in blocking buffer containing 
secondary antibodies consisting of horseradish peroxidase conjugated to either anti-mouse 
or anti-goat IgG (both 1:20,000; Santa Cruz Biotechnology).  Membranes were then 
washed in TBS-T (3 x 5 minutes) and incubated in Super Signal West Pico 
Chemiluminescent reagent (Pierce Biotechnology, Rockford, IL, USA) to allow 
visualisation on Hyperfilm ECL (Amersham Biosciences GE Healthcare, Pistcataway, NJ, 
USA).   174 
Immunohistochemistry 
  Sections  (5  µm)  of  paraffin  embedded  phaeochromocytoma  specimens  were  from 
patients  with  VHL  syndrome  (n=6),  patients  with  MEN  2  (n=7).    The  slides  were 
deparaffinised,  antigen  retrieval  performed,  and  the  immunohistochemistry  procedure 
conducted according as described previously in Chapter 2.  The primary antibody consisted 
of a monoclonal mouse anti-CGA antibody (1:500).  The secondary antibody consisted of 
donkey anti-mouse FITC (1:500).  Sections were examined using a Zeiss LSM 510 “405” 
confocal  microscope  as  described  in  Chapter  2.    Staining  was  described  as  negligible, 
moderate or intense, and the distribution pattern of immunoreactive cells was noted. 
Statistics 
Levels of CGA mRNA in tumour tissue and concentrations of CGA protein and 
total catecholamines (summed concentrations of noradrenaline and adrenaline) in plasma 
and tumour tissue showed non-normal distributions. The data were therefore 
logarithmically transformed prior to statistical analysis, and are presented as geometric 
means with standard error bars calculated on either side of mean values.  Differences in 
plasma, mRNA and protein levels between VHL and MEN 2 patients were assessed using 
an unpaired t-test. Relationships between variables were examined by linear regression 
analysis, with significance determined using Pearson’s correlation coefficient.  Multiple 
linear regression analysis was used to assess for influences of genotype (i.e., VHL versus 
MEN 2 patients) on relationships between plasma concentrations of CGA or total 
catecholamines with tumour volume and between relationships plasma concentrations of 
CGA with plasma catecholamines.     175 
IV.  Results 
 
CGA Quantitative PCR and ELISA 
  Quantitative PCR indicated that tumour tissue from MEN 2 patients expressed 3-fold 
higher amounts of CGA mRNA (P<0.02) than tumour tissue from VHL patients (Figure 
6.1a). By ELISA, the difference in expression of CGA protein was even greater — tissue 
CGA protein levels in tumours from MEN 2 patients were 20-fold higher (P<0.005) than in 
tumour samples from patients with VHL syndrome (Figure 6.1b).  Tumour tissue levels of 
CGA mRNA were positively correlated (r = 0.702; p<0.01) with levels of CGA protein 
(Figure 6.1c).  
  Tumour tissue levels of CGA mRNA and protein were both positively correlated to 
tumour tissue concentrations of total catecholamines (Figure 6.2a, b). The relationship 
between expression of CGA and tissue concentrations of catecholamines was stronger for 
expression at the CGA protein level (r = 0.84, P<0.0001) than at the mRNA level (r=0.60, 
P<0.02).   176 
 
Figure 6.1  Greater CGA mRNA and protein expression in MEN 2 than VHL 
phaeochromocytoma tumour extracts   177 
 
Figure 6.2  The relationship between catecholamines and CGA mRNA and/or protein 
expression   178 
 
CGA Western Blot 
  Western blot analysis of CGA expression in tumour protein extracts (Fig 6.3a) showed 
no observable CGA in two of the seven VHL patients (Figure 6.3a; asterix).  Five of the 
seven VHL samples analysed showed bands.  Of these, the band intensity was strong in two 
samples and weak in three.  Two distinct bands (approximately 65 kDa and 51 kDa) were  
detected in all MEN 2 samples. A single band with equivalent intensity was observed for 
actin in all tumour samples analysed. 
CGA Immunohistochemistry 
  There were no clear differences in CGA immunoreactivity between tumours from 
MEN 2 (n=7) and VHL (n=6) patients (Figure 6.3b i, ii).  Samples from both tumour 
groups examined (4 from MEN 2; 5 from VHL) exhibited intense cytoplasmic staining of 
CGA in the majority of cells present throughout the section.  No staining was observed in 
negative controls, or in the adjacent cortical tissue.   179 
 
Figure 6.3  CGA Western Blot and Immunohistochemistry   180 
 
CGA plasma concentrations 
  Plasma concentrations of CGA tended to be higher in MEN 2 than VHL patients 
(796±276 ng/ml versus 497±101 ng/ml); however, this difference did not reach significance 
(P = 0.354), possibly in part due to large variances in plasma levels associated with 
differences in tumour size and secretion of tumour vesicular contents. These potential 
influences were examined from relationships of plasma concentrations of CGA with 
tumour size, as assessed by volume, and the extent of secretory activity, as assessed by 
plasma concentrations of total catecholamines (Figure 6.4). 
  Linear regression analysis indicated a significant positive relationship (r = 0.52, 
P<0.02) between plasma concentrations of total catecholamines and tumour volume (Figure 
6.4a). Use of multiple linear regression analysis to examine for the effects of genotype (i.e., 
VHL versus MEN 2) on the relationship indicated that relative to tumour volume plasma 
concentrations of total catecholamines were higher (P<0.03) in VHL patients than in MEN 
2 patients with phaeochromocytoma.  Consequently, the ratio of plasma concentrations of 
total catecholamines to tumour volume was significantly higher (P<0.03) in VHL than in 
MEN 2 patients, indicating that relative to tumour volume VHL patients had 3.5-fold 
higher plasma concentrations of total catecholamines than MEN 2 patients (Figure 6.4b). 
  There was also a significant positive relationship (r = 0.63, P<0.005) between plasma 
concentrations of CGA and tumour volume (Figure 6.4c). However, there was no apparent 
influence of tumour genotype on the relationship. Thus, there was also no difference 
between ratios of plasma concentrations of CGA to tumour volume between MEN 2 and 
VHL patients (Figure 6.4d).    181 
  Plasma concentrations of CGA were also positively correlated (r = 0.58, P<0.004) to 
plasma concentrations of total catecholamines (Figure 6.4e).  Multiple linear regression 
analysis demonstrated a near significant (P = 0.053) influence of genotype on the 
relationship between plasma concentrations of CGA and catecholamines, with a tendency 
to higher plasma concentrations of CGA in MEN 2 patients. Relative to plasma 
concentrations of total catecholamines, plasma concentrations of CGA were 2-fold higher 
(P<0.05) in MEN 2 than in VHL patients with phaeochromocytoma (Figure 6.4f). 
We compared the relationship between plasma CGA and plasma metanephrines, and found 
that CGA positively correlated with both metanephrine (r = 0.74, P<0.0001) and 
normetanephrine (r = 0.82, P<0.0001) concentrations.    182 
 
Figure 6.4  Relationships between plasma catecholamines (CAT), tumour volume and 
plasma CGA   183 
 
V. Discussion  
   
  In this study we show that phaeochromocytoma tumour samples from MEN 2 patients 
express substantially more CGA than tumours from VHL patients. We also extend 
observations that plasma CGA levels are elevated in patients with phaeochromocytoma and 
furthermore, demonstrate that relative to increases in plasma catecholamines, patients with 
phaeochromocytomas associated with MEN 2 have higher plasma concentrations of CGA 
than patients with VHL syndrome.  
CGA and secretory granules: observations extended 
  Previous studies have established that phaeochromocytomas from VHL patients 
contain fewer secretory granules than MEN 2 tumours (Eisenhofer et al., 2001b, Huynh et 
al., 2005).  This may imply that lower expression of CGA in VHL tumours is simply a 
consequence of the decreased numbers of secretory vesicles, yet mounting evidence argues 
that to the contrary, CGA itself may be responsible for driving secretory granule 
biogenesis. For example, CGA knockout mice show marked reductions in numbers of 
adrenal chromaffin granules compared to wildtype littermates (Kim et al., 2005, Mahapatra 
et al., 2005). Furthermore, when CGA is transfected into non-endocrine cells, or cell lines 
lacking a regulated secretory pathway, cells form dense-core granules, leading to the 
proposal that CGA may act as a master “on/off” switch in secretory granule biogenesis 
(Kim et al., 2001).  Other in vitro data also lends support for a critical role of CGA in   184 
granulogenesis (Kim et al., 2001, Huh et al., 2003, Taupenot et al., 2005, Courel et al., 
2006). Such a role, however, is not without controversy with at least one report showing no 
clear relationship between alterations in CGA expression and granule formation (Hendy et 
al., 2006).  The overall available evidence, nevertheless, appears to indicate an important 
role of CGA in granulogenesis. 
No difference in plasma CGA between groups? Take a closer look 
  In this report, we did not find a significant difference in the plasma CGA levels 
between VHL and MEN 2 patients. Our limited population of plasma samples in which to 
assay CGA may have contributed to the lack of significance.  Alternatively, it may be due 
to the influence of extra-adrenal sources of CGA. Thus we explored whether CGA release 
in our cohort of patients was related to factors influencing tumour catecholamine release – 
tumour volume and plasma catecholamines.  The findings that relative to tumour size, VHL 
patients with phaeochromocytoma had larger increases in plasma total catecholamines than 
MEN 2 patients is in agreement with previous studies indicating more continuous secretion 
of catecholamines from tumours of VHL patients and lower baseline release in MEN 2 
patients (Eisenhofer et al., 2001b, Huynh et al., 2005).  These findings explain the present 
observation that while tumours from MEN 2 patients express higher levels of CGA than 
those from VHL patients, this does not translate into similar differences in circulating 
levels of CGA. Since CGA is co-secreted with catecholamines, differences in circulating 
levels of CGA between the two groups of patients were only apparent when differences in 
secretion were also considered. 
Given the differences in tumour CGA levels between MEN 2 and VHL samples in this 
study, together with even larger differences in chromogranin B expression observed   185 
elsewhere (Brouwers et al., 2007), could VHL tumours possess deficiencies in the 
mechanisms governing (i) the regulated pathway of secretory vesicle formation and (ii) the 
storage and release of granular contents? Interestingly, CGA knockout mice have increased 
plasma catecholamines concentrations and NPY but decreased adrenal catecholamine and 
NPY contents compared to wildtype animals (Mahapatra et al., 2005).  Equally, decreased 
levels of plasma catecholamines and NPY in phaeochromocytomas from VHL vs. MEN 2 
patients, but increased plasma concentrations of total catecholamines in VHL vs. MEN 2 
patients (Eisenhofer et al., 2001b, Huynh et al., 2005) have also been reported.  Hence, akin 
to the CGA knockout mice, our data suggest a deficit in the storage mechanisms of VHL 
tumours and enhanced propensity to release granule contents.  In culture, a loss of CGA 
also translates to impaired mechanisms of regulated secretion, such that the regulated 
release of secreted proteins is essentially converted into a process similar to constitutive 
release (Kim et al., 2001).  But what role could CGA play in this?  Possibly, the higher 
continuous baseline release of catecholamines in VHL than in MEN 2 tumours might 
reflect impairment of the catestatin-mediated mechanisms that normally limit vesicular 
secretion.  Catestatin is a biologically active peptide derived from CGA (CHGA 352-372) 
with potent actions as an endogenous nicotinic cholinergic antagonist inhibiting 
catecholamine release from chromaffin cells (Mahata et al., 1997, Mahata et al., 2000, 
Mahapatra et al., 2005).  Accordingly, the lowered levels of CGA in VHL than MEN 2 
tumours may translate into a diminished pool of CGA available for the conversion into 
catestatin. Lowered availability of catestatin for feedback inhibition of vesicular secretion 
might then consequently lead to higher baseline rates of catecholamine release in VHL than 
in MEN 2 tumours.     186 
What causes decreased CGA in the first place? 
  An avenue not explored in this study was down-stream controller(s) of CGA 
expression.  A possible explanation of the findings presented is that the entire regulated 
secretory pathway might be down regulated in VHL compared to MEN 2 tumours.  The 
repressor element 1-silencing transcription factor (REST, also known as the neuron 
restrictive silencing factor or NRSF) appears to play a crucial role in determining 
expression of the regulated pathway of secretion in neuroendocrine cells (Bruce et al., 
2006).  In particular, REST-infected PC12 cells show significant reductions in 
catecholamine storage capacity, chromaffin granule formation, and reduced expression of 
CGA and chromogranin B (Bruce et al., 2006). Using cDNA micro-array profiling (Huynh 
et al., 2006), it has been shown that higher rates of REST expression are seen in 
phaeochromocytomas from VHL compared to MEN 2 patients.  Further studies are 
required to confirm a role for REST in determining differences in secretory phenotypes of 
VHL and MEN 2 phaeochromocytomas. 
Can these findings be used clinically? 
  Plasma CGA levels are elevated in patients with phaeochromocytoma and 
consequently plasma CGA is often endorsed a diagnostic marker for phaeochromocytoma 
(Hsiao et al., 1991, Stridsberg & Husebye, 1997, Giovanella et al., 2006).  Consistent with 
this notion, plasma CGA levels were elevated in all but one sample of our patient cohort.  
Additionally, plasma CGA is highly related to tumour size (Hsiao et al., 1991), and plasma 
and/or urinary metanephrines (Giovanella et al., 2006, Grossrubatscher et al., 2006) and 
similarly, our results confirmed these relationships.  Metanephrines are considered the   187 
“gold-standard” diagnostic markers of phaeochromocytoma due to their high sensitivity for 
the tumour.  Thus, some investigators have advocated CGA as an important diagnostic test 
for phaeochromocytoma (Giovanella et al., 2006).  However, despite the belief that CGA 
could be a useful alternative to plasma metanephrines, plasma CGA is also elevated in a 
number of other conditions including essential hypertension (Takiyyuddin et al., 1990, 
Hsiao et al., 1991, Takiyyuddin et al., 1994), impaired kidney function  (O'Connor et al., 
1989, Hsiao et al., 1990, Hsiao et al., 1991), impaired liver function (O'Connor et al., 
1989), chronic atrophic gastritis (Borch et al., 1997), prostatic carcinoma (Berruti et al., 
2001) and in an assortment of neuroendocrine tumours such as medullary thyroid 
carcinoma and carcinoids (Stivanello et al., 2001, Taupenot et al., 2003).  Thus, plasma 
CGA measurement may provide a useful adjunct to other tests for the tumour, but as a 
primary diagnostic test, due to the poor specificity of this marker, it is unlikely to provide a 
definitive as metanephrine measurements.   
 
  The findings of this study on CGA add to the burgeoning picture of VHL and MEN 2 
phaeochromocytomas. However, the observed differences in tumour CGA expression, 
insensitivity of plasma CGA and differences in secretory activity between VHL and MEN 2 
tumours (Eisenhofer et al., 2001b, Huynh et al., 2005) still represent major limitations for 
the use of CGA, either in tumour tissue or plasma, as a marker for distinguishing VHL 
from MEN 2 phaeochromocytomas. 
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Chapter 7 – Differential expression of chromaffin 
cell markers in the mouse adrenal and 
adrenal lesions of a novel mouse 
metastatic phaeochromocytoma model 
 
I.  Abstract 
 
  Chromaffin cells of the adrenal medulla can be classified according to whether or 
not they express PNMT.  The distinction between these two chromaffin cell populations is 
recapitulated by several other proteins and peptides, which in normal tissues demonstrate a 
strict spatial relationship with PNMT.  We have shown previously that this relationship is 
often lost in phaeochromocytoma.  In this study we examined whether the strict expression 
pattern between PNMT and the sympathoadrenal markers NAT, NPY, Leu-Enk, VMAT1 
and VMAT2 demonstrated in an outbred balb/c mouse strain are also maintained in the 
adrenal phaeochromocytomas of a recently developed metastatic phaeochromocytoma nude 
mouse (MPNM) model generated by injecting MPC cells into the tail vein of antithymic 
nude mice. In the balb/c (n=5) and control nude mice (n=5; not injected with MPC cells), 
intense NAT and NPY staining was seen in the adrenergic cells of all normal adrenals 
examined, however alongside the intense NPY staining, weak NPY staining within adjacent 
noradrenergic chromaffin cells of the same adrenals was also detected. Intense VMAT2 and 
Leu-Enk staining was observed in the noradrenergic cells of all adrenals sections tested, 
while Leu-Enk was confined to a sub-population of noradrenergic cells. Intense VMAT1   189 
staining was present in all chromaffin cells of all normal adrenals examined. In contrast the 
expression profile of NAT, NPY, Leu-Enk, VMAT1 and VMAT2 observed in the adrenal 
phaeochromocytomas of MPC-injected nude mice (n=9) was dramatically altered. The 
expression of NAT and NPY were not spatially related to PNMT and the level of 
expression of both markers was highly variable. Leu-Enk was still present only in PNMT-
negative cells, but staining was diminished in all samples. In contrast to normal adrenal 
glands, VMAT2 was co-localised with PNMT in some samples, and the level of VMAT2 
seemed to exceed that of VMAT1.  Thus, we report that similar to human 
phaeochromocytoma, the adrenal phaeochromocytomas in animals from the MPNM model 
demonstrate significant alterations to the normal expression profiles of sympathoadrenal 
markers.  These data indicate that this novel animal model is useful for the study of 
metastatic and adrenal phaeochromocytoma. 
II. Introduction 
 
  Chromaffin cells of the adrenal medulla are typically divided into two distinct cell 
groups, defined on the basis of whether or not they express PNMT.  In normal tissues, the 
expression profiles of a number of chromaffin cells markers follow a strict relationship with 
PNMT. For instance, NAT (Phillips et al., 2001), the serotonin transporter, SERT 
(Schroeter et al., 1997), NPY (Lundberg et al., 1986), Leu-enkephalin, Leu-Enk (Henion & 
Landis, 1990) and the glucocorticoid receptor (Ceccatelli et al., 1989) are confined to 
adrenergic cells. In contrast other proteins are preferentially expressed in noradrenergic 
chromaffin cells including the vesicular monoamine transporter isoform 2, VMAT2 (Hou   190 
& Dahlstrom, 1996), growth associated protein 43, GAP43 (Grant et al., 1992), and the L1 
cell adhesion molecule, L1CAM (Leon et al., 1992a, Leon et al., 1992b).  
 
  The occurrence of phaeochromocytoma within the general population is incredibly 
rare, however malignant transformation has been suggested to occur in up to 36% of 
patients with sporadic phaeochromocytoma (John et al., 1999).  Despite the rarity of 
metastatic forms of phaeochromocytoma, the outlook for these patients with metastatic 
disease is poor and the therapeutic options available for these patients are limited.  
Therefore, an appropriate animal model of metastatic phaeochromocytoma in which novel 
therapeutic compounds or treatment strategies could be tested at the pre-clinical level is 
necessary. A metastatic phaeochromocytoma nude mouse (MPNM) model generated by 
injecting mouse phaeochromocytoma (MPC) cells directly into the tail veins of antithymic 
nude mice, has recently been described as a reproducible model of metastatic 
phaeochromocytoma (Ohta et al., 2006b). Animals in the MPNM model frequently develop 
metastatic lesions within the liver and this observation closely mirrors human forms of the 
disease where the liver is a common site of metastases (Ohta et al., 2006b, Zelinka et al., 
2007).  Further, liver metastases in patients with metastatic phaeochromocytoma are also 
characterised with a more aggressive clinical picture, are harder to treat and have the worst 
prognosis (Zelinka et al., 2007).  
 
  As described respectively in Chapters 3 and 5 the expression of NAT and NPY in 
human phaeochromocytomas is significantly disrupted compared to the normal adrenal. 
Therefore in this study we sought to determine whether this disregulation of marker   191 
expression is also seen in the adrenal phaeochromocytomas generated in MPNM model, 
relative to the normal adrenals of an outbred mouse strain (balb/c).  We examined the 
expression of three markers suggested to be specific for adrenergic chromaffin cells: NAT, 
NPY and Leu-Enk, in addition to the noradrenergic marker VMAT2. The VMAT1 protein, 
which is expressed in all chromaffin cells regardless of catecholaminergic phenotype was 
also examined. These markers were chosen because in addition to showing a strict 
expression profile in relation to PNMT in normal tissue, they are also clinically relevant to 
phaeochromocytoma tumour biology.  Elevated plasma and tumour levels of NPY and Leu-
Enk have both been detected in patients with phaeochromocytoma, while NAT, VMAT1 
and VMAT2 are critically important for the diagnosis and localisation of 
phaeochromocytoma with I-MIBG and F-FDA and have been shown to be aberrantly 
expressed in human forms of the tumour (Huynh et al., 2005).  
III.  Materials and Methods 
 
Animals 
  Two separate strains of mice were used in the study. Cohort 1, representing the 
‘normal’ controls, consisted of female 8-week old balb/c mice (n = 5; Taconic, 
Germantown, NY, USA). Cohort 2 consisted of female anti-thymic nude mice (NCr-nu; 
Taconic, Germantown, NY, USA), and was further comprised of two groups: (i) mice 
injected with MPC cells (n = 10) and (ii) mice injected with buffer only (n = 5). All animals 
were bred under controlled pathogen-free conditions, maintained ad libitum on a normal   192 
diet and were observed three times weekly for evidence of distress, ascites, paralysis or 
excessive weight loss. 
Cell Culture and generation of tumour lesions 
  MPC cells were cultured in RPMI 1640 medium supplemented with 10% (v/v) 
horse serum, 5% (v/v) foetal calf serum and 25 U/ml penicillin-streptomycin and 
maintained at 37°C in 5 % CO2. Cells were grown until approximately 80% confluent, 
trypsinised for 10 minutes, and counted such that approximately 5 x 10
6 MPC cells were re-
suspended in 100µl of Phosphate Buffered Saline (PBS; ph 7.4; 0.1M) and held on ice until 
injected into the animals. To generate the tumour lesions in vivo, 8 – 10 week old female 
nude mice underwent tail vein injections with MPC cells suspended in 100µl of PBS. 
Control nude mice of the same age were injected with 100µl PBS only. Mice were then 
returned to their cages and housed for three to four weeks. At approximately six-weeks 
post-injection, animals were sacrificed, by deeply anaesthetising with CO2 followed by 
cervical dislocation. Adrenal glands and other tissues were then immediately collected, and 
the adrenal glands were fixed in 3.7% (v/v) formaldehyde in phosphate buffer (PB; 0.1M; 
pH 7.4) for five hours at room temperature. Following fixation, adrenals were washed in 
0.1M PB for 30 minutes. Adrenals were then cryoprotected in 30% sucrose in PB for 2-3 
days at 4 °C, embedded in OCT, frozen on dry ice and stored at -80 °C until time of 
processing.  Samples taken from the other organs were not formalin fixed, but were 
immediately snap-frozen on dry ice and stored at -80°C for later use.   193 
Anatomical and functional imaging 
  To determine whether animals injected with MPC cells were developing metastatic 
lesions MicroCT and MRI were performed on a subset of the animals.  MicroCT technique 
was performed on animals from 3-weeks post-injection of MPC cells. The rationale for 
performing microCT with Fenestra™LC contrast agent at 3 weeks or later is based on 
previous observations by Ohta et al, in which no evidence of tumour growth is detected in 
the first 3 weeks but is followed by rapid tumour growth and proliferation in the period 
following (Ohta et al., 2006a). After the confirmation of liver lesions using microCT with 
Fenestra™LC, MRI (n=4) was performed with a magnetic field upto 3 Tesla.  As MRI is 
more sensitive to soft tissue lesions than microCT (Martiniova et al., 2006), no contrast 
agent was necessary for MRI.  When the liver tumours were ≥ 2mm in diameter, F-FDA 
PET was also performed (n=3).  
Immunohistochemistry 
  The immunohistochemistry methodology performed for the free-floating mouse 
adrenal gland slices is described in Chapter 2. The primary antibodies consisted of rabbit 
anti-NAT (1:500), rabbit anti-NPY (1:500), rabbit anti-Leu-Enk (1:500), mouse anti-TH 
(1:750), goat anti-VMAT1 (1: 500), rabbit anti-VMAT2 (1: 1000) and guinea pig anti-
PNMT (1:500).  
 
  Triple-labelling experiments were performed with the following primary antibody 
combinations (specific-secondary antibody indicated in parentheses): NAT/TH/PNMT 
(anti-rabbit Cy3/anti-mouse FITC/guinea pig anti-Cy5), NPY/TH/PNMT (anti-rabbit   194 
Cy3/anti-mouse FITC/guinea pig anti-Cy5), Leu-Enk/TH/PNMT (anti-rabbit Cy3/anti-
mouse FITC/guinea pig anti-Cy5), VMAT1/VMAT2/PNMT (anti-rabbit Cy3/anti-goat 
FITC/guinea pig anti-Cy5).  
Confocal Microscopy 
  Sections were examined using a Zeiss LSM 510 “405” confocal microscope 
according to the settings described in Chapter 2.  Staining was described as negligible, 
moderate or intense, and the distribution pattern of immunoreactive cells was noted.   195 
 
IV.  Results 
 
Anatomical and functional imaging 
MicroCT imaging and MRI scanning 
  Animals were imaged with microCT in the 3
rd week following injection with MPC 
cells, however no liver lesions were detected at this time. When animals were imaged in the 
4
th week following injection, potential liver lesions greater than 350 µm were detected, 
however the liver structures and abdominal organs were not distinguishable. 
MRI with respiration gating was used for detecting hepatic and lesions in other organs, 
including the presence of enlarged ovaries and adrenal glands.  Abnormalities were not 
detected in the control animals (not injected with MPC-cells) also scanned with MRI 
(Figure 7.1a).  However, in the animals injected with MPC-cells, liver lesions were also 
clearly visible in week 4 (Figure 7.1b). In week 5 the liver metastases were approximately 
1-5 mm in diameter (Figure 7.1c) and therefore we were able to use PET technique.   
F-FDA PET scanning 
  For physiologic confirmation of phaeochromocytoma lesions F-FDA PET scanning 
was performed on 3 animals identified by MRI as having large liver lesions for PET 
technique. Animal PET scans were performed using the Advanced Technology Laboratory 
Animal Scanner, (ATLAS) PET scanner (Seidel, 2002).  The active F-FDA compound was   196 
obtained from the clinical imaging of patients with F-FDA (Pacak et al., 2001, Martiniova 
et al., 2006).  With F-FDA PET liver lesions were detected in all animals (3/3) on the 
beginning of the 6
th week (Figure 7.1e).  Adrenal lesions were able to detect only if their 
size is more than 2mm in diameter. (2\3).  Lung lesions were not visible due to their small 
size.  Ovary lesions were visible in one animal. 
Gross Necropsy of MPC-treated nude mice 
  One MPC-treated animal was found to be in extreme discomfort three weeks post-
injection due to extensive disease, and the animal was therefore immediately euthanised. 
The tissues from this animal were not included in this study. At the time of euthanasia, 
necropsy of the remaining nine MPC-treated animals revealed that all animals developed 
liver lesions (n=9 animals), however the extent and size of liver lesions varied between 
animals (Table 7.1), with some animals demonstrating numerous metastatic foci within the 
liver, with others only developed one or two isolated liver lesions. Other suspected lesions 
were also found in the ovaries or lungs. One animal had a lymph enlargement, and another 
animal had a bone lesion.  Seven animals also demonstrated grossly enlarged adrenal 
glands. 
  Control nude mice were also examined for the presence of abnormalities by 
necropsy, however no abnormalities were detected in any of the control animals. Samples 
of normal tissue (liver, lung, ovary, kidney, lymph and adrenal) from control nude mice 
were also collected and stored.    197 
 
Figure 7.1  Localization of phaeochromocytoma metastases using MRI and F-FDA   198 
 
Table 7.1  Gross necropsy findings of nude mice injected with MPC-cells.   
Asterix indicates animals in which microMRI was performed, † indicates animals which 
were also scanned with F-FDA.   
 
Animal  Necropsy (Gross findings) 
1   Single, small liver lesion (approx 1 mm diameter), enlarged 
adrenals, enlarged ovaries. 
2 *†  Extensive liver lesions (ranging from 1 – 5 mm diameter), 
enlarged adrenals, ovary. Suspected lung lesion, and bone 
lesion 
3   Single, small liver lesion (approx 1-2 mm diameter), enlarged 
ovaries 
4   Multiple liver lesions (<3; ranging from 1 – 4 mm diameter), 
ovary tumour 
5   Multiple liver lesions (<3; ranging from 1 – 2 mm diameter), 
enlarged lymph nodes, ovaries and adrenals. Suspected lung 
lesion. 
6*†  Extensive liver lesions (ranging from 1 – 5 mm diameter), 
enlarged adrenals, ovary. Suspected lung lesion, and bone 
lesion. 
7  *†  Extensive small liver lesions (ranging from 1 – 2 mm 
diameter), one lung lesion – 0.5 mm diameter, ovary tumor, 
enlarged and possible adrenal gland lesions 
8 *  Extensive small liver lesions (ranging from 1 – 2 mm diameter) 
and one large 5 mm diameter liver lesion; enlarged adrenals, 
ovary and lymph nodes. 
9   Extensive small liver lesions (ranging from 1 – 2 mm 
diameter); ovary lesion, Enlarged adrenals. 
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Histopathology of Adrenal Lesions 
  Routine H&E staining of adrenal sections of control animals (PBS-injected nude 
mice and balb/c) demonstrated normal chromaffin architecture.  No gross abnormalities in 
the cortex or medulla of control animals.  However, H&E staining of adrenal sections from 
all nine MPC-treated animals indicated the development of bilateral phaeochromocytomas. 
Amongst the nine glands examined, the degree of abnormality ranged from extreme 
disruption to the ultrastructural architecture including enlargement of the medullary region 
and displacement of cortex, to development of lesions within the cortex.  Adrenals of two 
animals appeared grossly normal but histopathology revealed the presence of microscopic 
lesions.  
Expression of sympathoadrenal markers in the adrenal glands of 
balb/c mice and control nude mice. 
  Expression of the respective sympathoadrenal markers within the adrenals of balb/c 
animals and control nude mice are summarised in Table 7.2.  Results did not differ between 
the two strains of mice. Intense TH staining was seen in all chromaffin cells (Figure 7.2-
4a), whereas PNMT expression was present in the cytoplasm of a sub-population of 
chromaffin cells, which represented the majority of all cells present within the medulla 
(Figure 7.2-4c).  NPY was present in the cytoplasm of all chromaffin cells, however intense 
NPY immunoreactivity was restricted to PNMT positive cells, whereas weak PNMT 
staining was observed in the PNMT negative cells (balb/c: figure 7.2b).  Strong Leu-Enk 
staining was detected in the cytoplasm of a sub-population of TH positive, PNMT negative   200 
chromaffin cells (nude mice: figure 7.3b) and was not detected in any PNMT positive cells.  
Intense punctate cytoplasmic NAT staining corresponding to TH positive, PNMT positive 
cells (balb/c: figure 7.4b) but was not seen in PNMT negative cells.  Intense VMAT1 
staining was present in the cytoplasm of all chromaffin cells (balb/c: figure 7.5a), in 
contrast to VMAT2 staining which was present in PNMT negative cells (balb/c: figure 
7.5b). Staining was not observed in the cortex with any of the markers tested, nor was 
staining observed in negative control sections not treated with primary antibody.   201 
Table 7.2  The expression of sympathoadrenal markers in chromaffin cells of balb/c and 
nude mice injected with PBS-only.  
Staining was described as: +++ intense, ++ moderate, + weak, – absent. * Leu-Enk was 
described in a sub-population of PNMT negative cells. 
 
  Sympathoadrenal Markers 
  NPY  Leu-ENK  NAT  VMAT1  VMAT2 
Balb/C mouse strain 
PNMT positive 
(adrenergic) 
+++    +++  +++   
PNMT negative 
(noradrenergic) 
+  +++*    +++  +++ 
Nude Mouse (PBS only) 
PNMT positive 
(adrenergic) 
+++    +++  +++   
PNMT negative 
(noradrenergic) 
+  +++*    +++  +++ 
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Figure 7.2  Intense NPY staining observed in adrenergic chromaffin cells in adrenal glands 
of balb/c mice.   203 
 
Figure 7.3  Leu-Enk immunoreactivity observed in sub-population of noradrenergic 
chromaffin cells in adrenal glands of nude mice   204 
 
Figure 7.4  Cytoplasmic expression of NAT in adrenergic chromaffin cells in adrenal 
glands of balb/c mice   205 
 
Figure 7.5  Intense staining of VMAT1 observed in adrenergic and noradrenergic 
chromaffin cells, whereas VMAT2 staining was restricted to noradrenergic 
chromaffin cells in adrenal glands of balb/c nude mice   206 
 
Expression of sympathoadrenal markers in adrenals of MPC-
injected nude mice 
Expression of peptide markers: NPY and Leu-ENK 
  NPY expression in the adrenal glands of MPC-injected nude mice ranged from very 
intense to negligible (Figure 7.6a,b), and the association between NPY and PNMT was also 
variable whereby in all samples NPY and PNMT appeared to be colocalised, but the levels 
of NPY and PNMT staining were not always the same (Figure 7.6b).   
 
  Leu-Enk expression in the adrenal glands of MPC-injected nude mice was 
negligible in all samples analysed. Two samples possessed marginal Leu-Enk staining, 
manifesting as isolated groups of cells with intense staining Consistent with the findings of 
untreated mouse adrenal glands, Leu-Enk staining was cytoplasmic, and in both cases of 
MPC-injected mice where intense Leu-Enk staining was observed, staining was not 
associated with PNMT (Figure 7.7a). 
Expression of monoamine transporters: NAT, VMAT1 & VMAT2 
  In general, NAT expression in the adrenal glands of MPC-injected nude mice was 
unremarkable, and while in some samples intense NAT staining was encountered this was 
the exception, not the rule.  Similar to findings in the mouse (Figure 7.4), NAT staining 
was consistently observed within the cytoplasm. However, in contrast to the observed 
pattern of NAT staining within untreated mouse adrenal glands, in phaeochromoctyoma,   207 
NAT was not strictly co-localised with PNMT-positive cells. (for representative example 
see Figure 7. 8a,b).    
 
  Expression of the VMATs was also highly variable with regard to the levels of 
staining and the relationship with PNMT (Figures 7.9a,b). Unlike the adrenal glands of 
untreated animals where VMAT1 was the major isoform present, in MPC-injected mice, 
while intense VMAT1 staining was observed, this typically existed as intense staining 
within clusters of cells (Figure 7.9). In contrast, moderate to intense diffuse VMAT2 
staining was present throughout large sections of the adrenals examined, in addition to the 
clusters of intense VMAT2 staining which colocalised to intense VMAT1 and PNMT 
staining. Thus, in general, VMAT2 immunoreactivity was more abundant than VMAT1 
(for representative samples see Figures 7.9).  VMAT1 and VMAT2 immunoreactivity were 
often colocalised with PNMT, especially within the areas of intense VMAT1/2 and PNMT 
expression, however, PNMT was also observed independent of both VMATs (Figures 7.9).   208 
Table 7.3  Variable expression of the respective sympathoadrenal markers in adrenal 
phaeochromocytoma of MPNM model  
(* generally weak staining with some isolated cells with intense staining; ** weak staining 
throughout most of sections with regions of moderate staining; *** moderate staining 
throughout most of sections with regions of intense staining; † weak staining throughout 
most of sections with regions of intense staining; ‘a’ large regions of intense staining with 
areas of moderate staining; ‘b’ large regions of intense staining  with areas of weak 
staining; ‘c’ moderate in most parts of section with some areas of weak staining; ‘d’ 




NPY  Leu-Enk  NAT  VMAT1  VMAT2  PNMT  TH 
1  +++
a  —  +  +++
d  ++/+++  +++
b  +++ 
2  ++
***  +++
*  +  —
d  —
d  ++
c  +++ 
3  +++  +++
*  +  +++  +




**  —  +
†  ++
***  ++ 
5  +
†  —  +  +
†  +
†  ++
***  ++ 
6  ++




***  ++ 
7  ++
***  +
*  —  —
d  +
†  +







†  ++ 
9  +
†  —  —  —
d  +
†  +
†  + 
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Figure 7.6  Highly variable level of expression of NPY in adrenal phaeochromocytoma 
from MPNM   210 
 
Figure 7.7  Negligible expression of Leu-Enk in adrenal phaeochromocytoma obtained 
from an animal generated in MPNM model   211 
 
Figure 7.8  Altered pattern of NAT expression in adrenal phaeochromocytoma from MPNM 
model, including disappearance of NAT expression in PNMT-positive cells   212 
 
Figure 7.9  Adrenal phaeochromocytoma from MPNM model showing abbarent VMAT2 




  In this study we report that in addition to hepatic metastatic lesions, the animals of 
the MPNM model also develop adrenal phaeochromocytomas, which display the classic 
histopathologic features of a phaeochromocytoma including diffuse expression of the 
catecholaminergic marker TH.  We also found that the expression of NAT, NPY, Leu-Enk, 
VMAT1 and VMAT2 (proteins and peptides known to be expressed in chromaffin cells and 
with clinical significance to human phaeochromocytoma) demonstrated significant 
disruption to the normal pattern established in the normal adrenal of control animals.  The 
observed changes include (i) altered association between the respective marker and PNMT, 
and (ii) altered level of marker expression within lesions.  
Neuropeptides 
  As established in Chapter 5, NPY expression in the human adrenal medulla is found 
in the cytoplasm of all chromaffin cells. In conjunction with our findings in Chapter 3, 
where PNMT expression was found in all chromaffin cells, our present finding of strong 
NPY immunoreactivity in mouse adrenergic chromaffin cells supports the work of others 
where NPY is associated with adrenergic chromaffin cells (Lundberg et al., 1986, Henion 
& Landis, 1990).  However, we also demonstrate NPY immunoreactivity (albeit weak) 
within mouse noradrenergic chromaffin cells.  This would tend to also support work by 
Majane et al (1985), who found an association between NPY and noradrenergic chromaffin 
cells in the bovine adrenal gland (Majane et al., 1985).  Our work showing the differing   214 
levels of NPY between the two cell phenotypes would suggest that the discrepancies 
between the findings of others might be related to methodological reasons.  In these earlier 
studies, fluorescent light microscopy was utilised.  In contrast, in the present work, we 
utilised fluorescent confocal microscopy which is said to be    In Chapter 5 we also report 
that NPY expression in human phaeochromocytoma from patients with hereditary and 
sporadic disease can vary between patients, with a tendency towards very intense 
expression of the peptide in all tumours except those from patients with 
phaeochromocytoma due to germline mutations in the VHL gene. NPY staining was also 
apparent in the adrenals of MPC-injected animals, and in this setting was not strictly 
associated with PNMT. The level of NPY found within the adrenals of MPC-injected mice 
also varied considerably, with some regions demonstrating ultra-intense NPY 
immunoreactivity while other adjacent areas possessed moderate staining.  Overall, our 
observations are consistent with the descriptions of highly variable NPY expression in 
human phaeochromocytoma.   
 
  Enkephalins (met- and leu-) are opioid pentapeptides found within central and 
peripheral nervous system tissues, including the adrenal medulla (Schultzberg et al., 1978, 
Lundberg et al., 1979), where they serve to provide an endogenous source of analgaesia. 
The met- and leu-enkephalin peptides are enzymatically generated from the gene 
proenkephalin, which was first cloned from phaeochromocytoma cDNA (Legon et al., 
1982).  With respect to the adrenal medulla, reports suggest that enkephalins are associated 
with adrenergic chromaffin cells (Dumont et al., 1983, Roisin et al., 1983, Pelto-Huikko et 
al., 1985, Henion & Landis, 1990). In our study, however, we did not observe this   215 
relationship, but rather found that in both mouse strains L-Enk was present within a sub-
population of PNMT-negative chromaffin cells, which represent a small fraction of total 
chromaffin cells (<10%).  The predominant cell type within the adrenal medulla is the 
chromaffin cell, however, small populations of SIF cells and type I and type II ganglion 
cells are also present (Holgert et al., 1996, Langley & Grant, 1999). Thus a possible 
explanation for our present finding is that L-Enk staining corresponds to type II ganglion 
cells, which are present in the adrenal medulla and express TH but not PNMT (Phillips et 
al., 2001).  However, intra-adrenal ganglion cells tend to be much larger than chromaffin 
cells and the Leu-Enk staining was observed in cells that appeared the same size as the 
surrounding chromaffin cells.  As enkaphalin expression within the normal human adrenal 
medulla has yet to be characterised, further work is required to determine whether or not 
enkephalin expression in normal human chromaffin cells corroborates our findings or those 
of others in which enkephalin has been linked to adrenergic cells (Dumont et al., 1983, 
Roisin et al., 1983, Pelto-Huikko et al., 1985, Henion & Landis, 1990).  In these studies 
enkephalins were associated with adrenergic cells in chromaffin cells of the rat, cow and in 
acutely isolated chromaffin cells fractions.  In our study, the adrenal phaeochromocytomas 
from MPC-treated animals generally demonstrated negligible Leu-Enk staining.  Although 
the literature suggests that enkephalins are elevated in the plasma and tumour extracts of 
human phaeochromocytomas, it is also apparent that expression and production of 
enkephalins by these tumours is also highly variable (Yoshimasa et al., 1982, Yoshimasa et 
al., 1983, Kodama et al., 1990).     216 
Monoamine Transporters 
  Similar to previous finding from the rat (Phillips et al., 2001) and human (Chapter 
3), in the mouse, NAT is expressed in adrenergic chromaffin cells.  In the adrenals of MPC-
injected animals we observed a significant disruption to NAT expression.  The intensity of 
NAT staining was highly variable amongst the tumours examined, ranging from intense 
cytoplasmic immunoreactivity to undetectable expression. In addition, in contrast to the 
specific colocalisation with NAT and PNMT present in the normal adrenal medulla, this 
pattern was lost in the in phaeochromocytoma lesions.  The data from this study are 
consistent with that obtained in Chapter 3 whereby NAT expression within human 
phaeochromocytoma tumour tissue was shown to have variable levels of expression and 
was disassociated from PNMT. In the rat adrenal gland, VMAT1 is expressed in all 
chromaffin cells while VMAT2 is confined to those with a noradrenergic phenotype (Peter 
et al., 1995, Hou & Dahlstrom, 1996). Our data generated in both the normal mouse 
adrenals (balb/c) and nude mice injected with PBS-only also demonstrated this pattern. 
However, in the adrenal glands of MPC-injected nude mice, the typical expression pattern 
of the two VMATs was disrupted.  In some instances VMAT2 and PNMT were 
colocalised, unlike the staining pattern observed in the normal mouse adrenal, possibly 
suggesting a loss of normal regulatory mechanisms in these cells.  Further, whereas 
VMAT1 is normally the predominant isoform in endocrine cells, in our study, it appeared 
that VMAT2 expression was greater implying a transition from VMAT1 to VMAT2 as the 
predominant isoform in this model.  Given the disrupted expression pattern of NAT and 
both VMATs in the adrenal phaeochromocytomas from this model, an important question 
is whether these alterations are relevant to the pre-clinical utility of this animal model,   217 
particularly in radionucleotide imaging studies.  The classical notion of 
phaeochromocytoma imaging with I-MIBG and F-FDA is that uptake is mediated by the 
noradrenaline transporter (Sisson et al., 1981, Jaques et al., 1984, Mairs, 1999, Pacak et 
al., 2001), and that expression of the transporter is critical factor in the accumulation of I-
MIBG and/or F-FDA.  Studies in which NAT mRNA and I-MIBG accumulation are 
closely correlated have supported this notion (Carlin et al., 2003). As described in Chapter 
3, NAT expression in phaeochromocytoma is highly variable and the results of F-FDA PET 
scans were not necessarily a good indication of NAT expression within tumour samples 
from these patients.  However, while expression of NAT is almost certainly an important 
factor in I-MIBG/F-FDA uptake, it now seems clear that VMATs are equally, if not more 
important in the utility of these compounds as imaging agents (Kolby et al., 2003, Kolby et 
al., 2006).  The VMATs are pharmacologically distinct proteins, where VMAT1 has a 
greater affinity for adrenaline (Brunk et al., 2006a) whereas VMAT2 has a three-fold 
greater affinity for serotonin, dopamine and noradrenaline than VMAT1 (Erickson et al., 
1992, Peter et al., 1994).  As I-MIBG and F-FDA represent noradrenaline and dopamine 
analogues respectively, possibly VMAT 2 is the more important isoform for I-MIBG/F-
FDA accumulation and visualisation than VMAT1.  In support of this suggestion are results 
showing poor uptake of I-MIBG in midgut carcinoids, which frequently lack VMAT2 
expression, compared to the high uptake of I-MIBG in human phaeochromocytomas, which 
express both VMAT1 and VMAT2 (Kimmig, 1994, Kolby et al., 2001).  Thus although in 
many of the adrenal phaeochromocytoma in the present study the staining patterns for NAT 
and VMAT1 are dismal, possibly the emergence of VMAT2 as the predominant isoform in   218 
these samples is sufficient for appropriate uptake and accumulation of imaging agents in 
these animals.   
Phaeochromocytoma animal models 
  Metastatic phaeochromocytoma within the human population is extremely rare.  
Consequently, while there is a need for better therapies for these patients, the ability to 
rigorously test novel drugs or treatment options is limited by the small number of patients 
who will develop the disease. Thus, the MPNM model generated at the NIH arose from the 
need for access to a suitable model in which novel therapeutic compounds or strategies 
could be tested and later be applied to humans with metastatic phaeochromocytoma. 
However, the MPNM model is not the only animal model of phaeochromocytoma to be 
developed. Other transgenic mouse models such as those with targeted disruptions to genes 
including c-mos (Schulz et al., 1992), c-RET (Smith-Hicks et al., 2000), Rb (Williams et al., 
1994), Pten (You et al., 2002) or NF1 (Powers et al., 2000) have all been linked to the 
appearance of adrenal phaeochromocytoma, with varying degrees of phaeochromocytoma 
penetrance. In the MPNM model, when trying to establish a methodology for generating 
animals with metastatic lesions, it was found that tail vein injections of MPC cells 
represented a superior route of entry compared to either intraperitoneal injection where 
approximately 45% of animals developed hepatic lesions, or the subcutaneous route in 
which no animals developed metastatic disease (Ohta et al., 2006a). In contrast, using the 
tail-vein injections, 92% of animals injected with MPC cells developed hepatic lesions 
(Ohta et al., 2006a).  The ability to establish a reproducible working model of metastatic 
disease by injecting a cancer cell line into the tail vein of nude mice has also been 
demonstrated with other forms of cancer including melanoma, neuroblastoma and   219 
pancreatic cancer (Engler et al., 2001, Michl et al., 2003, Garcia et al., 2004, Streck et al., 
2004).  The study conducted by Ohta et al, also reported that microCT, when combined 
with the long-lasting hepatobiliary contrast agent Fenestra™LC (Advanced Research 
Technologies, Inc.), is a highly efficient method for the detection the liver lesions. The 
Fenestra™LC contrast agent provides visualization of the hepatobiliary system by 
exploiting the endogenous lipid metabolism pathways present in the body, and provides the 
ability to assess both hepatobiliary anatomy as well as the liver function (Martiniova et al., 
2006).  However, while microCT is an effective methodology for detecting hepatic lesions, 
its is less effective at detecting lesions outside of the liver in sites including the kidneys, 
ovaries and adrenal glands (Martiniova et al., 2006).  Thus in order to identify these other 
metastatic lesions in the MPNM animal model, MRI technology adapted from clinical 
diagnostic imaging of phaeochromocytoma in humans was also utilised.  
Phaeochromocytomas have been described as highly vascular heterogeneous masses having 
characteristic high signal intensity on standard T2-weighted exams (Varghese et al., 1997).  
To use a clinical scanner however requires the use of dedicated local coils with improved 
signal-to-noise to support the higher resolutions necessary in animal imaging (Martiniova 
et al., 2006).  
New information about the MPNM model 
  Our study serves to provide important new additional information about the MPNM 
model.  We show that 100% of animals developed hepatic lesions with varying degree of 
tumour burden. However, we also detected abnormalities in other tissues, including 
suspicious lesions in the lungs, ovaries, lymph nodes, and in the hipbone in one animal.  
Further, all animals developed adrenal phaeochromocytomas. Given that we treated our   220 
animals according to an identical methodology used by Ohta et al, why we observed a 
different phenotype is unclear.  Previous work by Ohta et al confirmed the liver lesions as 
histolopathologically proven phaeochromocytomas, thus we have extrapolated this to 
assume that the lesions seen in our study are also true phaeochromocytomas, however 
histopathology on the samples would need to be performed for this to be proven 
unequivocally.  
  Importantly, we did not examine the expression of the respective markers (TH, 
PNMT, NPY, Leu-ENK, NAT, VMAT1 and VMAT2) within the MPC-cell in vitro prior to 
injecting the cells into the mice.  Thus subsequent studies should also incorporate the 
endogenous expression of the respective markers in this cell line prior to the injection of the 
cells into the mice to determine the expression profile of these markers in the cell line.  
However, although NPY, Leu-Enk and VMAT expression have not been examined in 
MPC-cells, Dixon et al examined TH, PNMT and NAT expression in this cells line and 
confirmed that MPC cells show endogenous expression of all three proteins (Dixon et al., 
2005).  Ergo, it is possible that the reduced VMAT1 expression and our failure to detect 
appreciable Leu-Enk levels in most of the phaeochromocytoma samples may be because of 
poor endogenous expression of these proteins in the MPC cell line.  
Further, while the focus of this study was limited to the phaeochromocytoma arising within 
the adrenals, additional investigation of this model should also be extended to the extra-
adrenal metastatic lesions. 
 
  In summary, in this study we validate previous work by Ohta et al (2006) 
demonstrating the ability to generate liver metasteses in nude mice injected with MPC cells.    221 
Furthermore, we also provide additional data relating to the MPNM model, particularly that 
this model is also a useful tool for studying intra-adrenal phaeochromocytoma.  The adrenal 
phaeochromocytoma generated in these mice demonstrate many similarities to human 
phaeochromocytoma, including significant disruptions to the normal expression profiles of 
chromaffin cell markers. 
   222 
Chapter 8 – General Discussion, Conclusions and 
Future Perspectives 
 
  Phaeochromocytoma represents a rare and under appreciated form of sympathetic 
nervous system dysfunction, characterised by the synthesis, storage and release of excess 
catecholamines and other components of chromaffin granules. The normal cells from which 
these perplexing tumours are derived – the chromaffin cell – are equally dynamic and 
represent an integral component of the autonomic nervous system which contribute to the 
maintenance of homeostasis and responses to stress.  In this thesis we have examined and 
compared the expression profile of a number of sympathoadrenal markers in the normal 
adrenal medulla and in phaeochromocytoma.  These markers were chosen for two 
important reasons.  Firstly, in normal adrenal tissue they have been reported to exhibit a 
spatial relationship with PNMT.  Secondly, these markers are clinically relevant to 
phaeochromocytoma, whether they have an effect on the presentation and/or 
symptomatology of the tumour (e.g., NPY, CGA, Leu-Enk, PNMT), or because they are 
relevant for diagnosis (e.g., NAT, VMATs).  Our data both confirm and contradict the 
normal pattern of marker expression that has been reported elsewhere.  We also present 
data showing that in phaeochromocytoma major disruptions to the normal appearance of 
cellular markers can be observed and these disruptions may be clinically important.  
Is there a local role for adrenal catecholamines?  
  Catecholamines have a well-described role as a neurotransmitter (e.g., noradrenaline 
release from sympathetic nerves) and hormone (e.g., adrenaline release from the adrenal).    223 
However, to date very little data shows evidence for a local (paracrine, autocrine) role for 
catecholamine release from the adrenal medulla.  Although chromaffin cells possess all the 
machinery required for catecholamine recycling (e.g., NAT, VMATs, chromaffin granules), 
whether catecholamine recycling occurs to any significant degree in this tissue is yet to be 
answered.  Pioneering studies by Kent and Coupland (1981) have shown that chromaffin 
cells can accumulate exogenous catecholamines.  These original studies demonstrated two 
salient ideas.  Firstly, that dopamine and noradrenaline were accumulated into chromaffin 
cells at a much higher concentration than adrenaline and secondly, that catecholamines are 
incorporated at the highest concentration in adrenergic chromaffin cells (Kent & Coupland, 
1981).  Despite these findings showing that catecholamine uptake can occur within the 
adrenal medulla, the role of NAT in reuptake of adrenal derived endogenous 
catecholamines is yet to be clarified.  One possibility is that catecholamine concentrations 
are regulated primarily via release rather than recapture.  As illustrated in Chapter 1, 
catecholamine release though exocytosis is a tightly regulated process, in which three 
alternative models have been put forth.  Data has shown that chromaffin cells express 
functional alpha2-adrenoceptors, which provide an inhibitory mechanism to control 
catecholamine overflow (Brede et al., 2003, Moura et al., 2006).  The extent to which the 
alpha2-adrenoceptors participate in regulating catecholamine release, especially in humans, 
remains to be determined.  However, the putative presence of an intrinsic feedback loop 
mediated by catecholamine released from the adrenal suggests that a local role for 
catecholamines may exist within the adrenal.      224 
Chromaffin cells also produce the CGA-derived fragment catestatin, which is a nicotinic 
receptor antagonist suggested provide a mechanism for modulating catecholamine release 
from the adrenal (Mahata et al., 1997, Mahata et al., 2000, Taupenot et al., 2000).   
In Chapter 6, we report that relative to tumour size, patients with phaeochromocytoma due 
to VHL syndrome have larger increases in total plasma catecholamines than patients with 
phaeochromocytoma due to MEN 2.  Our data is in agreement with previous studies 
indicating more continuous secretion of catecholamines from tumours of VHL patients and 
lower baseline release in MEN 2 patients (Eisenhofer et al., 2001b, Huynh et al., 2005).  
Why do phaeochromocytoma related to the VHL syndrome display this pattern of 
continuous release? One possibility is that the normal feedback loops in chromaffin cells 
that inhibit catecholamine release (e.g., catestatin) are impaired in the cells of VHL-related 
tumours.  For example, VHL related phaeochromocytomas show less CGA expression 
(Chapter 6) and have fewer chromaffin granules than other forms of phaeochromocytoma, 
including those due to MEN 2 (Eisenhofer et al., 2001b, Huynh et al., 2005). Thus, the 
uncontrolled catecholamine release observed in these tumours maybe a consequence of 
impaired catestatin-derived feedback inhibition pathways that would normally provide an 
internal checkpoint.  Alternatively, the normal mechanisms regulating exocytosis may also 
be impaired, but this is yet to be clarified.     
Are noradrenergic chromaffin cells more neuronal than adrenergic 
chromaffin cells?  
  The findings of Chapter 3 show that the human adrenal gland is composed of a 
single population of PNMT-positive chromaffin cells.  In contrast, other species such as the 
mouse and rat adrenal possess distinctive PNMT-negative and PNMT-positive cell   225 
populations (Chapter 7)(Suzuki & Kachi, 1996).  Why species such as the rat and mouse 
have evolved two populations of chromaffin cells compared to a single population as 
observed in humans is unclear.  Noradrenergic chromaffin cells preferentially express a 
number of proteins also found in noradrenergic neurons.  For instance, the proteins GAP43, 
a protein expressed at high levels in during neuronal development (Strittmatter et al., 1995) 
and L1CAM, a neural adhesion molecule also found in sympathetic neurons and considered 
a neuronal index, are preferentially localised to noradrenergic chromaffin cells (Leon et al., 
1992a, Holgert et al., 1995).  The VMAT isoform VMAT2, which is considered the 
‘neuronal’ isoform of the two VMATs, is also located in noradrenaline-producing 
chromaffin cells.  The absence of NAT from noradrenergic chromaffin cells has also been 
suggested to reflect may differences in the developmental regulation of the noradrenergic 
and adrenergic sub-populations (Phillips et al., 2001), although it has also been suggested 
that noradrenergic chromaffin cell are closer to a neuronal phenotype than adrenergic cells 
(Langley & Grant, 1999). 
Arrested development 
  The classical view of chromaffin cell development is that cells of the 
sympathoadrenal lineage are derived from a common TH-positive precursor, which diverge 
following exposure to environmental cues (Huber, 2006). Other thoughts suggest that while 
some neural crest progenitors are multipotent, a subset of these neural crest progenitors are 
fate-restricted before they leave the dorsal aorta, and through their own autonomous 
intrinsic signals can migrate to a final destination (Harris & Erickson, 2007). Studies have 
shown that in the developing mouse embryo cells expressing MASH-1 but lacking TH are   226 
found in the adrenal analgen at E11.5 while developing sympathetic neurons located nearby 
have already begun to express TH (Gut et al., 2005). Observations in MASH-1 knockout 
mice show that while chromaffin cells migrate to the adrenal, most are grossly deformed 
and ultrastructurally immature (Huber et al., 2002).  Yet despite the ablation of MASH-1, a 
small number of fully differentiated chromaffin cells expressing TH and PNMT are 
detected (Huber et al., 2002).  This could be interpreted to indicate that at least a small 
proportion of chromaffin cells develop along a separate, yet parallel pathway.  Consistent 
with this theory, other data suggests that the neural crest population is more heterogeneous 
than could be explained under the common theory in which multipotent neural crest 
progenitor cells undergo a series of steps towards lineage restriction as a final cell type 
(Huber, 2006, Harris & Erickson, 2007).   
 
  The development of phaeochromocytoma, particularly tumours related to hereditary 
disorders, has been suggested to reflect the failure of progenitor cells to undergo apoptosis 
and developmental culling (Lee et al., 2005).  The findings of Chapters 5 and 6 on the 
differential expression of NPY and CGA in phaeochromocytoma from patients with VHL 
disease and MEN 2 add to the increasing body of data that phaeochromocytomas from the 
two respective patient groups possess numerous differences.  Both NPY and CGA are 
chromaffin granules constituents, but importantly, they appear early in chromaffin cell 
development (both at approximately E15) and before chromaffin cells invade the adrenal 
analgen (Henion & Landis, 1990, Ehrhart-Bornstein et al., 1997), indicating that both NPY 
and CGA are early sympathoadrenal markers. Possibly, the lack of CGA and NPY, 
especially in VHL-related phaeochromocytomas, relative to other types of the tumour, may 
hint that the cells from which these tumours are composed represent a more immature   227 
chromaffin cell.  Possibly, disease-causing mutations exert their erroneous effects at a 
critical point in chromaffin cell development and while the cells forming these tumours are 
able to migrate to the normal adrenal, they are later incapable of normally expressing 
chromaffin cell markers.  The idea that tumourigenesis occurs within a critical window of 
opportunity may also explain the variable penetrance of phaeochromocytoma as a 
presenting feature in the hereditary forms of the disease.  
 
  As discussed in Chapter 1 chromaffin cell development is explained by two separate 
but complementary concepts:  migration and differentiation.  The latter, differentiation, in 
chromaffin cells is embodied by the appearance of the adrenaline-synthesising enzyme 
PNMT.  Along the timeline of chromaffin cell development, the induction of PNMT 
expression occurs relatively late in embryogenesis, and only once progenitor chromaffin 
cells have migrated to the site, which later becomes the adrenal medulla (Teitelman et al., 
1979, Verhofstad et al., 1979, Souto & Mariani, 1996).   
In Chapters 3 and 7, we show that phaeochromocytomas (murine and human) also 
demonstrate altered PNMT expression.  Our data validate other studies in humans reporting 
altered PNMT levels in phaeochromocytoma (Isobe et al., 1998).  The most striking 
example of disruptions to PNMT expression in phaeochromocytoma is in tumours derived 
from VHL germline mutations.  These types of phaeochromocytoma have been shown to 
express negligible levels of PNMT and synthesise minimal amounts of adrenaline (Chapter 
5)(Eisenhofer et al., 2001b).  Several transcription factors influence PNMT expression 
including the glucocorticoid receptor, GR (Tai et al., 2002), Sp1 transcription factor, 
Sp1(Ebert & Wong, 1995), MYC-associated zinc finger protein, MAZ (Her et al., 1999, 
Her et al., 2003) and the early growth response 1 transcription factor, Egr-1(Ebert et al.,   228 
1994).  Work by Huynh et al, shows that the lack of PNMT expression in VHL tumours 
cannot be explained by a lack of expression of the above transcription factors (Huynh et al., 
2006).   
The absence of PNMT in some phaeochromocytomas may reflect a population of cells 
which either never acquired PNMT expression, or have regressed to a cell type incapable of 
supporting the expression of this enzyme. 
Methodological considerations  
  Immunohistochemistry is a valuable tool for examining the expression of one 
protein relative to another (i.e., colocalisation) or the cellular distribution of a protein (i.e., 
cytoplasmic, nuclear, membranous).  For instance in this study, we showed that NAT and 
PNMT are colocalised in the normal adrenal but not colocalised in some of the 
phaeochromocytoma samples.  However, immunohistochemistry may be less valuable 
when attempting to quantify protein expression between samples.  Evidence of this is our 
failure to reproduce the findings of Huynh et al (2005), which show a difference in NAT 
expression between samples from VHL and MEN 2 patients.  In Chapter 6 we found that 
differences in CGA expression were detected using Q-PCR, ELISA and Western Blot, yet 
these differences were not apparent with immunohistochemistry.  Our Q-PCR results 
demonstrated that the difference in CGA mRNA expression between the normal adrenal 
(used as a reference) and phaeochromocytoma samples was more that 3-orders of 
magnitude, illustrating that the phaeochromocytoma tumour samples used within Chapter 6 
contained vast amounts of CGA.  Chromogranin A is a major protein component of 
chromaffin cells, which represents between 7-10% of the total protein content of these cells 
(O'Connor & Frigon, 1984, Eiden et al., 1987).  Our inability to replicate findings obtained   229 
using Q-PCR, ELISA and western blot using immunohistochemistry may relate to the 
relative insensitivity of immunohistochemistry as a quantitative method when dealing with 
proteins such as CGA, which are expressed in abundance.  Alternatively, our failure to 
demonstrate an appreciable difference in CGA expression between the MEN 2 and VHL 
tumours may be because the difference in CGA expression between these tumour groups 
was not vast enough.  For instance, in Chapter 5 we found that NPY levels between MEN 2 
and VHL samples varied by nearly 84-fold (mRNA) and 99-fold (peptide).  In this study 
differences in NPY were also detected using with immunohistochemistry.  In contrast, in 
Chapter 6 there was a 3-fold (mRNA) and 20-fold (protein) difference in CGA levels 
between the groups.  Thus possibly, despite the 20-fold difference in CGA levels between 
VHL and MEN 2 samples (detected by ELISA) such a difference may not be extensive 
enough to be detected by immunohistochemistry.  Thus, when aiming to establish 
difference in the level of protein expression between samples, it is advisable to use a 
number of complementary techniques, especially those such as ELISA and/or Western 
Blot, which have greater quantitative capacity than immunohistochemistry.   
 
  In Chapters 3 and 7, immunohistochemistry was also used extensively to 
qualitatively assess the expression of several chromaffin cell markers (NAT, TH, PNMT, 
VMAT1, VMAT2, NPY, Leu-ENK).  In this setting, immunohistochemistry provided 
valuable information relating to the pattern of expression (e.g., location within the cell), the 
type of expression (e.g., punctate or diffuse) or whether markers were colocalised (e.g., 
findings of NAT in secretory granules).  These sorts of patterns would not have been 
detected using Q-PCR, ELISA or Western Blot.  However, in the case of Chapter 3 and   230 
Chapter 7 where we assessed the level of marker expression, Q-PCR, ELISA and/or 
Western Blot techniques represent far superior methods for mRNA and protein 
quantification than immunohistochemistry.  Again, using a number of techniques to answer 
different aspects of the same question is the preferable option.   
 
  Another important consideration is antibody specificity.  In the thesis we validated 
the specificity of NAT antibody utilised herein by demonstrating that preabsorption with a 
NAT blocking peptide ablated staining.  Others have validated the specificity of the PNMT 
primary antibody used within Chapter 3 of this study in animal tissues (Afework & 
Burnstock, 2005).  Preliminary data (obtained following the completion of work for 
Chapter 3) examining PNMT staining in tumour samples from VHL and MEN 2 patients 
showed some PNMT staining in VHL tumours (data not shown).  As described in Chapter 
1, phaeochromocytomas from patients with VHL syndrome are characterised as having 
negligible PNMT expression and/or adrenaline synthesis (Eisenhofer et al., 2001b).  For 
this reason, the findings of PNMT immunoreactivity in these VHL samples led us to 
question the specificity of this antibody for use in human tissues.  Possible explanations 
include non-specific binding, which could be confirmed through PNMT antibody peptide 
block experiments.  Examining whether these results are due to a non-specific reaction with 
the sheep serum may also provide useful information.  However, PNMT immunoreactivity 
in VHL phaeochromocytoma may also be explained by other factors.  First, the PNMT 
immunoreactive cells may represent normal chromaffin cells rather than 
phaeochromocytoma cells.  Second, PNMT mRNA expression in VHL related 
phaeochromocytomas is negligible, but is still detectable, while at the protein level no   231 
PNMT can be detected by western blot (Eisenhofer et al., 2001b); Chapter 5,  indicating 
that the enzyme, at least at the mRNA level, is not absent from these samples.  Third, and 
most importantly, while phaeochromocytomas from VHL patients produce very small 
amounts of adrenaline relative to noradrenaline, the tumour still do produce some 
adrenaline (though this is rarely manifest by increases above normal in plasma levels of 
adrenaline or its O-methylated metabolite, metanephrine) see (Eisenhofer et al., 2001b); 
Chapter 5.  While it is possible that the PNMT mRNA and adrenaline (from plasma and/or 
tumour) detected in these samples may potentially be derived from small microscopic 
populations of normal chromaffin cells located amongst the phaeochromocytoma tumour 
cells, this is yet to be determined. Together, these data show that while there is minimal 
PNMT expression and adrenaline production from these tumours, our detection of PNMT 
immunoreactivity could be a valid finding and thus confirm the utility of the PNMT 
antibody in human tissues.  
 
  In conclusion, the work presented in this thesis further validate the heterogeneity 
observed in many aspects of phaeochromocytoma tumour biology, including the expression 
several chromaffin cell markers such as the VMATs, NAT, NPY, CGA and PNMT.  The 
altered expression of these markers may contribute to the clinical picture of these tumours, 
particularly relating to hereditary phaeochromocytomas from VHL and MEN 2 disease.  
Future studies including examining the mechanisms underlying the development of 
hereditary tumours and how the specific germline mutations translate into a distinct tumour 
phenotype would also be worthwhile and may provide useful information relating to 
sporadic forms of phaeochromocytoma and other tumours derived from the neural crest.   
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Chapter 10 – Appendix: Examination of key neural 
crest developmental genes in VHL & MEN 
2 tumours 
 
I.  Introduction  
 
  According to the widely accepted paradigm of sympathoadrenal cell development, 
chromaffin cells and sympathetic neurons are derived from a common pluripotent 
progenitor.  As the sympathoadrenal cells migrate from the dorsal aorta, they encounter 
specific environmental cues, which prompt the divergence of two similar yet distinct cell 
types:  chromaffin cells and sympathetic nerves. The molecular cascades guiding the 
diversification of cells derived from the sympathoadrenal lineage are complicated and 
poorly understood, however several genes have been identified as playing a crucial role.   
The transcription factors MASH-1 and PHOX2b are putative candidates.   
 
  The development of hereditary phaeochromocytomas has been suggested to reflect 
the failure of progenitor cells to undergo apoptosis during development (Eisenhofer et al., 
2004b, Lee et al., 2005) thus, the idea that phaeochromocytomas from VHL and MEN 2 
possess such significant differences may arise because these tumours are composed of cells 
which are arrested at different stages of development or differentiation has been proposed.  
Further, preliminary findings of a microarray conducted at the National Institutes of Health, 
NIH (Brouwers et al., 2006b) comparing the gene expression profiles of   269 
phaeochromocytomas from MEN 2 and VHL patients revealed differential expression of a 
number of genes known to be important in sympathoadrenal differentiation, including 
ASCL1 and PHOX2b.   
  In this study, we used Q-PCR to validate the preliminary findings of the microarray 
study, which included expression of four genes with (i) a role in sympathoadrenal 
differentiation or (ii) known to act as a neuronal markers in sympathoadrenal cells were 
compared in tumour extracts from VHL and MEN 2 patients.   
II. Materials & Methods 
 
Oligonucleotide Microarrays 
  Microarray slides consisted of 34, 580 seventy-base pair oligonucleotide probes 
(Qiagen, Valencia, CA, USA).  For specific details on the microarray, please refer to 
Brouwers et al, 2006.  
Quantitative Polymerase Chain Reaction (PCR) 
  Multiplex PCR reactions were performed for the target genes PHOX2b, ASLC1, and 
NCAM1 using 0.9 µmol/L of forward and reverse primers (for specific sequence see Table 
9.1; Biosynthesis Inc. Lewisville, TX, USA) and 0.25 µmol/L probe (Applied Biosystems). 
A  singleplex  reaction  for  SCG10  was  also  conducted,  using  the  same  concentration  of 
primer  and  probe  (TaqMan  Gene  Expression  Assays,  Applied  Biosystems).    All  target 
genes were normalized against the house-keeping gene 18s RNA using 0.15 µmol/L of   270 
forward and reverse primers and 0.25 µmol/L of probe (TaqMan Endogenous Controls, 
Applied Biosystems).  
 
Table 9.1.  Prime and Probe sequences 
Target  Forward  Reverse  Probe 
PHOX2b  atc ttc gtc cca aag acc ca  ccg cag gat tcc aga tca ga  cca aag ccg cct tag tga aga gca gta tg 
ASCL1  gag cag gag ctt ctc gac ttc a  gat gca ggt tgt gcg atc ac  agg ccc tcc tgc gaa gg act ttg 
NCAM1  tcg caa gga acg cag cat  cgg acg gcg tac gtt gtt tcg  atc gtc acc atc gtg gg 
 
III.  Results 
 
  Quantitative PCR (Figure 8.1a-d) was performed for ASCL1 (a), PHOX2b (b), 
SCG10 (c) and NCAM1 (d), and while the general trend was that gene expression was 
higher in MEN 2 samples, when differences were tested for statistical significance, there 
was no significant difference observed between VHL and MEN 2 tumours for any of the 
genes examined.   
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Figure 9.1  Expression of developmental genes in tumour samples from patients with MEN 
2 and VHL disease.   272 
 
IV.  Discussion 
 
  The aim of this study was to validate the preliminary findings of our microarray 
study, and specifically, to establish whether tumours from VHL and MEN 2 show 
differential expression of neural crest developmental genes and hence support the 
hypothesis that tumours from VHL and MEN 2 are composed of cells arrested at different 
stages of development.  However, despite the promising findings of the microarray, which 
showed significant differences (P<0.001) in the expression profile of PHOX2b, MASH-1, 
SCG10 and NCAM1, we did not replicate these findings with Q-PCR.   
As discussed in Chapter 1 – Part A, MASH-1 is transiently expressed in all autonomic 
progeny, including cells of the sympathoadrenal lineage and mice lacking MASH-1 fail to 
develop an autonomic nervous system (Guillemot & Joyner, 1993, Sommer et al., 1995).  
MASH-1 is also required for the acquisition of catecholaminergic traits such as the 
expression of TH and DβH, and also the expression of neuronal markers including SCG10 
(Sommer et al., 1995).  Chromaffin cells are also affected by MASH-1, and in spite of the 
absence of MASH-1, chromaffin cells are able to migrate to the adrenal but are incapable of 
expressing TH and DβH and are structurally immature (Huber et al., 2002).  Similarly, 
ablation of PHOX2b prevents autonomic neurogenesis and animals lack autonomic markers 
and other genes such as neurofilament, c-Ret or Hand2 and demonstrate the appearance of 
chromaffin cells that are arrested at an even earlier stage of development (Huber et al., 
2005).  However, similar to MASH-1 knockouts, extinguishing PHOX2b does not prevent   273 
the migration of immature progenitor chromaffin cell to the adrenal (Huber et al., 2005).  
Thus, given the preliminary findings of the microarray, we hypothesised that the 
pronounced differences between tumours from VHL and MEN 2 could be, in part, due to 
aberrant expression of either of the two transcription factors.  However, as demonstrated, 
we could not validate our hypothesis with the selected genes.  Had we examined the 
expression of other putative developmental genes from tumour samples from VHL and 
MEN 2 patients differences may have emerged.   
 